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Abstract 
Background: The natural history of early HCV infection has been only partially characterised 
previously, as primary infection is usually asymptomatic.  An emerging epidemic of acute HCV virus 
(HCV) infection in HIV-positive men in Europe, Australia and the USA has allowed the recruitment of 
new cohorts of patients with early HCV.  We aimed to describe the natural history of virus evolution 
and cellular immune responses in a rare cohort of acute HCV infected HIV-positive patients in order 
to identify key determinants of spontaneous clearance. 
Methods: 110 patients were recruited and followed at 1-3 monthly intervals for a median period of 
3 years. HCV E2 envelope, NS5B polymerase and NS5A genes were amplified at multiple time points 
using PCR and cloning techniques from plasma, liver and lymphocytes.  A library of 2295 HCV E2 
sequences were available for analysis .The functional immune response was assessed by ELISpot and 
flow cytometry. 
Results: 14% of patients cleared HCV spontaneously while 86% progressed towards chronicity. Three 
patterns of infection were observed based on viral load dynamics; spontaneous clearance (SC) and 2 
patterns of progression; plateau (PV) and fluctuating viraemia (FV).  SC was associated with a 
>1.7log10 viral load drop within 100 days of infection (OR=2.76; p=<0.001), slow viral diversification 
of the envelope E2 gene and the emergence of an early multi-specific T-cell response. PV was 
associated with positive selection within E2 and rapid viral diversification. Superinfection with new 
HCV strains (40% of the cohort), delayed T-cell responses and the presence of HCV within 
lymphocytes were all associated with FV.  CD4+ responses were particularly important in defining 
the final outcome of infection. 
Conclusions: Spontaneous clearance of acute HCV in HIV-positive men can be predicted by rapid 
decline in viral load, low viral diversity and T-cell response.   
Key words: HIV, HCV, HVR-1 
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Chapter 1: General introduction 
 
1.1 The epidemiology of HCV in HIV-positive individuals  
Around the world, silent infection with hepatitis C virus (HCV) is emerging as a major cause 
of future morbidity and mortality in individuals infected with human immunodeficiency 
viruses 1 (HIV-1). Liver disease has recently overtaken AIDS-defining illnesses as a cause of 
death in many patient populations following the successful introduction of highly active 
antiretroviral therapy (HAART) for the treatment of HIV (Bica et al 2001; Arnold et al 2006).  
In 2006, a total of 130 million people were estimated to be infected with HCV and 40 million 
with HIV. Shared routes of transmission mean that co-infection is common, affecting at least 
4–5 million individuals (Alter et al, 2006). In the developing world, infection with HCV is 
frequently associated with unsafe injection practices and unscreened blood transfusions. In 
westernized countries it is most commonly transmitted as a result of recreational 
intravenous drug use (IDU). Patients who have received untested blood products prior to 
the introduction of screening blood for HCV are also at risk. Sexual transmission of HCV 
occurs infrequently in HIV-negative couples (Hallam et al, 1993; Scott et al, 2010) but is 
commoner in HIV-positive patients, particularly in men-who-have-sex-with-men (MSM) 
(Danta et al, 2007). 
 
1.1.1 Blood transfusion and unsafe injections 
Following the identification of HIV in 1983 (Barré-Sinoussi et al, 1983) and HCV in 1989 
(Choo et al, 1989), diagnostic tests were rapidly developed and screening of blood and 
blood products became routine in resource-rich countries. Prior to this, patients receiving 
21 
 
blood products were at risk of acquiring both HCV and HIV; haemophiliac patients, for 
example, were frequently infected with both HIV and HCV from contaminated Factor VIII. 
Between 1982 and 2003, 96.5% of Canadian HIV-infected haemophiliac patients also had 
HCV (Arnold et al, 2006). In countries with established effective screening programmes 
transmission of HIV and/or HCV is now very rare (Pillonel, 1998). 
The risk of HIV and HCV acquisition in resource-poor countries unfortunately remains high. 
Between 2001 and 2002, 47.5% of blood transfusions in developing countries were 
unscreened for HCV infection (WHO Global Database on Blood Safety). Blood transfusions in 
the developing world are most often given to women as a result of peripartum 
haemorrhage (the commonest cause of death in women of child-bearing age) and to 
children with anaemia secondary to severe falciparum malaria (70% of blood transfusions in 
Africa). Between 8 and 12 billion injections are administered yearly around the world and 
50% of these are thought to be unsafe through non-properly sterilised needles and syringes 
(given mainly in sub-Saharan Africa and Asia) (Kane et al, 1999). This estimate does not 
include medical injections given by non-traditional practitioners and exchange of blood 
during ceremonial activities such as circumcision, tattooing and body piercing. HIV positive 
patients from countries in sub-Saharan Africa have an HCV antibody prevalence of 3.7–8.2%, 
the majority of which are likely to have been the result of nosocomial transmission (Ayele et 
al, 2002; Agwale et al, 2004; Karuru et al, 2005).  These figures may be somewhat artificially 
elevated by the inclusion of highly selected populations of patients. The above studies are 
surveys of hospital attendees and may therefore be biased as iatrogenic transmission of 
HCV is known to be common in this setting. The largest documented outbreak of HCV 
infection associated with unsafe injection practice was in Egypt following mass treatment 
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for schistosomiasis with intravenous tartar emetic resulting in an estimated seroprevalence 
of 25% in at-risk populations (Frank et al, 2000). Health care workers have often been 
implicated in transmission of HIV and HCV to patients. Unsafe injection practice at the Al-
Fateh hospital, Benghazi, Libya is likely to have resulted in transmission of HCV and HIV to 
418 children (111 of whom were infected with both viruses) and until recently the health 
care workers thought to be responsible were threatened with the death penalty (de Oliveira 
et al, 2006). 
 
1.1.2 Intravenous drug use 
HCV is highly prevalent in HIV-infected IDUs. A cross-sectional analysis of the US adult AIDS 
Clinical Trials Group revealed an overall HCV seroprevalence of 16.1% with a prevalence of 
72.7% in the high risk subgroups – those with haemophilia or a history of IVDU (Sherman et 
al, 2002). Similarly, a study of HIV-infected current and ex-IDUs in New York City 
demonstrated an HCV seroprevalence of 75% (Strasfeld et al, 2003). European HIV-infected 
individuals have an extremely high prevalence of HCV (33%) which is related to high levels of 
IDU (Mendel et al, 1995). The distribution of HCV in the HIV positive population in Europe 
varies from country to country with highest prevalence levels in urban areas of eastern and 
southern countries. European HIV-infected patients who practice IDU have an HCV 
prevalence of 78–97% (Quaranta et al, 1994; Rauch et al, 2005; Quaglio et al, 2003), and 
90% of injecting drug users who have injected drugs for more than 10 years have HCV 
(Quaglio et al, 2003).  
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1.1.3 Sexual transmission 
HIV positive MSM have an estimated prevalence of HCV infection of 4–11.5% with a higher 
risk in men who use condoms inconsistently (Cohen et al, 2006). An epidemic of acute HCV 
infection in HIV positive MSM has recently been reported in urban centres in the UK, 
Germany, France, the Netherlands and the USA (Cohen et al, 2006; Gilleece et al, 2005; 
Vogel et al, 2005; Dominguez et al, 2006; van de Laar et al 2007). The majority of these 
patients have been asymptomatic and identified by deranged liver function tests at routine 
HIV follow-up clinics. Risk factors for acquisition of HCV in such patients include multiple 
sexual partners (median number of partners 30 versus 10 in the preceding 12 months), 
unprotected anal intercourse, sex under the influence of drugs, internet-arranged sex, and 
sexual practices with a high risk of mucosal trauma such as fisting and use of sex toys. 
Patients were noted in one study to be seven times more likely to use the internet as first 
point of contact (Danta et al, 2007). It is likely that high risk (mucosally traumatic) sex is 
significantly associated with transmission of HCV. Limited data are as yet available on HIV-
negative MSM and incidence of HCV, but early reports would suggest that it is uncommon 
(Scott et al, 2010). Heterosexual spread of HCV in HIV-infected patients may also be higher 
than in HIV negative couples (Eyster et al, 1991; Vandelli et al, 2004; D'Oliveira et al, 2005). 
Again it has been suggested that this relates to the higher levels of HCV RNA in genital 
secretions of those with HIV infection. A French study investigating 1000 patients who 
acquired HIV sexually found a prevalence of HCV infection of 5.7% in MSM compared with 
12.9% in patients who acquired HIV through heterosexual sex (D'Oliveira et al, 2005). The 
female partners of haemophiliac men are more likely to have become HCV infected if their 
partner also has HIV infection (Eyster et al, 1991).   
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It is clear that the high rate of HCV infection in HIV-positive MSM is at least in part related to 
increased exposure to infection (Danta et al, 2007). What remains unclear is if the immune 
response to HCV in HIV-infected individuals results in a higher risk of sexual transmission of 
the virus. HCV viral loads in plasma tend to be higher in HIV-positive individuals (Cribier et 
al, 1995) and HCV is also more commonly detected in semen and genital secretions (Leruez-
Ville et al, 2000). In MSM, a reduction in CD4+ cells in the rectal mucosa associated with HIV 
infection (Bishop et al, 1987) could also theoretically facilitate sexual transmission of HCV.  
 
1.1.4 Control of infection 
It is estimated that 70% of injections given by primary health care providers in developing 
and transitional countries are unnecessary or could have been given in an oral formulation 
(WHO Global Database on Blood Safety 2001–2002). About 40% of these may have been 
administered with no sterilization procedure. Blood transfusions in developing countries are 
often donated by first-degree relatives without screening for HIV or HCV. In an attempt to 
reduce nosocomial transmission events, the World Health Organization co-ordinates the 
Safe Injection Global Network which provides advice on safe injection practice and 
mechanisms by which health care providers in developing countries can access equipment, 
and promote the training of health staff in order to change health care worker behaviour 
patterns, ensure the availability of adequate equipment and advise on appropriate waste 
disposal. Screening of blood used for transfusion is also a priority but there is still limited 
availability in resource-poor settings. 
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Intravenous drug users have been shown to develop multiple infections over time 
suggesting multiple and ongoing transmission events (Herring et al, 2004). We have 
observed the same phenomenon in HIV positive men who have contracted HCV sexually. 
Patients who have access to treatment should be given advice on reducing reinfection risk 
either by risk avoidance or modification strategies such as attending needle exchange 
facilities, using clean needles, syringes and paraphernalia for injection drug use and using 
condoms. 
In summary, HIV/HCV infection is common and has a variable distribution around the world 
reflecting differing routes of transmission. Reduction of transmission of HCV in coinfected 
patients is a priority and will only be achieved by a combination of public health campaigns 
targeting affected groups and health care workers in resource-poor settings. 
 
1.2 HCV discovery  
The 9600kb in length RNA genome of HCV was first characterised in 1989 using a shotgun 
sequencing approach. The genetic sequence places the virus in the Hepacivirus genus within 
the Flaviviridae family (Simmonds 1994; Lindenbach & Rice, 2001). The identification of 
multiple genotypes and strains of HCV have subsequently provided evidence that it 
originated between 500 and 2000 years ago (Simmonds, 2001). Infection with HCV, the 
infecting pathogen in the majority of cases of “nonA-nonB” hepatitis is currently estimated 
to account for about 130 million carriers around the world, 4-5 million of whom have HIV 
co-infection (Alter et al, 2006). 
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1.3 HCV structure and function 
The HCV genome organisation as shown in Figure 1.1 is so arranged that the structural 
genes (blue) are located at the 5' end of the genome and the non-structural ones at the 3' 
end. It is flanked by 5' and 3' untranslated regions (UTRs) on either side of an open reading 
frame (ORF) that encodes a polyprotein which is post-translationally cleaved into ten 
proteins divided by function into structural and non-structural ones. A small protein 
translated from an alternative short open reading frame of unknown function is also 
formed.  
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1.3.1 HCV models of infection 
While many aspects of the early stages of the HCV life cycle remain unknown, recent 
advances in in vitro cell culture systems have made the prospect of a stronger 
understanding of these events more likely. A number of systems are now available, 
including replicon-based culture, pseudovirus culture, chimeric cell culture and culture of 
the genotype 2a JFH-1 strain. In vivo, chimpanzees can be infected with HCV and have been 
used to characterise host-virus dynamics during early infection (reviewed by Bukh, 2004). 
Other models include tamarins infected with GBV-B (a closely related Flavivirus, Karayiannis 
et al, 1995) and transgenic mice with human liver xenografts.  
 
The development of viral sub-genomic replicons (RNA molecules capable of replicating 
autonomously but not capable of forming infectious viral particles) was the first successful 
in vitro culture strategy. Subgenomic replicon systems (in which the structural genes core, 
E1 and E2 are absent) have allowed study of the non-structural protein functions in an 
artificial setting, for example, by site-directed mutagenesis. Bicistronic replicons may include 
selection genes e.g. neomycin or reporter genes such as luciferase (Lohmann et al, 2003). 
Retroviral pseudoparticles (HCVpp) (Bartenschlager et al 2003) consisting of a retroviral 
backbone attached to HCV envelope glycoproteins have allowed studies into attachment 
and entry of HCV and the development of neutralisation assays. A further advance in the in 
vitro culture of HCV was the successful introduction of chimeric virus particles infectious in 
cell culture (HCVcc) consisting of the structural proteins of genotype 2a (Lindenbach et al 
2005), 1b, 1a or 3a HCV (Pietschmann et al, 2002) fused to the replicase (non-structural 
proteins) of the genotype 2a strain JFH-1.  In 2005, cDNA prepared from RNA extracted from 
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a genotype 2a virus from a Japanese patient with Fulminant Hepatitis (designated JFH-1) 
was successfully cloned and transcribed RNA shown to replicate in the Huh-7 hepatoma cell 
line. Moreover, such cultures were able to release mature infectious virions as shown by 
infection of other cells in vitro as well as chimpanzees (Wakita et al, 2005) and transgenic 
mice with human liver xenografts (Lindenbach et al, 2005). Other genotypes, however, have 
not yet been cultured successfully in vitro. Use of these culture systems have allowed 
investigation into the attachment and entry stages of infection, as well as replication of HCV 
in vitro. 
 
1.3.2 HCV life cycle 
1.3.2.1 Attachment and entry 
The search for the attachment receptor on hepatocytes has focussed on a number of 
proteins. It is clear that the HCV envelope protein E2 binds with high affinity to the 
ubiquitous tetraspanin protein CD81 (Pileri et al 1998), and this has been found to be 
required as a co-receptor during the cell-entry process using both HCVpp and JFH-1 culture 
systems (Bartosch et al, 2003; Hsu et al, 2003; Cormier et al, 2004; Zhang et al, 2004; Wakita 
et al, 2005; Morikawa et al, 2007). Inhibition of entry in Huh-7 hepatoma cells with anti-
CD81 monoclonal antibodies or siRNA prevents infection, while expression of CD81 in 
previously non-permissive HepG2 cells renders them susceptible to infection.  
 
Various attempts have been made to identify the area of E2 required for binding to CD81 
using each of the in vitro models available and a variety of techniques including blocking 
monoclonal antibodies, deletion and mutagenesis studies. Using the Con1 chimera in 
30 
 
culture (genotype 1b structural proteins attached to the JFH-1 replicase) and blocking 
monoclonal antibodies, amino acids 412-447 of the HCV E2 protein appear to be required 
for attachment to CD81 (Hsu et al, 2003). Mutagenesis studies have revealed that the HVR-1 
(Callens et al 2005) and residues 420, 527, 529, 530 and 535 may also be required for CD81 
binding (Patel et al, 2005). However, HCV cannot penetrate into all CD81 positive cells and 
HCV lacking the HVR1 sequence resulted in attenuated infection in chimpanzees.  It is likely, 
therefore, that another receptor present on hepatocytes facilitates binding to the cell 
surface.  There is evidence that the low-density lipoprotein (LDL) receptor (Agnello et al 
1999; Monazahian et al 1999), scavenger receptor class B type 1 (Scarselli et al 2002), 
glycosaminoglycans (GAGs) (Germi et al 2002; Barth et al 2003; Morikawa et al 2007), 
Claudin 1 also appears to facilitate entry into hepatocytes.  
Other cells may also be involved in binding HCV. DC-SIGN which is expressed on dendritic 
cells and L-SIGN expressed on endothelial cells in liver sinusoids (Gardner et al 2003; Lozach 
et al 2003; Pohlmann et al 2003) may capture circulating HCV particles and facilitate virus 
infection of proximal hepatocytes and lymphocytes (Cormier et al, 2004). HCV can also enter 
and replicate within other cells such as peripheral blood mononuclear cells (PBMCs), 
especially in HIV-infected individuals (Blackard et al 2005; Laskus et al 2007; Blackard et al 
2007), intestinal cells (Deforges et al 2004) and the central nervous system (Forton et al 
2004). The presence of negative strand RNA within such cells is highly suggestive of active 
replication. 
1.3.2.2 Replication within the cell 
After entry into a hepatocyte, the positive strand RNA acts as mRNA and binds directly to 
the 40S ribosomal subunit via a highly conserved 4-domain region of the 5’UTR of the viral 
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genome called the internal ribosome binding site (IRES), which then recruits the 60s subunit. 
This direct binding of the IRES to the ribosome occurs without requirement for pre-initiation 
factors and induces a conformational change allowing translation to commence. The 5’UTR 
also binds to eukaryotic initiation factor 3 (eIF3) via the IRES and a liver-specific microRNA 
miR-122 (Jopling et al, 2005) initiating translation and then acting as a template for 
replication by an error-prone RNA-dependent RNA polymerase. Translation of the 
monocistronic RNA genome results in the formation of a polyprotein which is cleaved into 
core protein, the envelope proteins E1 and E2, p7 and the non-structural proteins NS2, NS3, 
NS4A, NS4B, NS5A and NS5B. Cleavage of the structural proteins is carried out by host cell 
signalases and a signal peptide peptidase.  The non-structural proteins are processed by the 
2 viral proteases: NS2 which cleaves the NS2/NS3 junction and the NS3 serine protease 
which acts at all other cleavage sites in the non-structural polyprotein region. 
The structural proteins consist of the core protein, envelope proteins E1 and E2 and the p7 
ion channel. Core protein is released as a 191-residue precursor of 23 kDa and further 
processing yields the predominant form of 21kDa. It is polyfunctional, forming the 
nucleocapsid which is highly conserved amongst HCV strains but is also involved in 
modulation of signalling pathways, cellular and viral gene expression, cell transformation, 
apoptosis, and lipid metabolism (reviewed in Suzuki et al, 2005).  
 
The envelope proteins E1 and E2 form heterodimers on the virus surface. In contrast to HCV 
core protein, HCV envelope proteins vary extensively in structure. The E2 protein contains 
two hypervariable regions (HVR-1 and HVR-2) where the amino-acid sequence varies 
considerably as a result of positive selection mediated by the adaptive (predominantly 
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antibody-mediated) immune response (Weiner et al 1991; Farci et al, 2000; Gaud et al, 
2003). The E2 protein is involved in cell entry and contains a binding region for the 
ubiquitous CD81 co-receptor, required for entry into cells. Antibodies binding to epitopes 
within HVR1 inhibit binding of E2 to cells and block HCV infectivity, both in vitro and in vivo 
(Habersetzer et al., 1998; Shimizu et al., 1996; Zibert et al., 1999).   
 
The P7 gene encodes 2 alpha helices which form a transmembrane ion channel (Patargias et 
al, 2006) the presence of which is essential for viral replication (Brohm et al, 2009). NS2 
encodes a cysteine autoprotease that is separated from p7 by host cell peptidases and 
which cleaves the NS2/NS3 junction itself.  
The NS3 protein has 2 domains. The N-terminal domain is a serine protease (Tomei et al 
1993) requiring NS4A as a co-factor, while the C-terminal domain has helicase and NTPase 
functions (Suzich et al 1993; Wardell et al 1999).  The structure of the NS3 protein complex 
has been well characterised. The NS3 serine protease requires NS4A to anchor the complex 
to cellular membranes via an N-terminal hydrophobic peptide (Wolk et al, 2000) and also for 
the insertion of a β strand which allows the NS3 protease to fold into an active 
conformation (Failla et al, 1994; Bartenschlagger et al, 1994; Lin et al, 1995). It may also 
cleave proteins which mediate interferon signalling. Inhibitors of the NS3/4 protease such as 
bocepravir and telaprevir, currently in clinical trials, are able to reverse this inhibition of the 
interferon pathway (Meylan et al, 2005; Li et al, 2005). The C domain of NS3 is a DExH/D-box 
RNA helicase (characterised by the DExH/D motif) which uses the energy of NTP hydrolysis 
to unwind double-stranded RNA and DNA homoduplexes and heteroduplexes in a 3' to 5' 
direction (Levin et al, 2005). It therefore plays a pivotal role in HCV-RNA replication. 
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The NS4B protein induces intracellular membrane alterations and results in the formation of 
a membranous web which supports RNA replication (Egger et al 2002).  
 
NS5A is a membrane-associated protein which is phosphorylated and exists in two forms: 
hypo- and hyper-phosphorylated forms with 3 structural domains. It is likely to be 
polyfunctional, but these functions are not yet fully characterised. NS5A binds to and 
associates with lipid particles (Barba et al, 1997) via host proteins such as apolipoprotein E 
(Benga et al, 2010). An interferon sensitivity-determining region (ISDR) within NS5A has 
been described which may be associated with resistance to interferon. Resistance to IFNα 
may occur due to inhibition of the double-stranded RNA-dependent protein kinase (PKR) 
which is induced by IFN. Mutations within the NS5A PKR binding region which includes the 
ISDR render the virus sensitive to IFNα (Gale et al 1998). The E2 protein may also inhibit PKR 
(Taylor et al, 1999). NS5A is also associated with the production of IL8, which may 
potentiate viral replication (Polyak et al, 2001).   
 
NS5B encodes the RNA-dependent RNA polymerase which replicates viral RNA. It lacks 5'-3' 
exonuclease (proofreading) capacity and therefore a large number of viral variants, the viral 
quasispecies are produced over time. 
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1.4 HIV-1 and HIV-2 discovery, structure and function 
The human immunodeficiency viruses 1 and 2 were identified in 1983 (Barre-Sinoussi et al) 
and 1985 (Barin et al) respectively, following the emergence of unusual opportunistic 
infections and cancers (Pneumocystis pneumonia and Kaposi’s sarcoma) in men-who-have-
sex-with-men (MSM) in San Francisco in 1981. The illness was subsequently found to have 
been prevalent for a number of years in the USA and sub-Saharan Africa. HIV-1 was 
retrospectively isolated from patients in Kinshasa, Democratic Republic of Congo from 2 
tissue samples obtained and stored in 1959 (Korber, 2000) and 1960 (Worobey, 2008).  
Phylogenetic analysis applying a molecular clock to multiple HIV sequences, including the 2 
earliest isolated samples dates the origin of the HIV virus to the beginning of the 20th 
century (Worobey, 2008) having diverged from variants of chimpanzee simian 
immunodeficiency virus (SIVcpz; HIV-1) and sooty mangabee SIV (SIVsm; HIV-2).  
HIV-1 and 2 are members of the Lentivirus genus within the Retroviridae family (Figure 1.2). 
The HIV virus binds to the CD4 receptor and the chemokine co-receptors CCR5 and CXCR4 
via the viral protein gp120. Most primary HIV isolates bind CCR5 but changes in the 
structure of the highly variable V3 loop component of gp120 (Trkola et al, 1996) allow 
binding to CXCR4, usually during chronic infection. Gp120 represents a major target for 
neutralising antibody responses which may limit HIV viraemia. After binding to the host cell 
membrane, the viral gp41 fusion peptide is inserted into the membrane and viral RNA is 
deposited into the cytoplasm of the cell. Dendritic cells may also be infected via the 
receptor DC-SIGN and HIV may be disseminated by these cells as well as macrophages, 
particularly from mucosal surfaces.  
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Once viral RNA has entered the cell, it is converted to double-stranded DNA by the viral 
enzyme reverse transcriptase. This proviral DNA is then integrated into the genomic DNA in 
the nucleus of the cell by another viral integrase. The viral genome encodes three structural 
protein genes gag, pol and env, 2 regulatory proteins tat and rev and 4 accessory proteins 
nef, vif, vpu and vpr. Once inserted into the host cell genome, proviral DNA is transcribed 
into mRNA and translated into a polyprotein which is then cleaved into functional proteins 
by the viral protease. The viral enzymes reverse transcriptase, integrase and protease as 
well as gp41 and CCR5 are all targets of highly active antiretroviral therapy (HAART).  
The env gene encodes the gp160 protein that is then cleaved into gp120 and gp41.  
The regulatory tat proteins activate transcription by binding the trans activation responsive 
(TAR) area of the long terminal repeat (LTR) promoter found at either end of the HIV 
genome (Gatignol et al, 1991). Rev promotes shuttling of viral mRNA from the nucleus and 
the cytoplasm by binding to the 200bp Rev-responsive RNA element (RRE; Felber et al, 
1989) within mRNAs encoding the structural proteins.  
The accessory proteins have a variety of functions. HIV viral infectivity protein (Vif) binds to 
the mRNA of the cellular cytosine deaminases APOBEC3G and APOBEC3F  inhibiting their 
translation (Mercenne et al, 2010).  Vpr protein arrests the cell cycle at the G2/M phase. 
This may occur via an interaction with E3 ligase and an unknown cellular factor whose 
ubiquitination (and subsequent proteasomal degradation) induces G2 arrest (Belzile et al, 
2010). Nef protein down-regulates MHC class 1 and 2 molecule expression as well as 
reducing CD4 receptor expression by the endocytic pathway (Garcia and Miller, 1991; 
Stumptner-Cuvelette et al, 2001).  
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The Vpu protein also reduces expression of CD4 by increasing degradation via the ubiquitin-
proteasome pathway. It also facilitates viral budding and appears to produce an ion channel 
which may aid this process (reviewed in Montal, 2003).  
 
1.5 The clinical course of HCV in HIV-infected patients 
Progression of HCV in HIV-positive individuals is accelerated with progression to fibrosis and 
liver cirrhosis occurring earlier and a higher risk of hepatocellular carcinoma which is more 
likely to have metastasised prior to presentation to hospital than in HIV-negative individuals 
(Singal & Anand, 2009; Benhamou et al, 1999; Graham et al, 2001; Giordano et al, 2004).  
 
One study has revealed high levels of liver fibrosis during acute infection in HIV-positive 
individuals, but this has not been confirmed in other cohorts and was weakened by the 
unusually broad inclusion criteria used for diagnosing acute HCV which may have resulted in 
the inclusion of chronically infected patients in the analysis (Fierer et al, 2008). The 3 
diagnostic criteria used in the study were 1) Seroconversion which is known to be delayed in 
HIV-positive individuals and is discussed in chapter 2 of this thesis, 2) Elevation in ALT level 
which could occur for a variety of reasons e.g. use of illicit drugs or HAART and 3) 
Fluctuation in the serum level of HCV RNA which may occur at any stage of HCV infection.  
 
The picture is clearer however in individuals with chronic HCV and HIV.  Immunosupression 
is associated with more rapidly progressive HCV-related liver disease. This has been 
recognized both in the setting of immunosuppressive therapy and in patients with HIV and 
HCV (Martin et al, 1989; Eyster et al, 1991; Telfer et al, 1994; Graham et al, 2001). In one 
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Spanish study carried out between 1989 and 1993, the outcome of HCV associated liver 
disease was assessed in 44 patients with HCV monoinfection and 32 patients with HIV and 
HCV infection (Sanchez-Quijano et al, 1995). Within 15 years 25% of those with HIV had 
cirrhosis compared with 6.5% of those who were HIV negative. Another study published in 
1999 compared liver histology in HIV positive patients with HCV correcting for age, sex and 
alcohol consumption (Benhamou et al, 1999). CD4 count, HIV status and alcohol intake were 
predictive of outcome: An HIV positive individual with a CD4 count of <200 ⁄mm3 and an 
alcohol intake of more than 50 g⁄day had a median expected time to cirrhosis of 16 versus 
36 years for a patient with a CD4 count of more than 200 ⁄mm3 and an alcohol intake of <50 
g ⁄day. Much of the first of these studies was carried out in the pre-HAART era, and many of 
the patients receiving HAART in the second study were treated with what are now regarded 
as hepatotoxic regimens (such as didanosine, stavudine and zalcitabine). Thus, following the 
advent of effective HAART, further studies investigated disease progression in treated 
individuals with HIV HCV coinfection. While the risk of hepatotoxic events are more 
frequent and serious in patients with HCV infection, immune restoration can slow down the 
rate of liver fibrosis towards that seen in HIV-negative individuals. One study compared 
disease progression in 85 HIV⁄HCV coinfected subjects with 296 patients with HCV who 
were HIV negative (Verma et al, 2006). The HIV-infected group were subdivided according to 
whether they had received no HAART, nucleoside analogue reverse transcriptase inhibitors 
(NRTIs) alone, or more effective combination therapy (generally those where therapy was 
started after 1996) and a third group who started on NRTIs and progressed on to more 
effective therapy as it became available. Serial liver biopsies showed that those who had 
received only more effective HIV combination therapy had similar disease severity to the 
HCV monoinfected group while more rapid progression was seen each of the other groups. 
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Another study of 285 HIV ⁄ HCV-infected patients revealed that both liver related and 
general mortality rates were decreased in patients who had taken HAART (Qurishi et al, 
2003). Furthermore, in patients treated with HAART, rapid progression of liver disease is 
associated with poor control of HIV and correlates with high viral load and low CD4 count 
(Brau et al, 2006).   
 
Thus, the availability of effective HAART has extended the life span of HIV and HCV co-
infected patients resulting in a Pandora’s box phenomenon; as the rate of mortality 
associated with HIV-related opportunistic infection has decreased, the morbidity and 
mortality rates of HCV-related liver disease have increased (Bica et al, 2001) and are likely to 
continue to do so.  
 
1.6 The clinical course of HIV in HCV-infected patients 
While the impact of HIV on the progression of HCV has been well studied, the impact of HCV 
on the progression of HIV is less clear. Hypothetically, it might be expected that the 
presence of HCV would be likely to subvert immune control of HIV by overwhelming, 
redeploying or subverting effective immune responses against the virus. This hypothesis is 
supported by observation disease progression in HCV-positive individuals monitored as part 
of the Swiss cohort study (1157 HIV and HCV positive patients compared with 1954 HIV 
positive patients). Coinfected individuals had a higher likelihood of progression to AIDS-
defining events or to death (hazard ratio 1.7 (95% CI 1.26-2.30)). This was independently 
also associated with active intravenous drug use; HR 1.38 (95% CI: 1.02-1.88)). HCV 
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seropositivity was also associated with impaired CD4+ cell recovery following HAART (hazard 
ratio for a CD4-cell count increase of at least 50 cells/µl=0.79 (0.72-0.87)).   
 
The association of accelerated disease progression in co-infected individuals is likely to 
reflect a disordered immune response and is the subject of discussion in Chapter 4 of this 
thesis. 
 
1.7 Treatment of HCV in HIV-infected patients 
1.7.1 Current treatments for HCV 
 At the time of writing, the only licensed treatments for HCV are conventional interferon 
alpha (IFNα), pegylated interferon alpha (pegIFNα) and ribavirin. These have variable 
success rates, dependent on a number of host and virus factors. Higher success rates in 
chronic HCV infection are obtained with combination therapy with pegIFNα and 
ribavirin.  Both host and viral factors are likely to define the response to treatment and 
are studied and discussed further in chapter 2 of this thesis. 
1.7.2 The treatment of chronic HCV in HIV-positive patients 
The advent of HAART has significantly improved the outlook for HCV-infected HIV-positive 
patients. Initial trials with conventional non-pegylated IFNα  as monotherapy or 
combination with ribavirin were disappointing with low sustained virological response (SVR) 
rates. However, the development of pegIFNα and ribavirin combination therapy has 
increased SVR rates considerably. In the RIBAVIC study 412 HIV/HCV-infected patients were 
randomized to receive standard IFNα and ribavirin vs pegIFNα and ribavirin (Carrat et al, 
2004). The overall SVR was higher in the pegIFNα arm (27 vs 20%) but nevertheless 
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disappointing and thought to relate to a very high (42%) treatment discontinuation rate. A 
similar trial compared the combination of an escalating regimen of ribavirin in combination 
with standard or pegIFNα and gave very similar results (Chung, 2004). 
The APRICOT study (Torriani et al, 2004) was the largest trial in this setting. This was an 
international study and enrolled 868 patients who were randomised to receive conventional 
IFNα three times weekly (3 MU) with ribavirin (800 mg/day), weekly pegIFNα monotherapy 
(180 μg) or a combination of weekly pegIFNα (180 μg) and ribavirin (800 mg/day) for 
48 weeks. The SVR was significantly higher in those who received combination therapy and 
reached 62% in genotype 2 or 3 infection but only 29% in genotype 1 infection. Treatment 
was associated with an average, reversible CD4 decline of 140 cells/mm3 and even in this 
highly selected group of patients, 25% of the patients in the combined arm of the study had 
to discontinue in view of side effects or other reasons. A serious concern was that liver 
failure occurred and was fatal in 6/14 patients. This was associated with cirrhosis with Child-
Pugh scores of 5 or more at baseline and didanosine-containing regimens (Mauss et al, 
2004). 
The pre-treatment viral load did not influence the response rate in those with genotypes 2 
and 3 infection but in pegIFNα/ribavirin-treated genotype 1 patients the SVR was 61% in 
those with HCV RNA levels of <800 000 IU/mL and 18% in those with higher levels. 
When the APRICOT study was designed there were concerns that higher doses of ribavirin 
may not be tolerated by patients in whom anaemia is a common problem, particularly those 
treated with concomitant zidovudine. Studies in HCV monoinfected patients revealed that 
higher doses of ribavirin in patients with genotype 1 infection were more effective 
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(Hadziyiannis et al, 2004) and this appears to be the case in HIV/HCV-coinfected patients 
also.  In the PRESCO study (Ramos et al, 2007), higher weight-based dosing of ribavirin was 
used and extension of treatment duration from 48 to 72 weeks also improved the SVR rate 
in genotype 1 infected HIV-positive patients (53% versus 31%). Premature treatment 
discontinuations were common, however, and occurred in 45% in the prolonged treatment 
arm (2.6% due to severe anaemia). Extension of treatment duration from 24 to 48 weeks in 
genotype 2/3 also resulted in a higher SVR (82% versus 67%).  
Viral kinetics have become increasingly important in this setting and it has been suggested 
that in genotype 2 or 3 infected patients, 24 weeks of therapy may be suitable, particularly 
for those with a low baseline HCV RNA level who demonstrate a rapid virological response 
(RVR; undetectable VL at 4 weeks), can demonstrate good adherence and have no evidence 
of advanced hepatic fibrosis (Perez-Olmeda, 2003). An extended treatment course may also 
be considered when patients show a consistent but slow decline in the HCV RNA level. In 
future, it is likely that there will be more tailoring of treatment courses according to the 
baseline host and virological parameters and to the initial virological response. 
The APRICOT study also showed that even if patients did not achieve an SVR that in those 
who agreed to have a follow-up liver biopsy, there was nevertheless an improvement in the 
liver histology (Lissen, 2006). 
Depression rates as high as 40% have been recorded when treating patients with HIV and 
HCV with interferon therapy. There are also reports of significant weight loss (Bani-Sadr et 
al, 2008). As discussed above, severe anaemia, neutropenia and reductions in CD4 count are 
important dose-limiting factors when treating co-infected patients. It is therefore important 
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to counsel patients regarding these potential side effects and review the nutritional state of 
the patient prior to initiation of therapy. 
 
1.7.3 Treatment of acute HCV in HIV-positive patients 
Studies investigating the efficacy of treatment of acute hepatitis C infection have been 
limited in numbers because hepatitis C infection does not often present in the acute phase 
due to lack of a clinical syndrome. If recognized in the acute phase, treatment with IFNα 
monotherapy in HIV negative patients is usually successful (98% SVR in patients treated at 
12 weeks from diagnosis) (Jaeckel et al, 2001). HIV positive patients have a less optimal 
response to treatment (summarized in Table 1.1). 
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1.7.3.1 Interferon monotherapy 
 
The use of IFNα monotherapy in HIV positive patients with acute HCV superinfection has 
not been extensively investigated. Two small retrospective studies (Gillece, 2005; 
,Serpaggi, 2006) have been published showing markedly different results (Table 1.1). 
One revealed an SVR rate of 0% while another small retrospective analysis revealed a 
high SVR rate of 91%. This contrasting difference in response rates to treatment is likely 
to reflect small sample sizes and differences in patient population. Further studies would 
be required prior to drawing any conclusions from these data. 
 
1.7.3.2 Interferon and ribavirin combination therapy 
Combination therapy with therapy with pegIFNα and ribavirin given 12 weeks from 
diagnosis has a reported success rate of 59–71% (Gillece et al, 2005; Dominguez et al, 
2006) significantly less than in HIV negative patients (Serpaggi et al, 2006). 
Variation in patient population and timing of diagnosis and treatment from study to 
study may partially explain these differences in outcome. Patients presenting with a 
clinical syndrome associated with infection may increase the likelihood of response to 
treatment in contrast with those identified as a result of deranged liver function tests 
taken at routine HIV follow-up appointments. It is likely, however, that the major 
difference in SVR rates is likely to be due to perturbation of the immune response 
associated with HIV infection. Cell-mediated immunity to HCV is of key importance in 
controlling infection. HCV-specific antibody responses in HIV-infected patients are 
known to be impaired in patients with a CD4 count <500 cells/mm3 (Netski, 2007). This 
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may limit control of the virus itself and may also impair early diagnosis of infection. 
Some HIV positive patients fail to produce an antibody response to HCV (Stramer, 2004) 
and therefore studies which include patients with a preceding negative antibody test 
followed by a positive polymerase chain reaction test may in fact include patients who 
are chronically infected with HCV but have not developed antibody seroconversion. 
 
1.7.3.3 Treatment limitations 
HIV positive patients with acute HCV may wish to elect for prompt treatment with IFNα 
and ribavirin in view of a higher likelihood of response during early infection. However, 
eligibility for treatment may be limited by comorbidity, lifestyle and access to specialized 
treatment centres. One study estimated that 70% of patients chronically infected with 
both viruses were ineligible for treatment (Fleming et al, 2003). The main reasons for 
exclusion were missed clinic visits, active psychiatric illness, active drug or alcohol use, 
decompensated liver disease or active medical illness. Ongoing IDUs with HCV represent 
a particularly challenging group of patients to treat because of increased clinic non-
attendance and associated poor health. Intervention strategies targeting IDUs may occur 
outside of the hospital, for example, in the prison setting. 
Patients who are considered eligible for treatment may require HAART or antidepressant 
medication prior to starting IFNα and this may result in a longer diagnosis treatment 
time period. Depression is a significant concern when treating such patients as it reaches 
a high prevalence in patients with dual infection (up to 42%) (Ryan, 2004). IFNα may 
cause depression itself and has been associated with suicide attempts while on therapy 
(Janssen, 1994). Many patients, therefore, require assessment by psychiatric services 
and antidepressant medication prior to initiating treatment. Specialist clinics treating 
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such patients benefit from a close psychiatry link in order to assess patient suitability for 
treatment and provide follow-up assessment and care during therapy. 
Patients with CD4 counts <350 cells/mm3 may benefit from the initiation of HAART prior 
to IFNα therapy in order to increase the likelihood of successful treatment and to avoid 
the risk of the CD4 count descending below 200 cells/mm3 with the potential for 
opportunistic infection while on therapy. 
In summary, treatment of HIV positive individuals infected acutely with HCV may 
achieve higher SVR rates with pegIFNα and ribavirin than those with chronic infection. 
However, a significant proportion of patients does not respond or qualify for treatment. 
Results of trials of novel therapeutic agents, e.g. polymerase and protease inhibitors are 
eagerly awaited.  
Early studies with standard IFNα therapy were disappointing in this group of patients. 
Decreases in the CD4 count associated with treatment occurred (Vento et al, 1993; 
Soriano et al, 1995), and in some cases, resulted in life-threatening opportunistic 
infection (Pesce, 1993). 
 
1.7.4 Prescribing antiretroviral therapy in HCV-infected individuals 
 Many HAART agents are potentially hepatotoxic and there have been concerns that there 
may be an increased risk of hepatotoxic reactions in those with hepatitis C. The Swiss cohort 
study showed that the number of treatment changes was similar in HCV positive and 
negative individuals when prescribed HAART (Greub et al, 2000). Several other studies, 
however, suggest that the incidence and possibly severity of HAART-associated 
hepatotoxicity is increased in patients with concomitant HBV or HCV infection (Sulkowski et 
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al, 2002). However, many reports of hepatotoxicity relate simply to biochemical liver 
function tests and a more detailed histological study (Mehta et al, 2005) found no evidence 
of increased long-term liver damage in patients with HIV/HCV who had been exposed to 
HAART. 
There have also been concerns regarding impaired drug metabolism in patients particularly 
with advanced liver disease. One study showed that higher levels of efavirenz and 
nevirapine were seen in patients with advanced disease, but that there was very little effect 
on the drug levels of protease inhibitors (Barreiro et al, 2007). Overall the benefit of 
judicially selected HAART therapy appears to outweigh the benefit (Tural et al, 2003). 
The situation becomes more complex when patients already taking HAART require HCV 
therapy and particular care is required in selecting the antiviral regimen – particularly the 
choice of nucleoside analogues. 
The nucleoside analogues used to treat HIV infection undergo intracellular phosphorylation. 
Ribavirin, a purine guanosine analogue, also undergoes this process towards the 
triphosphate-active form. Ribavirin, in vitro, inhibits the intracellular phosphorylation of 
zidovudine, stavudine and zalcitabine. This does not seem to impair the efficacy of the 
HAART regimen. However, didanosine and abacavir phosphorylation is increased and it is 
thought that the increased intracellular levels of the active triphosphate form of didanosine 
contributed to the cases of mitochondrial toxicity/lactic acidosis reported in the APRICOT 
(51) study. A multivariate analysis of cases of spontaneous hepatic decompensation in the 
RIBAVIC study also found a significant association with didanosine use (Bani-Sadr et al, 
2005). 
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Patients receiving a didanosine-containing regimen should therefore be switched to an 
alternative HAART regimen. There have also been concerns that patients with more severe 
liver disease taking stavudine-containing regimens may be at risk of lactic acidosis and many 
physicians also avoid stavudine-containing regimens in this setting. 
Zidovudine and ribavirin can both cause anaemia so the concomitant use of both of these 
agents may require dose reductions of ribavirin or the use of erythropoietin. 
A recent report suggests that abacavir may interact with ribavirin and that patients taking 
an abacavir-containing regimen have a reduced SVR, possibly as both are guanosine 
analogues  (Bani-Sadr et al, 2007; Vispo et al, 2008) although this remains controversial 
(Amorosa et al, 2010; Laufer et al, 2008). 
It has been suggested that an ideal time to treat the HCV infection is at an early stage in the 
HIV disease when the patient has a reasonable CD4 count and does not require HAART. This 
is supported by a study which found that the risk of hepatotoxicity with HAART was reduced 
in patients who had achieved an SVR with antiviral therapy for HCV (Labarga et al, 2007). 
 
1.8 The natural history of acute HCV infection in HIV-negative and positive 
populations 
Twenty-one years after the characterisation of the HCV virus (HCV) genome (Choo et al, 
1989), the asymptomatic nature of early infection has meant that its natural history has only 
been partially described. Exposure to the virus is usually unnoticed by patients until they 
develop cirrhosis of the liver or hepatocellular carcinoma following many years of silent 
infection. Thus, while large cohorts of patients with chronic infection have been extensively 
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described, insights into early host-virus dynamics have largely been limited to follow-up of 
point-source outbreaks, for example, rhesus-negative women who received contaminated 
immunoglobulin during pregnancy (Power et al, 1995; Wiese et al, 2005) or case series 
including large proportions of patients with symptomatic disease (Farci et al, 2000). These 
latter studies are small-scale and may not represent the most usual course of early 
infection. Young women (such as those infected with immunoglobulin) and patients with 
symptomatic infection are known to have a better prognosis which is likely to have biased 
these studies. Even less is known about early HCV in HIV-infected individuals, in whom HCV 
is emerging as a key concern, with liver disease now a major cause of mortality in patients 
with access to HAART (Bica et al, 2001). An emerging epidemic of acute HCV infection in 
HIV-positive men in urban centres in Europe (Gillece et al, 2005; Dominguez et al, 2006; 
Vogel et al, 2005),  USA (Fierer et al, 2008) and Australia (Matthews et al, 2009) has 
provided the opportunity to prospectively study the progression of early disease in a large 
number of individuals. Patients are identified early in infection, despite lack of symptoms, 
due to the detection of abnormal liver function tests at routine clinic follow-up.    
 
In chimpanzees, acute HCV infection is characterized by positive viraemia by day 7 of 
infection and peak viral loads of 105-107copies/ml. These are higher and decrease more 
slowly in animals which progress towards chronic infection than those which resolve (Major 
et al, 2004; Bukh, 2004). Vigorous intrahepatic CD4+ and CD8+ responses correlate with viral 
load descent and spontaneous clearance (Major et al, 2004; Thimme et al, 2001; Cooper et 
al, 1999; Shoukry et al, 2004).   
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Delayed seroconversion, higher ALT levels and later IFNγ responses correlate with persistent 
infection.  Interestingly responses to the HCV HVR-1 are associated with viral persistence, 
suggesting that this region could serve as an immunological decoy (Major et al, 2004; Table 
1.2). 
Table 1.2: Predictors of spontaneous clearance of HCV in experimentally infected chimpanzees 
(adapted from Major et al, 2004) 
 Acute Resolving  
infection  (n=4) 
Persistent infection  
(n=6) 
 
Appearance of viremia Week 1 Weeks 1-2 
Peak titres 105-106 genome copies/mL 106-107 genome copies/mL 
Initial decrease in titres Weeks 6-9 Weeks 7-10 
Peak ALT 200-250 IU/mL (weeks 8-9) 200-650 IU/mL (weeks 9-17) 
Seroconversion (ELISA 3.0) Weeks 6-9 Weeks 7-14 
Anti-HVR1 None detected Weeks 11-15 (none detected  
in one animal) 
IFNγ Weeks 6-10 Weeks 8-12 
Monocyte-induced protein 
1  
Weeks 2-20 Detected in only 1 animal  
(week 8) 
 
While providing important insights into the early host-virus dynamics of HCV infection, it is 
unlikely that the chimpanzee model is entirely representative of the situation in humans. 
Viral load dynamics have not been well described in humans and while many studies have 
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investigated the role of B and T cell responses in small groups of patients, longitudinal 
responses in a larger group of patients have not been published to date. In humans, a 
number of predictors of spontaneous clearance are known (Table 1.3). 
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Table 1.3: Predictors of spontaneous clearance of acute HCV in humans   
 
 
 
Host  Favourable  Unfavourable  Reference  
Sex Female  Male  Micallef et al 2006 
Bilirubin  High Normal   Micallef et al 2006 
T cell response  Multispecific CD4  
and CD8 
Narrow weak  
response  
Lauer et al 2005, Gruner 
et al 2000,  
Gerlach et al1999  
HLA   HLA-B27  
HLA-DQB1*0301  
HLADRB1*01  
HLA-DRB1*0701  
HLA-DRB4*0101  
Neumann et al 2007,  
Thursz et al 1999,  
Barrett et al 1999  
KIR/HLA C KIR2DL3/KIR2DL3-
HLA-C1C1  
 Khakoo et al 2004  
HIV Negative Positive  Thomas et al 2000  
Route of 
transmission 
Sexual IDU  Shores et al 2008  
 
IL28B (IFN-λ3) 
promoter single 
nucleotide 
polymorphism 
rs12979860  
C/C genotype T/T genotype (Thomas et al, 2009) 
Virus     
Viral diversity Low  High  Farci et al 2000  
dN/dS ratio Low (<1)  High(>1)  Ray et al 1999,  
Farci et al 2000  
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1.9 Aims and hypotheses 
 
In this thesis, a cohort of 110 HIV-positive MSM with acute HCV and a background of HIV-1 
infection was followed longitudinally in order to address the following research hypotheses: 
1. HCV diversification and evolution predicts the outcome of acute infection in a cohort of HIV-
infected individuals 
2. Diversification occurs early during the course of infection and defines the later viral 
population and response to treatment 
3. The evolution of acute HCV in this cohort is defined by the adaptive cellular immune 
response  
We aimed to: 
1. Characterise the natural history of acute HCV in an HIV positive MSM cohort (Chapter 2) 
2. Determine the diversification and immune-mediated selection of HCV in HIV co-infected 
patients over time by phylogenetic analysis of the HCV E2 HVR-1, NS5A and NS5B regions 
(Chapters 2-3) 
3. Characterise the adaptive immune response during acute HCV infection (Chapter 4) 
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Chapter 2: Predicting outcome in HIV-positive MSM with acute HCV 
 
2.1 Background 
2.1.1 The phyloepidemiology of acute HCV in HIV-positive men  
In 2004, three reports of acute HCV infection occurring in HIV-positive men in London, Paris 
and Amsterdam appeared in the scientific literature (Gilleece et al, 2005; Ruys et al, 2004; 
Ghosn et al, 2004). All of the affected individuals were MSM and it was considered likely 
that the route of transmission was sexual. A detailed case-control and phylogenetic study 
carried out by Danta and colleagues (2007) later prospectively investigated routes of 
transmission in 111 HIV-positive patients with acute HCV recruited from 3 centres in the UK. 
In this study, the main risks for infection were found to be sexual. Intranasal and rectal 
recreational drug use were also significantly more common in cases than in controls when 
univariate statistical tests were used to analyse each risk factor separately, but became 
insignificant following multivariate logistic regression. Interestingly only 1 patient in the case 
group admitted to using intravenous drugs, although 57% admitted to using crystal 
methamphetamine which is commonly injected but may also be smoked, suggesting the 
possibility of under-reporting of parenteral drug use, even when using a confidential 
questionnaire. Other cohorts have reported higher rates of parenteral drug use; 4/11 in one 
study which examined the first cases in New York (Fierer et al, 2008). The sample size and 
resultant statistical robustness of this study was not comparable, however, to that 
presented by Danta et al. Furthermore, the inclusion criteria in this study for the diagnosis 
of acute HCV were extremely broad.  It is highly likely, therefore, that the primary mode of 
transmission of HCV in this group of patients is sexual. Intranasal mucosal exposure and 
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parenteral drug use also remain a possible route of transmission in at least a minority of 
these individuals.   
 
Case control evidence that transmission events are interrelated is further supported by 
genetic sequence analysis providing evidence of a new predominantly sexually-transmitted 
emerging epidemic.  Phylogenetic analysis of a region of the HCV E2 gene, including the 
HVR-1, revealed  several distinct monophyletic lineages in MSM when compared with 
reference strain sequences obtained from IDU patients,  indicating a number of interrelated 
introductions of HCV into the MSM population (Danta et al, 2007). A subsequent cross-
sectional phylogenetic analysis of HCV NS5B sequences from multiple centres in Australia 
and Europe also revealed several distinct monophyletic lineages (van de Laar et al, 2009).  
Each lineage contained interrelated sequences obtained from different countries, revealing 
evidence of a global transmission network in MSM.  
 
2.1.2 Methods used to assess viral diversity 
Clonal sequencing is a powerful research tool, providing a sample of viral population 
diversity and has been the gold standard approach for a number of years, providing key 
insights into host-virus interactions. It has a number of limitations, however. A particular 
concern is that errors may be introduced during the PCR, particularly when Taq polymerase 
is used, rather than a proof-reading enzyme. If an error is generated early on in the PCR 
reaction, it will be introduced into many cDNA amplicons and give an unrealistic picture of 
diversity. Unfortunately, cost may limit the use of proof-reading enzymes in large-scale 
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analyses. A limiting dilution PCR approach can help to overcome some of this error, but is 
laborious and also unsuitable for large-scale studies. Reverse transcription and amplification 
in E coli may also result in the introduction of error as can the sequencing reaction itself. 
Bidirectional sequencing may reduce error rates at this stage, but again has cost 
implications. Another problem is primer selection where the primers are designed to anneal 
to a region of high viral diversity e.g. the HVR-1 and will not amplify all variant strains. Use 
of multiple primer sets or degenerate primers may help to reduce this problem. 
 
While clonal sequencing has been traditionally used in the past to analyse quasispecies 
diversity, it is usually used to generate 10-20 sequences at a time. Thus minority variants 
may be undetected. The recent development of ultradeep pyrosequencing is starting to 
revolutionise analysis of viral populations as it may be used to analyse tens of thousands of 
variants in a single step. Pyrosequencing is discussed further in Chapter 3. 
 
Another technique, designed to overcome the more laborious or expensive analyses 
described above is the heteroduplex diversity assay. This assay is a PCR assay, designed to 
identify DNA heteroduplexes which occur as a result of quasispecies diversity. In order to 
carry it out, a PCR reaction is set up, following which ethylenediaminetetra-acetic acid 
(EDTA) is added to the reaction mix to deactivate DNA polymerase. A denaturation step to 
separate the cDNA into single strands is then carried out at 95°C followed by slow cooling to 
allow annealing of homologous and heterologous strands. This technique can detect up to 
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2% variation in viral quasispecies when compared with sequence analysis. The duplexes are 
then counted under ultraviolet light following gel electrophoresis (Shire et al, 2006). 
 
2.1.3 Predicting spontaneous clearance of acute HCV using measures of viral evolution 
Although the cross-sectional phyloepidemiology of acute HCV in this population has been 
well characterised (Danta et al, 2007; van de Laar et al, 2009), the evolution of viral 
populations over time in individual patients has not. As the virus has an extremely rapid 
generation time and each viral genome is copied imperfectly due to the lack of proof-
reading function of the HCV viral RNA polymerase (Neumann et al, 1998), within any 
individual, a swarm of related, but genetically different viral sequences circulate at any 
given time; the viral quasispecies. The ability of the host immune system to recognize and 
eliminate each variant strain is highly likely to influence the final outcome.  In a small, well-
characterized cohort (n=12) of HIV-negative individuals, it has been shown that those who 
progress to chronicity have a higher rate of viral diversification than those who clear the 
virus spontaneously (Farci et al, 2000).  In this study, patients were selected based on 
outcome and divided into 3 clinical groups: 3 patients had fulminant hepatitis, 3 
spontaneously cleared infection and 6 had acute hepatitis that progressed to chronicity. The 
progressor group were further subdivided into slow and rapid progressors (mild stable 
disease versus severe and rapidly progressive disease leading to death within 5 years). The 
number of viral variants and the genetic diversity of the HCV quasispecies were assessed by 
examining viral sequences spanning the envelope genes (E1 and E2) both within and outside 
the hypervariable region 1 (HVR1). Genetic diversity was calculated using the mean 
Hamming distance which is a measure of the mean number of amino acid differences 
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between paired sequences. While the genetic diversity and the number of viral variants 
within the HCV quasispecies in early samples did not differ significantly between patients 
who resolved their infection and those who developed chronic disease, later samples, 
obtained after antibody seroconversion revealed significant differences between groups. 
Patients with spontaneous clearance had a decrease in genetic diversity of the HVR-1, 
whereas those with progressing hepatitis showed a marked increase in diversity. The 
patients with fulminant hepatitis (a rare complication of acute HCV infection) showed the 
lowest degree of genetic diversity, both before and after seroconversion, despite high HCV 
RNA levels. These results suggest that the immune system is key both in eradication of the 
virus and in the pathogenesis of disease. To analyse differences in genetic sequence further, 
a calculation of the ratio of nonsynonymous (amino acid replacement; dN) nucleotide 
substitutions per nonsynonymous site to synonymous (silent; dS) nucleotide substitutions 
per synonymous site was carried out. The dN/dS ratio was highest in progressor patients; 
evidence of ongoing positive selection and low in spontaneous clearers and patients with 
fulminant hepatitis.   
The relationship between viral sequence diversity and spontaneous clearance of acute HCV 
in HIV-positive patients has not previously been described and is the subject of investigation 
in this chapter. 
 
2.1.4 Response to treatment 
The disparity in SVR rates between HIV-negative and HIV-positive patients treated with 
pegIFNα and/or ribavirin is not fully understood (Jaeckel et al, 2001; Gilleece et al, 2005; 
Serpaggi et al, 2006, Dominguez et al, 2006; Table 1.1) with only one small study (n=11) 
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reaching a sustained virological response (SVR) rate comparable with that achieved in HIV-
negative individuals (Vogel et al, 2005). Early diagnosis and treatment of HIV-infected 
patients with pegIFNα and ribavirin results in improved SVR rates [59% in acutely versus 
40% in chronically infected patients (Gilleece et al, 2005; Torriani et al, 2004)], but does not 
reach the 98% treatment success rate reported in HIV-negative individuals (Jaeckel et al, 
2001).  
 
Impaired immune control of HCV secondary to HIV-infection may result in a higher rate of 
viral evolution and the formation of multiple variants. A number of studies have been 
carried out using either clonal sequencing or heteroduplex diversity assays to assess 
variation within the HCV quasispecies and response to treatment during chronic HCV 
infection, mainly in HIV-negative populations, but also more recently in HIV-positive 
patients. Two regions of the genome have been analysed in multiple studies; the E2 HVR-1 
and the interferon sensitivity determining region (ISDR) within NS5A. 
 
Pre-treatment quasispecies complexity within the E2 HVR-1 and NS5A region is negatively 
associated with viral clearance rate and SVR during chronic HCV infection using 
heteroduplex (Shire et al, 2006) and clonal sequence analysis (Ueda et al, 2004) in both HIV-
positive and negative patients. These studies focussed primarily on genotype 1 infection. A 
recent study confirmed similarly that interferon non-responders with genotype 3 infection, 
normally associated with higher SVR rates in chronically infected patients also had evidence 
of higher viral complexity within the E2 HVR-1 (Moreau et al, 2008). Hypothetically, high 
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viral diversity may result in a higher likelihood of IFN-resistant strains within the 
quasispecies.  
A number of studies have shown that certain ISDR prototype sequences are associated with 
resistance to pegIFNα. The phenomenon has been well described in Japanese genotype 1b 
isolates (Enomoto et al, 1995; Enomoto et al, 1996) where ‘mutant type’, meaning 4 or 
more nucleotide differences between the 1b isolate and the HCV-J reference strain within 
the ISDR, are associated with a high SVR rate. A more recent analysis revealed that as few as 
2 differences from the HCV-J 1b reference sequence increase the chances of SVR with an 
odds ratio of 5.18 (Nakagawa et al, 2010).  Another study carried out in Japan used a sliding 
window approach (discussed further in Chapter 3) following a full genome analysis to 
identify a specific mutation within HCV core - the R (arginine) 70Q (glutamine) substitution, 
which was found to be strongly associated with resistance and lack of early virological 
response (EVR). The predictive value of the ISDR in European and American genotype 1b 
isolates has revealed varying results, possibly due to small study populations, but a 
metanalysis suggested that the phenomenon extended to isolates from around the globe 
(Pascu et al, 2004). A similar phenomenon has been reported also in genotype 1a infection 
(MacQuillan et al, 2004). A region upstream of the ISDR within NS5A has also been 
associated with interferon treatment response (Durante Mangoni et al, 2003) with a higher 
prevalence of mutations in responder-relapsers versus non-responders (p<0.001).    
 
The mechanism behind increased resistance to pegIFNα and ribavirin in certain HCV strains 
is not yet fully understood. Previous studies in subgenomic replicon systems revealed that 
both E2 and NS5A may inhibit the double-stranded RNA-dependent protein kinase (PKR) 
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which is induced by IFN (Gale et al 1998; Taylor et al, 1999). However, a recent publication 
making use of the JFH-1 infection system revealed that IFN strongly induces interferon 
stimulated gene mRNA transcription in HCV-infected cells, reaching higher levels than in 
uninfected cells, indicating that HCV may not in fact block IFN signalling. However, despite 
high mRNA levels, IFNα-induced, interferon stimulated protein expression is attenuated in 
HCV-infected cells in parallel with the strong phosphorylation of PKR and eIF2α (Garaigorta 
& Chisari, 2009) Thus the phenomenon of reduced interferon stimulated protein expression 
is well-described, but the mechanism remains unclear. 
 
Although the correlation between high viral diversity and low SVR rate is well described, the 
time at which the diversity reaches a level less likely to be amenable to treatment is not 
known.  It is not clear for example, if the diversity level at transmission defines the outcome, 
or if there is a gradual accumulation of mutations over time reflecting the window period 
during acute disease when the infection may be treated more easily. If transmission 
diversity is a factor, it might be expected that patients with haemophilia as a route of 
transmission would have greater diversity and lower SVR rates than intravenous drugs 
users, who in turn might have greater diversity than those with mucosal exposure through 
sexual or intranasal exposure.  
 
If the time at which the quasispecies diversity reaches a threshold level defines 
suitability/timing of treatment, this could potentially be used to target treatment 
appropriately in individual patients. 
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2.2 Hypotheses 
HCV diversification and evolution predicts the outcome of acute infection in a cohort of HIV-
infected individuals 
2.2.1 Viral diversification of HCV in HIV-positive patients during early infection determines 
the likelihood of spontaneous clearance, and 
2.2.2 Viral diversification of HCV in HIV-positive patients during early infection determines 
the likelihood of SVR following treatment with pegylated interferon alpha and 
ribavirin 
2.3 Aims 
To characterise the natural history of acute HCV in an HIV positive MSM cohort  
2.3.1 To identify the best diagnostic test for acute HCV in HIV-positive patients 
2.3.2 To characterise the viral dynamics and clinical outcomes of the acute HCV cohort, 
and 
2.3.3 To quantify viral diversity and rate of evolution of the HCV E2 HVR-1, NS5A and NS5B 
during acute infection 
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2.4 Methods  
2.4.1 Patient cohort 
A cohort of 110 patients with HIV and acute HCV (100 with chronic HIV/acute HCV and 10 
with acute HIV/acute HCV coinfection) were prospectively recruited from 2005-2010 in a 
single centre (the St Mary’s Acute HCV Cohort; Figure 2.1). Plasma and peripheral blood 
mononuclear cell (PBMC) samples were obtained prospectively at 1-3-monthly intervals. 
Stored frozen samples (taken for the routine measurement of HIV viral load between 1994 
and 2010) were also analyzed retrospectively.  
 
Informed consent in writing was obtained from each patient, and the study protocol 
conformed to the ethical guidelines of the 1975 Declaration of Helsinki. The study was 
approved by St Mary's Hospital Research Committee and ethical approval granted by the 
Riverside Research Ethics Committee (Reference number 05/Q0401/17). Patients gave 
written consent for participation in the study. 
Patients were offered 48 weeks of treatment with pegIFN and weight-based ribavirin 
(800-1200mg) 12-24 weeks following HCV diagnosis unless this was contraindicated or 
spontaneous clearance occurred.    
2.4.2 Case definition and end-points 
Acute HCV diagnosis was defined by a positive HCV RNA result by RT-PCR within 6 months of 
a preceding negative RT-PCR or antibody test.   The date of infection was estimated as the 
midpoint between the last negative and first positive test. 
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Spontaneous clearance of HCV was defined as 2 successive negative RT-PCR tests (<12IU/ml) 
3 months apart. 
Sustained virological response (SVR) was defined as a negative HCV RNA by RT-PCR 
(<12IU/ml) 24 weeks after the end of 48 weeks of treatment with pegIFNand ribavirin.  
Samples for HCV viral load and liver function (ALT, bilirubin, and albumin) were taken at 
monthly intervals for 3 months following diagnosis and at 3 monthly intervals thereafter. 
CD4 count and HIV viral load were assessed at 3 month intervals. Viral diversity within the 
E2 HVR-1, NS5A, NS5B and the 5’UTR was determined by clonal analysis at 1-3 monthly 
intervals. 
2.4.3 Storage of blood samples 
Blood samples were obtained in EDTA-containing vacutainer tubes. Plasma and PBMCs were 
separated on the day of clinic attendance and stored at -80oC and in liquid nitrogen (-180 oC) 
respectively. All samples were processed in a designated category 3 laboratory. 
2.4.4 Anti-HCV Enzyme Linked Immunosorbent Assays (ELISAs) 
Stored plasma samples were tested for the presence of antibodies to HCV core, NS3 and 
NS4 using a third generation enzyme-linked immunosorbent assay (ELISA) according to 
manufacturer's instructions (Monolisa, BioRad). A second kit designed to detect core 
antigen as well as antibodies was also used (Monolisa AgAb Ultra, Biorad). Assays were 
carried out in duplicate in a 96-well plate. Positive and negative controls were included in 
each assay. Diluent (80μl) was added to each well followed by 20μl of plasma, covered with 
cling film and incubated for 1 hour at 37oC. The film was removed and plasma in the wells 
washed 3 times with 370μl of washing solution. Conjugate solution (100μl) was then added 
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to each well and incubated at 37oC for 30 minutes. The contents of the wells were washed 4 
times, 100μl development solution added and incubated in darkness at room temperature 
for 30 minutes. Stopping solution (100μl) was added and absorbance readings were 
obtained at 450 and 620nm. A cut-off value (CO) for positive and negative samples was 
obtained according to the formula: 
CO 
                         
 
 
Borderline samples were those within 10% of the CO value. The date of infection with HCV 
was taken as the date of the first positive PCR result. The date of antibody seroconversion 
was the date of the first positive antibody result. 
 
2.4.5 Extraction of viral RNA from plasma samples 
Plasma stored at -800C was thawed and ultracentrifuged at 25,000g for 1 hour at 4oC. RNA 
was extracted using the QIAamp Viral RNA kit (Qiagen). An aliquot (140μl) of plasma was 
added to 560μl cell lysis solution (buffer AVL) containing 5.6μl carrier RNA and incubated for 
10 minutes. Ethanol (560μl) was then added and the sample applied to columns and 
centrifuged at 8,000g. Two further centrifugation steps were carried out using 500μl of 
wash buffers AW1 and AW2. Finally, extracted viral RNA was eluted in 60μl of buffer AVE 
(RNase-free water containing 0.04% sodium azide). 
2.4.6 Quantitative RT-PCR assays 
Quantitative HCV RNA levels were measured using automated real-time RT-PCR (Abbott) in 
the clinical virology laboratory at St Mary's Hospital. Backdated plasma samples were 
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diluted 1:10 in PBS prior to analysis. The ABBOTT Real Time HCV assay is an in vitro RT-PCR 
kit for the quantitation of HCV RNA in human serum and plasma from HCV infected 
individuals. An RNA sequence that is unrelated to the HCV target sequence is simultaneously 
amplified by RT-PCR and serves as an internal control (IC) to demonstrate that the process 
has proceeded correctly. The target sequence for the Abbott Real Time HCV assay is in the 5′ 
UTR of the HCV genome, which is highly conserved. The primers are designed to hybridise to 
the 5′ UTR region with the fewest possible mismatches among HCV genotypes 1–6. The limit 
of detection of the assay is 12 IU/mL (48 copies/mL).   
 
2.4.7 Amplification of the HCV 5’Untranslated Region (5'UTR) 
Following clinical diagnosis of acute HCV, stored plasma samples (obtained for HIV viral load 
testing) were retrospectively tested for the presence of HCV RNA using nested RT-PCR with 
primers 26, 27, 28 and 29 (Table 2.1) from the 5' UTR. This region was chosen as it is one of 
the most conserved between isolates.  
 
Table 2.1: Primers used for RT-PCR amplification of the 5'UTR 
Outer (5'-3') Inner (5'-3') 
26 GTCTAGCCATGGCGTTAG 28 GTGTCGTGCAGCCTCCAG 
27 GCACGGTCTACGAGACCT 29 GGGGCACTCGCAAGCACC 
   
First-round PCR reactions were carried out using a OneStep RT-PCR kit (Qiagen) with a 
reaction mix as follows: 2-10μl of template RNA, 10μl of RT-PCR buffer (final MgCl2 
concentration of 2.5mM), 10μl of Q solution, 2μl of dNTP Mix (containing 10 mM of each 
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dNTP), 2μl of enzyme mix, 1μl of each primer (0.3μM/reaction) and RNase-free water to a 
final total volume of 50μl. The PCR cycling conditions were as follows: Reverse transcription 
50oC 30 minutes; reverse transcriptase inactivation 95oC 15min; 40 cycles of denaturation at 
94oC for 30seconds, annealing at 55-60oC for 30second and elongation at 72oC for 
30seconds. A final extension was carried out for 10 minutes at 72oC. Second round PCR was 
carried out using a PCR mastermix (Megamix, Helena Biosciences). An aliquot (10μl) of 
round 1 PCR product was added to 40μl mastermix and cycled as above. 
An end-point dilution assay was carried out to estimate the sensitivity of the 5’UTR assay.  
 
2.4.8 Amplification of the HCV Hypervariable region-1 (HVR-1)  
Amplification of the HCV E2 HVR-1 was optimised using nested PCR with genotype-specific 
primers (Table 2.2) and PCR cycling conditions, as described above.  
 
Table 2.2: Primers used in RT-PCR for amplification of the E2 HVR-1 
Outer (5'-3') Inner (5'-3') 
 E4 GGTGTGGAGGGAGTCATTGCAGTT E3 
 
 GGGCAGTGCTGTTGATGT 
 E5 
 
GCTTGGGATATGATGATGAACTGGTC E3 
 
 AGGCCGTGCTATTGATGT 
 E6  
 
CGCCACTGGACCACCCAGGATTGCAATTGTTC E3  GGGCAGTCCTATTTATATGCC 
 E7 
 
CCCAGTGTTTAAGCTGTCATTGC E1U 
 
GGGATATGATGATGAACTGG 
 214 CACTGGGGAGTCCTGGCGGGC 
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PCR was carried out using genotype-dependent primers, as shown above. These were 
adapted from previously published primers (Gaud et al 2003) by aligning with genotype 1a, 
4d and 3a isolates and selecting a 17-28bp region with a GC content of 50-60% and similar 
melting temperatures (Tm; 55-80oC) using Primalign (http://hcv.lanl.gov/content/hcv-
db/PRIMALIGN/PRIME.html). Each primer name is followed by the genotype it may be used 
to amplify in parentheses. Primer design was carried out using the primer design 
programme Primer3 available at http://primer3.sourceforge.net/   which predicts potential 
problems with secondary structures such as hairpin formation which may reduce 
subsequent amplification.  
 
2.4.9 Amplification of NS5A by RT-PCR 
Amplification of NS5A was optimised using semi-nested PCR with primers (Table 2.3) and 
PCR cycling conditions as described above. Primers were adapted for use from previously 
published primer sequences designed for genotype 1b HCV (Durante Mangoni et al 2003) by 
aligning with genotype 1a, 4d and 3a isolates, as above.  
 
Table 2.3: Primers used for amplification of NS5A 
Outer (5'-3') Inner (5'-3') 
378 
 
GTGTTGACGTCCATGCTCACTG 379 
 
CCCATATAACAGCAGAGGCGGC 
382 
 
GTTGCCGCCCATCTCCTGCCTCC 382 
 
GTTGCCGCCCATCTCCTGCCTCC 
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2.4.10 Amplification of NS5B by nested PCR 
Amplification of a 376bp region of NS5B was optimised using semi-nested PCR with 
degenerate primers (Table 2.4; Enomoto et al, 1990). The PCR reaction was carried out using 
a blend of Taq polymerase and the proof-reading enzyme Tgo polymerase as part of the 
Titan One-Step PCR Kit (Roche). Reaction mixes were prepared on ice.  Master mix 1 
consisted of 10.5μl sterile water, 4μl dNTP, 2.5μl DTT solution, 1μl (5U) RNase Inhibitor, 1μl 
primers (0.4 μM) and 5μl RNA and was added to master Mix 2 consisting of 14μl water, 10μl 
5x RT-PCR buffer and 1μl of enzyme mix. Reverse transcription was carried out at 50°C in a 
thermocycler. 40 cycles of denaturation at 94°C for 2 min, annealing at 50-72°C for 30 s and 
elongation at 68°C for 1 minute. PCR samples were then analysed on a 2% agarose gel. 
Table 2.4: Primers used for amplification of NS5B 
Outer (5'-3') Inner (5'-3') 
ENO2 
 
TGGGSTTYKCSTATGAYACYCGMTGYT
TTGA 
NS5S3 
 
TATGATACCCGCTGCTTTGACTCCAC 
ENO4 
 
ARTACCTRGTCATAGCCTCCGTGAA NS5A5 GTCATAGCCTCCGTGAAGGCTC 
 
2.4.11 Gel Electrophoresis and DNA extraction 
PCR products were run on a 1% agarose gel containing ethidium bromide with lane markers 
and a 100bp ladder (Promega). DNA bands visualised under ultra-violet light and bands of 
appropriate size were cut out using a clean scalpel blade.  These bands were purified to 
remove extraneous products by column centrifugation using a QIAquick gel extraction kit 
(Qiagen), and resuspended in 30μl of dH20. 
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2.4.12 Cloning 
Purified PCR products were ligated into a plasmid vector (pCR®4-TOPO®; Appendix 1) using a 
TOPO-TA Cloning kit, Invitrogen). An aliquot (2-4μl) of PCR product was added to 0.5-1μl of 
salt solution (1.2M NaCl plus 0.06M MgCl2) and 0.75-1μl of pCR®4-TOPO® vector and 
incubated at room temperature for 5-30 minutes.  Ligation of the PCR product disrupts 
expression of the lethal Escherichia coli suicide gene, ccdB permitting growth of only 
positive colonies upon transformation in TOP10 or Mach-1 cells (Invitrogen).   
 
The cloning reaction (2μl) was added to a vial of TOP10 or Mach-1 E. coli cells and incubated 
on ice for 5-30 minutes. The cells were then heat-shocked for 30 seconds at 42°C in a water 
bath and transferred back to ice. A volume (250μl) of room temperature S.O.C. medium (2% 
tryptone, 0.5% yeast extract 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 
mM glucose) was added to each vial, capped and shaken horizontally (250rpm) at 37°C for 
1-2 hours. An aliquot of 30-100μl from each transformation was spread on a pre-warmed 
agar plate containing 100μg/ml ampicillin or 50 μg/ml kanamycin and incubated overnight 
at 37°C. Incorporation of the insert into the plasmid disrupts transcription of a suicide gene, 
enabling selection of clones containing the product. 
 
2.4.13 Preparation of DNA following clonal amplification 
Twenty bacterial colonies per plate were selected and transferred to 10ml Falcon tubes 
containing 2ml of LB medium (10g tryptone, 5g yeast extract, 10g NaCl  in 800ml of distilled 
water) and 100g/ml ampicillin. These were cultured in a horizontal shaker (250rpm) 
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overnight at 37 oC. Bacterial cultures were transferred to 1.5ml Eppendorf tubes or a 96-well 
plate and centrifuged for 1 minute at 8,000g. The supernatant was removed and cells 
resuspended. DNA extraction was carried out using a Qiagen miniprep kit. Plasmid DNA was 
resuspended in 30μl of dH20. Spectrophotometry was carried out at an absorbance (A) of 
260nm in order to quantitate the concentration of DNA. The ratio of values obtained at 
A260/A280 was calculated to estimate the purity of DNA produced. Successful 
transformation was confirmed by digestion using the enzyme EcoR1, which cuts the vector 
at two sites located on either side of the insert, generating 2 linear strands of DNA. Digested 
products were run on a 1-2% agarose gel stained with ethidium bromide and visualised 
under ultraviolet light. 
 
2.4.14 Sequencing 
Envelope products were sequenced using the ABI BigDye Terminator v3.0 system (Applied 
Biosciences, UK). The reaction mix consisted of an 8μl reaction mix, 1μl 3.2μM sequencing 
primer (Table 2.5) with 500ng of DNA template. dH2O was added to make a total volume of 
20μl. Cycling conditions were as follows: 25 cycles of 10 sec at 96oC, 15 sec at 50oC  and 4 
min at 60oC. 2μl of 3M sodium acetate and 50μl of 95% ethanol were added to each sample 
and left on ice for 30 minutes. The sample was then centrifuged at 13,000g for 30 min. The 
supernatant was removed and a further 200μl 70% ethanol added. The samples were 
centrifuged for 5 min at 13,000g, the supernatant aspirated and left to air dry for 10 min.  
T7, T3, M13 forward (M13F) and M13 reverse (M13R) primers were tested; these bind 
specifically to the vector, allowing the insert to be sequenced in both directions.  M13F was 
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associated with superior results and was used for the majority of experiments due to a 
longer distance from the DNA insert sequence. 
Table 2.5: Sequencing primers 
Forward (5'-3') Reverse (5'-3') 
T3 ATTAACCCTCACTAAAGGGA T7 TAATACGACTCACTATAGGG 
M13F GTAAAACGACGGCCAG M13R  CAGGAAACAGCTATGAC 
 
2.4.15 Estimated PCR error rate 
Universal precautions to avoid PCR contamination were followed at all times. PCR mixes 
were prepared in an allocated room separate from clinical samples. In order to confirm the 
possibility of multiple superinfection events and to rule out PCR contamination error, PCR 
amplification of the HCV NS5B region (in addition to E2 HVR-1 amplification) was carried 
out.    
An estimate of PCR error rate was carried out using the QIAgen one-step PCR kit and 
MegaMix Blue PCR kit (Helena Biosciences), containing Thermus aquaticus (Taq) DNA 
polymerase. In order to calculate the actual PCR and cloning error rate, a subcloning 
experiment was carried out. Firstly, the 5’UTR was amplified by nested PCR using primers 
25, 26, 27 and 28 (Table 2.1). The PCR product was then inserted into the pCR®4-
TOPO®vector (Invitrogen) and amplified. One colony was picked and grown in LB medium 
containing ampicillin (50µg/ml). Following centrifugation, the DNA was extracted by column 
centrifugation (QIAgen miniprep kit). An end-point dilution was carried out and 10 copies of 
cDNA product was reinserted into the vector in order to avoid PCR saturation. 175 colonies 
were picked, grown in LB medium, and DNA extracted following centrifugation.  
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Recombination of DNA may occur in vitro during PCR amplification. In order to assess the 
presence of recombination in samples, similarity plots and bootscanning was carried out 
using Simplot and PHYLIP software. In order to distinguish between recombination occurring 
in vitro and in vivo, end-point dilution PCR is necessary in order to amplify single DNA 
molecules. In order to minimise the necessity for multiple PCR reactions, the presence of 
possible recombination was assessed as above for all cloned sequences from each PCR 
reaction. 
 
2.4.16 Sequence analyses and construction of phylogenetic trees 
Sequences were aligned using Clustal W. Phylogenetic trees were constructed with MEGA 
4.0 using the neighbour-joining method and Kimura two-parameter distance for all 
substitutions, and the inferred phylogenies were tested with 1,000 bootstrap replications.  
Genetic diversity was calculated using the Hamming distance, which is defined as the 
number of amino acid differences between two sequences using the formula (1 - s) x 100, 
where s is the fraction of shared sites in two aligned nucleotide sequences. Genetic distance 
was calculated as the mean percentage difference between all samples at any time point. 
Mean intra-strain corrected genetic distance and Hamming distances were also calculated 
(separate strains were defined as those originating from distinct branches following 
phylogenetic analysis with >10% difference from other strains derived from the same 
patient). dN/dS ratios were calculated using MEGA 4.0.  dN/dS values >1 were considered as 
evidence of positive selection. 
75 
 
 
2.4.17 Statistical analyses 
Univariate logistic regression, students t-test, Mann-Whitney, Chi square and Fisher exact 
tests were used to analyze the significance of observations using the statistical computer 
package STATA 10.0.  Odds ratios were calculated with 95% confidence intervals. P values of 
less than or equal to 0.05 were considered to be statistically significant. 
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2.5 Results 
2.5.1 Patient cohort diagnosis, treatment and follow-up 
Patients were recruited following referral to a dedicated acute HCV clinic on the basis of a 
new positive HCV antibody or PCR test. The diagnosis was confirmed by retrospective PCR 
testing of stored plasma obtained for routine measurement of HIV viral load in the clinical 
laboratory as described below and the date of infection was estimated as the midpoint 
between the last negative and first positive PCR test. Patients were followed up at 4 weekly 
intervals for 3 months and 3-monthly thereafter. Treatment was offered at 3-6 months 
following diagnosis unless contraindicated (Figure 2.1). 
 
2.5.2 Diagnosis of acute HCV   
Three tests were assessed and compared with RT-PCR for the diagnosis of acute HCV on a 
subset of 43 patients who had had frequent plasma sampling prior to inclusion in the study, 
allowing retrospective dating of infection by RT-PCR; ALT (ALT), the Monolisa HCV Antibody 
assay and the Monolisa HCV Antigen–Antibody Ultra assay. In this group, the median HCV 
viral load was 1 836 595 IU/ml. A variety of HCV genotypes were identified; 1a in 75%, 4d in 
17.5%, 1b in2.5% and 3a in 2.5% while 2.5% were coinfected with genotypes 1a and 4d. The 
median CD4 cell count at the time of HCV acquisition was 570 cells/μl. The median nadir 
CD4 cell count was 325 cells/μl. Those patients who spontaneously cleared infection had a 
trend towards a higher nadir CD4 cell count (median 440 cells/μl versus median 320 cells/μl; 
P=0.07). 
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2.5.2.1 Seroconversion time 
The median time from HCV RNA detection by PCR to the development of anti-HCV 
antibodies was estimated to be 91 days (range 0–1206 days; Thomson et al, 2009). An 
analysis of seroconversion time in a subset of patients where the last negative and first 
positive RT–PCR were less than 30 days apart (n=8) revealed a median seroconversion time 
of 158 days (range 47–209 days). Two patients (4.7%) developed anti-HCV antibodies more 
than 1 year after the initial infection, one of whom did not become antibody positive until 
after 3 years. Seroconversion in one of these patients was associated with a superinfection 
with genotype 1a virus on a background of genotype 4 infection. No correlation between 
CD4 cell count at the time of HCV diagnosis and seroconversion time was found (P=0.96) 
although a weak negative association between nadir CD4 cell count and seroconversion 
time was observed that did not reach statistical significance (p=0.09). Seroconversion time 
in spontaneous clearers and progressors was not significantly different (P=0.88). However, 
seroconversion time was significantly longer in patients with a low HCV viral load (P=0.04) or 
low ALT (P=0.0005) at the time of the first positive PCR. A low ALT level at 3 months into 
HCV infection was also weakly associated with prolonged seroconversion time (P=0.08). The 
early development of anti-HCV antibodies did not correlate with patient age (P=0.78), HCV 
genotype (P=0.51) or HIV viral load (P=0.22). 
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Figure 2.2 Time to seroconversion 
 
Figure 2.2: Seroconversion time (days) was calculated as the time from the first PCR positive sample to the first 
positive antibody in 43 patients (range 0–1206 days). Four patients (patients 30, 36, 39 and 40 shown in white) did 
not produce an antibody by 133, 183, 205 and 218 days of follow-up. Seven patients (asterisked) spontaneously 
cleared the infection, two of whom did not produce an antibody response. 
 
 
2.5.2.2 Diagnostic testing 
The sensitivity of antibody, antibody-antigen and ALT testing was assessed at 1–3 monthly time-
points.  
 
On first amplification of HCV, only 25% of patients were serologically positive. Antibody 
detection rose from 63% by 3 months to 87% at 6 months, 90% at 9 months and 95% by 12 
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months (Figure 2.2). A combined assay detected HCV antigen–antibody in 52% of HCV RNA 
positive baseline samples (Nastouli et al, 2009). In 18% cases the assay gave an equivocal 
result and a negative result was obtained in 32%. In practice, equivocal results would trigger 
HCV RNA testing and can, therefore, increase the overall sensitivity of the assay. 
 
The median ALT at the time of the first positive PCR test (baseline) was 65 IU/ml (normal 
range <40 IU/ml). Elevated ALT levels were present in 76% of patients at baseline and 74% 
at 3 months. Most patients (88%) had an elevated ALT either at baseline or 3 months post 
infection. An elevated ALT level was significantly more sensitive than antibody testing 
(P=0.017). When a lower normal value of less than 30 IU/ml was used (recently proposed as 
normal in men (Prati et al, 2002)), the sensitivity of ALT testing increased to 79% at baseline 
and 82% at 3 months. As many as 93% of patients had an ALT level higher than 30 IU/ml at 
either baseline or 3 months postinfection.  
 
2.5.3 Viral load dynamics during early HCV infection 
Sequential viral load (VL) measurements were analysed in the whole cohort (n=-110) 
revealing 3 patterns of infection (Figure 2.3); progression to chronicity with an initial peak 
viraemia and chronic plateau viraemia (PV) phase (48%), fluctuating viraemia (FV) defined as 
a fall followed by a rise in VL of >1 log10 (38%) and spontaneous clearance (SC; 14%).   
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Figure 2.3 : Median HCV viral load, bilirubin and ALT levels over time in a) the whole cohort and b) 
representative individual patients 
 
a) Median HCV viral load, bilirubin and ALT levels over time in the whole cohort 
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b) Median HCV viral load, bilirubin and ALT levels over time in representative individual patients 
 
 
 
  Figure 2.3: Longitudinal HCV viral load measurements taken prior to treatment revealed 3 patterns of 
infection: spontaneous clearance (SC;14%; red) and 2 patterns of progression (86%); peak and plateau 
(PV;48%; black) or fluctuating viremia (FV;38%; blue) defined as a viral load peak followed by a decline 
(>1log10) and subsequent rise in viremia (>1log10).  Group data is shown in panel a while representative 
individual patients are shown in panel b. 
 
Figure 2.3 continued 
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 Spontaneous clearance was associated with an initial increase followed by a rapid fall in VL 
(1.7 log10 drop within 100 days and 4.03 log10 drop within 200 days; Table 2.6) leading to 
clearance at a median of 108 days (95% CI: 38, 170 days).  Thirteen FV patients became 
transiently PCR negative, but took on average 154 days to reach negativity (95% CI=113, 323 
days; p=0.04) and 129 versus 27 days (p=0.009) to achieve a 1.7 log10 drop in VL.  
 
Table 2.6: Sequential viral load measurements in untreated spontaneous clearers and 
progressors  
 
 Spontaneous  
clearers  
(95% CI) 
Progressors 
(plateau) 
(95% CI) 
Progressors 
(fluctuating) 
(95% CI) 
Odds ratio 
 
(95% CI) 
p value 
      
Maximum HCV VL drop 100  
days from first positive PCRa 
1.70       
(1.39, 5.87) 
 
0.001  
(-0.47, 0.21)b 
0.57       
(0.25, 0.96) 
 2.76 
(1.55, 4.90) 
 
0.001* 
      
Maximum HCV VL drop 200  
days from first positive PCR 
4.03 
(1.70, 7.32) 
 
0.13 
(-0.22, 0.34)b  
0.85  
(0 .45, 1.77) 
2.48 
(1.56,  3.97) 
<0.0001* 
 
2.5.4 Cohort characteristics 
Demographic and clinical parameters are shown in Table 2.7.  Early infection in progressors 
(PV and FV groups) and spontaneous clearers (SC) was associated with a rise in ALT and 
bilirubin. The peak SC bilirubin was significantly higher than in the progressor groups; in 
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particular, a peak bilirubin level of ≥40 µmol/l was associated with a hazard ratio of 
spontaneous clearance of 5.04. Elevation in bilirubin levels was temporally associated with a 
fall in HCV VL (Figure 2.3). Elevated ALT was also associated with spontaneous clearance 
(ALT ≥1000 IU/ml; HR=2.62; Table 2.7). Low peak and baseline HCV VL were associated with 
spontaneous clearance as was a baseline CD4 count of ≥650x106/l. Age, HIV VL and the use 
of HAART were not associated with outcome. All patients were men-who-have sex-with-
men and had had recent unprotected sex recorded in the medical notes while 31% also  
admitted to the use of intravenous or intramuscular drugs. 
 
 
 
 
 
 
Clinical 
measure 
(units, 
normal 
range) 
Spontaneous 
clearance  
(median, 
95% CI) 
Progression Range Hazard 
ratio  
(95% 
CI) 
p value† 
Plateau 
viraemia 
(median,95% 
CI) 
Fluctuating 
viraemia 
(median, 
95% CI) 
Number 15 (14%) 53 (48%) 42 (38%) - - - 
Age  
(years) 
43 
(32, 45) 
39 
(37, 42) 
39 
(37, 40) 
HR represents 
change in 
hazard per 
year of age 
1.00  
(0.94, 
1.06) 
1.00 
Baseline 
HCV VL log10 
(IU/ml) 
6.42 
(1.70, 7.37) 
6.25        
(5.71, 6.44) 
5.89 
(5.06, 
6.13) 
 
HR represents 
change in 
hazard per 
log10 change 
in VL 
0.75  
(0.55, 
1.01) 
0.06 
 
Peak HCV VL  
log10 (IU/ml) 
6.42         
(1.70, 7.37) 
6.52         
(6.36, 6.88) 
6.21 
(5.87, 
6.72) 
0.61  
(0.46, 
0.80) 
<0.0001** 
HIV VL 
(copies/ml) 
<50 
(<50, 7044) 
<50               
(<50, 1185) 
87 
(<50, 
6847) 
1.00  
(1.00, 
1.00) 
0.40 
Table 2.7: Clinical measures and outcome (spontaneous clearance versus progression) 
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Clinical 
measure 
(units, normal 
range) 
Spontaneous 
clearance  
(median, 
95% CI) 
Progression Range Hazard 
ratio  
(95% CI) 
p  
value† 
Plateau 
viraemia 
(median, 
95% CI) 
Fluctuating 
viraemia 
(median, 
95% CI) 
Elevated 
bilirubin 
(0-17 µmol/l) 
30 
(12, 60) 
16 
(14, 19)  
14 
(12, 17) 
<20                 
20-40             
≥40                 
1a 
1.64 (0.48, 
5.6) 
5.04 (1.60, 
15.92) 
 
0.43 
0.006** 
Peak ALT  
(0-40 IU/l) 
340 
(127,  1814) 
308              
(204, 420) 
500 
(316, 659) 
<1000            
 ≥1000            
1a 
2.62  (1.01-
6.80) 
 
0.048* 
 
 
CD4 count  
(300-1400 
x106/l) 
630         
(484,   
854) 
510         
(439, 640) 
520         
(455,  617) 
<650   
≥650   
1a 
2.66 (1.02-
6.91) 
 
0.045* 
Nadir CD4  
(300-1400 
x106/l) 
340              
(200, 519) 
310             
(280, 350) 
315          
(270,  367) 
≥200          
<200  
1a 
1.51 (0.52-
4.35) 
 
0.45  
Transmission 
 
     IDUb 3/13  
(23%) 
13/44  
(30%) 
13/36  
(36%) 
All patients 
were men-
who-have 
sex-with-
men and 
had had 
recent 
unprotected 
sex. 
1.63 
(0.27, 
2.75) 
0.36 
     INDUc 9/12  
(75%) 
31/42  
(74%)  
27/34  
(79%) 
0.92  
(0.25, 
3.46) 
0.94 
     Sexual   14/14  
(100%) 
46/46  
(100%) 
39/39  
(100%) 
 - 
 
 
- 
HAART 11/15  
(73%) 
31/53  
(58%) 
23/42  
(55%) 
 1.63 
(0.57, 
4.70) 
0.36 
† p values shown represent all progressors (FV and PV) versus clearer (SC) groups 
* Significant p value<0.05 
a Median values are given for all variables 
b Intravenous, intramuscular or subcutaneous drug use (crystal methamphetamine, cocaine, anabolic steroids, heroin) 
c Fisher's exact test  
d Intranasal drug use (ketamine, cocaine) 
 
Table 2.7 continued 
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2.5.5 HVR-1 sequence analysis 
2.5.5.1 Cross-sectional phylogenetic analysis of the HIV-positive MSM 
population with acute HCV 
Phylogenetic analysis of majority quasispecies compared with reference sequences revealed 
several monophyletic clusters of infection within genotype 1a (77%), 4d (15%), 3a (7%) and 
1b (4%) indicating several introductions of the virus into the men-who-have-sex-with-men 
(MSM) population (Figure 2.4). Six percent were infected with 2 genotypes and 2% (a 
transmitting couple) had 3 genotypes (1a, 3a and 4d).   
 
Figure 2.4 Multiple strains of HCV are circulating in the HIV-positive MSM population 
 
Figure 2.4 A neighbour-joined phylogenetic tree was constructed (using MEGA 4.0 and Figtree; Kimura 2-
parameter method) with patient majority quasispecies sequences (n=97; coloured lines) and reference 
sequences (n=212; black lines) obtained from the Los Alamos database. This revealed several monophyletic 
clusters of infection suggesting several introductions into the MSM population. The majority of infections were 
genotype 1a but genotypes 1b, 3a and 4d were also identified. 
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2.5.5.2 E2 HVR-1 sequence evolution within patients and prediction of 
spontaneous clearance 
In order to determine which phylogenetic factors predicted spontaneous clearance, 
Hamming distance (diversity), number of quasispecies and dN/dS ratios were calculated in 
50 patients (40 progressors and 10 clearers) at multiple (median=3) time points. Initially, 
genetic diversity was noted to vary considerably over time in all groups (Figure 2.5) but did 
not correlate with VL.   
 
Figure 2.5: Genetic diversity within HVR-1 (uncorrected) over time 
 
 
Figure 2.5 Cumulative genetic distance was calculated for each group of patients (plateau 
progressors; black, fluctuating viraemia; blue, spontaneous clearers; red) at multiple time points 
(range 0-450 days) showing marked non-linear variation over time. 
 
In order to investigate if this variation was the result of superinfection events, neighbour-
joining phylogenetic analyses of all longitudinally acquired E2 HVR-1 sequences obtained 
from the first 50 recruited patients (n=2295) were carried out, revealing 3 groups of patients 
(Figure 2.6); those who spontaneously cleared infection (n=10; 20%), those who progressed 
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to chronicity with increasing quasispecies diversity but no evidence of superinfection (n=20; 
40%) and those who progressed to chronicity with evidence of superinfection events (n=20; 
40%). Superinfecting strains were evident both of the same genotype (30%) and with new 
genotypes (10%). A gradual increase in genetic diversity can be seen in the illustrated PV 
and FV progressor patients, while clones derived from the spontaneous clearer reveal a 
narrower repertoire. A single case of possible HCV reactivation is shown in Figure 2.6d. The 
patient acquired acute HCV following an episode of anonymous unprotected sex and was 
treated with 48 weeks of pegIFNα and ribavirin, following which he had an SVR. One year 
later, he developed a rapid decrease in CD4 count (nadir 106x106/l) and was hospitalised 
with Pneumocystis jeroveci pneumonia. During this time, his ALT became elevated and HCV 
RNA was once again detected in his blood. He denied any risk factors for reacquisition of 
HCV. Branches derived from patient HVR-1 sequences (n=56) are coloured in filled green 
(baseline sample) and open green (3 years later). These samples derive from the same 
lineage. A paraffin-embedded liver biopsy taken at the time of hospital admission and 
PBMCs were later examined for compartmentalisation of HCV (Chapter 3). 
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Figure 2.6: Patterns of acute HCV based on phylogenetic analysis a). Spontaneous clearance, b) 
Progression to chronicity (PV patient) c) Superinfection (FV patient) and d) Reactivation 
 
  c) Superinfection (FV patient)  d) Reactivation of HCV 
       
  
Spontaneous 
clearance 
Progression 
to chronicity 
(PV patient) 
Figure 2.6 Circular neighbour-
joined phylogenetic tree analysis 
(Kimura 2-parameter model) of 
305 HVR-1 sequences derived 
from 10 representative patients 
at 2-4 time points. Clones 
derived from each patient are 
given a different colour and filled 
circles represent time point 1, 
clear circles time point 2, filled 
triangles time point 3 and clear 
triangles time point 4. Bootstrap 
values greater than 70% are 
shown. 2.6a OTUs from clonal 
sequences derived from two 
timepoints in a patient with 
spontaneous clearance are 
highlighted in red. 2.6b OTUs 
from clonal sequences derived 
from a patient with plateau 
viraemia at 4 timepoints are 
highlighted in black. 2.6c A 
patient with evidence of 
superinfection (blue)  is 
highlighted. Clones derived from 
timepoints 1, 2 and 3 (filled 
circles, clear circles and filled 
triangles respectively) are 
derived from the same branch 
on the phylogenetic tree. 
Sequences from time point 4 
(clear triangles, red brackets) 
consist of a dominant 
superinfecting strain (one clone 
related to the previous lineage is 
also present). This patient had a 
recrudescent viral load, with a 
negative HCV PCR (limit of 
detection=12 IU/ml) between 
time points 3 and 4.  2.6d A case 
of probable HCV reactivation is 
shown. 
a) 
 
b) 
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In order to assess the role of positive selection and viral variation over time, intrastrain 
calculations of genetic diversity and dN/dS ratio were used for patients found to have 
multiple strains of infection. Following this correction, diversity and dN/dS ratios increased 
gradually with time in progressors, but decreased in clearers (Figure 2.7, Table 2.8). Both 
progressor groups were combined in order to assess measures of genetic diversity 
compared with SC patients to see if they had predictive value which might have potential 
clinical value (Table 2.8). While baseline measures of diversity were not significantly 
different in progressors (FV and PV groups combined) versus SC patients (baseline Hamming 
distance 0.64 versus 0.39, p=0.38), by 150 days, evidence of higher diversity in the 
progressors was apparent (2.045 versus 0.03; p=0.02) with a higher dN/dS ratio in the 
progressor group indicating positive selection (dN/dS ratio 1.02 versus 0.17; p=0.03). The 
number of quasispecies, genetic distance, Hamming distance and dNdS ratios were not 
significantly different between PV and FV progressor groups. However, differences were 
observed when FV patients were divided into those with a single-strain infection and those 
with evidence of superinfection based on longitudinal clonal sequence analysis. 
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Figure 2.7: Genetic variation within E2 HVR-1 over time by group 
 
Figure 2.7 Viral load and measures of genetic diversity; genetic distance, Hamming distance and dN/dS ratios 
are plotted over time in each patient group (plateau progressors; black, fluctuating viraemia; blue, 
spontaneous clearers; red). 
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 Table 2.8: Viral sequence analyses and predictors of spontaneous clearance 
 
 Clearers 
 
(95% CI) 
All progressors 
FV + PV  
(95% CI) 
p value 
Number 10 40 - 
Baseline  quasispecies 3 
(2, 5) 
4  
(3, 6) 
0.21 
Cumulative Quasispecies  
(2 samples taken <150 days apart) 
7 
(7,8) 
9 
(8, 12) 
0.24 
Baseline Hamming distance 0.39 
(0.22, 0.92) 
0.64  
(0.36, 2.97) 
0.38 
Cumulative Hamming distance  
(2 samples taken <150 days apart) 
0.03 
(0, 0.06) 
2.045 
(0.81, 10.47) 
0.02* 
Baseline HVR-1 dN/dS  0 
(0, 0.325) 
0.28 
(0, 0.95) 
0.18 
Cumulative HVR-1 dN/dS 
(2 samples taken <150 days apart) 
0.17 
(0, 0.35) 
1.02 
(0.71, 1.84) 
0.03* 
 
 
Fluctuating Viraemia 
Patients with a fluctuating VL were more likely to have evidence of superinfecting strains 
than those with plateau persistence (63% versus 29% p=0.04; Figure 2.6). However, not all 
FV patients had evidence of superinfection. Amongst those with single strain infection, 
persons with recrudescent viraemia had similar dN/dS ratios at baseline but higher 
cumulative ratios following a second sample than plateau progressors (1.78 versus 0.76; 
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p=0.02). At baseline, those with single strain recrudescent viraemia had higher viral diversity 
(Hamming distance 2.84 versus 0.49; p=0.04). Peak bilirubin, ALT and number of 
quasispecies did not differ between these groups. One patient showed evidence of 
reactivation of HCV 2 years after successful treatment (Figure 2.6d). 
 
2.5.5.3 E2 HVR-1 sequence evolution and prediction of SVR 
 
Thirty-two patients completed treatment with 48 weeks of IFNα and ribavirin within the 
study period (Figure 2.1). Twenty-one of these (70%) achieved an SVR. We analyzed the 
same clinical, virological and phylogenetic variables as above in relation to response to 
therapy (Table 2.9).  Clinical parameters did not significantly differ between groups and pre-
treatment viral loads were not significantly different. However, the diversity (Hamming 
distance) at baseline and within 150 days from infection was significantly lower in those 
who achieved an SVR (p=0.008 and 0.004 respectively). The E2 HVR-1 dN/dS ratio did not 
differ at baseline, but was subsequently higher in those who did not respond to treatment 
(p=0.007).  
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Table 2.9:  Viral sequence analyses and predictors of SVR 
 SVR 
(95% CI) 
No SVR 
(95% CI) 
p value 
Number 14 (70%) 6 (30%) - 
Baseline quasispecies 3 
(2, 5) 
4  
(3, 11) 
0.23 
Cumulative Quasispecies  
(2 samples taken <150 days apart) 
8 
(6, 12) 
9 
(8, 9) 
 0.63 
Baseline Hamming Distance 0.44         
(0.07,  0.59) 
4.56 
(1.88, 15.50)  
0.008* 
Cumulative Hamming distance  
(2 samples taken <150 days apart) 
2.05         
(0.70, 12.61) 
7.815  
(0.4, 21.5) 
0.004* 
HVR-1 dN/dS baseline 0.26 
(0-1.04) 
0.28 
(0-5) 
0.77 
Cumulative HVR-1 dN/dS  
(2 samples taken <150 days apart) 
0.76 
(0.35-0.99) 
4.76 
(4.3-6.5) 
0.007* 
Baseline VL (log10IU/ml) 6.17 5.83 0.64 
Week 4 drop (log10IU/ml) 3.78 0.63 0.24 
Week 12 drop (log10IU/ml) 6.17 0.04 0.01* 
95 
 
2.5.6 NS5B sequence analysis 
In order to confirm the results found following amplification of the E2 HVR-1, amplification 
of NS5B was carried out in 12 patients at 2 time points  (11 clones/patient/timepoint=total 
274 sequences). The mean genetic distance between all strains using NS5B was lower than 
that of the HVR-1 (0.14 versus 0.25; p=0.01).  
 
The median genetic distance within patients with spontaneous clearance was lower than 
progressor patients but did not reach statistical significance (0.009 versus 0.015; p=0.59). 
Similarly the dN/dS ratio was higher in progressors than clearers (0.22 versus 0.04; p=0.59).  
 
Neighbour-joined phylogenetic trees were next constructed using sequences derived from 6 
patients at 2 time points following amplification of HVR-1 and NS5B. The genetic distance 
between NS5B sequences was 14% and HVR-1 sequences was 25% and thus branches were 
shorter on the tree constructed using NS5B sequences. However, trees derived from 
sequences obtained at the same time points showed similar results on both trees.  
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Figure 2.8: Phylogenetic tree using HVR-1 and NS5B sequences derived from the same time points 
in a) a patient with evidence of 3 circulating strains at baseline and b) a patient with similar strains 
at 2 time points 
 
a) HVR-1      NS5B 
 
b) HVR-1      NS5B 
 
Figure 2.8: Bootstrap scores >70% are indicated for the relevant branches. Figure 2.8a shows branches derived 
from a patient with 2 genotypes at baseline (genotype 1a in red; genotype 4d in blue). Figure 2.8b shows 
samples taken at baseline (filled circles) and 3 months later (open circles). 
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2.5.7 NS5A sequence analysis 
A region of NS5A (including the ISDR) was amplified in 20 patients (mean =16 
sequences/patient= total 314 sequences).  The mean genetic distance between all strains 
using NS5A was 0.17. However, this variation was accounted for by a large amount of 
variation within 3 patients. It did not vary significantly within patient groups over time 
(0.002 in progressors versus 0.005 in clearers; p=0.63). The median dN/dS ratio was 0 in 
both groups suggesting that the region is not under positive selection during early infection.  
 
Figure 2.9: Phylogenetic tree using NS5A sequences derived from 20 patients at 2 timepoints 
a)       b) 
  
Figure 2.9: A neighbour-joined phylogenetic tree was constructed using MEGA 4.0 and the Kimura 2 
parameter. a) Sequences derived from individual patients are allocated a different colour b) Sequences derived 
from patients with an SVR are shown in green while sequences derived from non-responders are shown in 
black. 
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NS5A and SVR 
Sequences derived from NS5A were aligned with genotype 1a prototype sequence HCV-1 
and the median number of amino acid differences counted for each patient (MacQuillan et 
al, 2004; Figure 2.9; Table 2.10). 
Figure 2.10 Alignment of NS5A sequences in a) Patients with SVR and b) Non-responders/relapsers      
a)      Patients with SVR                                                      
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b)Non-responders/relapsers      
a)  
 
Figure 2.10 NS5A sequences are aligned in a) Patients with SVR and b)Non-responders/relapsers. The 
putative ISDR is highlighted in pink. More variation in the ISDR region can be seen in the SVR group.                                                                 
Table 2.10:  Amino acid differences within the ISDR compared with the HCV-1 reference 
strain 
 
 
 
 
 
 
Number of ISDR mutations 
per sequence 
No SVR SVR 
1 13 0 
2 11 38 
3 0 5 
6 1 1 
8 0 1 
Total 25 45 
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The number of mutations within NS5A from patients with an SVR was significantly higher 
than the number of mutations in sequences derived from patients without an SVR when 
compared with the HCV-1 reference sequence strain  (p<0.0001). This was accounted for by 
the number of mutations within the ISDR region (Figure 2.10, Table 2.10; p<0.0001). 
Mutations in the region of NS5A upstream of the ISDR were not significantly different in 
sequences derived from patients with or without an SVR (p=1.0).  
 
2.5.8 PCR and cloning error rate 
2.5.8.1 Sensitivity of PCR assays 
5’UTR: An end-point dilution PCR was carried out to assess the sensitivity of the 5’UTR assay 
for detecting genotypes 1a, 3a and 4d by serial dilution of samples with a known HCV VL 
(determined by quantitative RT-PCR). All 3 genotypes were detected with a sensitivity of <10 
IU/ml. 
HVR-1: The sensitivity of the HVR-1 PCR was 693 IU/ml using the Roche One Step PCR kit 
containing Taq polymerase. Detection of positive samples was reduced by 60% when using 
the proof-reading enzyme Pfu. 
2.5.8.2 Estimated PCR error rate 
Taq polymerase has previously been estimated to have an error rate of 0.2-2x10-4 to 10-5 
errors/bp/cycle. Proof-reading enzymes are thought to be more accurate with error rates of 
around 10-6 but are significantly more expensive than Taq-containing preparations. Using 
Taq polymerase to determine variation would add a maximum expected error rate of 220 
base pairs x 65 cycles x 2 x 10-4= 2.86 errors/sequence = 1.3% variation/sequence. Reverse 
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transcription adds an expected error rate of 6.4 x 10-5 nucleotide substitutions/site. Thus 
220 base pairs x 6.4 x 10-5 =0.01 errors/sequence= 0.005% 
 
2.5.8.3 Actual PCR/cloning error rate 
A positive band was visible at up to 10IU/ml. This was excised and extracted by column 
centrifugation as above and the concentration of DNA measured using spectrophotometry 
giving a concentration of 90ng/ul. The molecular weight of one copy of plasmid with 
incorporated NTR DNA (3956bp plasmid + 217bp cDNA) was estimated to be 2578790 Da 
using an online molecular weight calculator available at 
http://www.changbioscience.com/genetics/mw.html. The total number of molecules of 
DNA present was calculated thereafter using Avogadro’s constant.  
                         
                               
                                       
 
                         
                     
                            
             
 
Thus for 10 molecules of plasmid DNA, 4.28x10-17g was obtained and used in the PCR 
reaction, following serial dilutions with sterile water. The NTR PCR product was then gel 
extracted and re-ligated into pCR®4-TOPO® vector. Twenty clones were then sequenced in 
order to calculate actual PCR error.  
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Figure 2.11: End-point dilution of the 5’UTR 
 
Figure 2.11: An end-point dilution PCR of the 5’UTR region was carried out and run on a 2% 
agarose gel at concentrations of 1-100,000 IU/ml.  
 
175 clones were selected and sequenced. Following this, a total of 50 introduced errors 
were calculated over 175x185 base pairs=50/32375 total= 0.0015/bp/80 cycles = 1.9x10-5 
errors/bp/cycle. This is likely to reflect the upper end of possible error, as PCR saturation is 
likely to have prevented the incorporation of as many errors due to higher starting 
concentrations of DNA pre-amplification. 
 
 
  
Negative  
control 
   100,000     10,000      1,000       100           10             1           100bp                                                
a  IU/ml         IU/ml        IU/ml       IU/ml       IU/ml       IU/ml   ladder                    
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2.6 Discussion 
An emerging epidemic of acute HCV in HIV-positive men-who-have-sex-with-men (MSM) 
has for the first time allowed characterization of the natural history of early HCV infection in 
a large number of HIV-positive patients. Unravelling the determinants of spontaneous 
clearance of HCV is crucial in order to increase our understanding of the biological 
mechanisms which define protective immunity and to improve the management of patients 
who face a lengthy course of treatment which is toxic, expensive, and not always effective. 
HCV infection in HIV-positive individuals is a growing clinical problem associated with an 
increased rate of disease progression and reduced response to treatment (reviewed by 
Klenerman et al, 2007).  In this longitudinal study of 110 patients with acute HCV and HIV 
infection, the key predictors of spontaneous clearance were VL dynamics, liver function and 
measures of viral diversity including Hamming distance and dN/dS ratio. 
 
2.6.1 Diagnosis of acute HCV in HIV-positive patients 
Early treatment for HCV improves outcome in HIV-positive patients (Gilleece et al, 2005; 
Torriani et al, 2004) and early diagnosis is therefore crucial. Tests available for the diagnosis 
of HCV infection in the acute phase vary in sensitivity. Third generation antibody ELISA tests 
which detect multiple antigenic determinants (core, NS3, NS4, NS5) are the current 
diagnostic test of choice in HIV-positive patients (Brook et al, 2010). HIV-negative patients 
generally produce an antibody to HCV within 6 weeks of infection (Netski et al, 2005). We 
have shown in this study that in HIV positive individuals, however, screening with a third-
generation antibody assay in the first 6 months of infection is inadequate in most patients. 
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Furthermore, at 1 year, nearly 5% of patients remain seronegative. The use of a combined 
antigen-antibody test in HIV-positive individuals increases screening sensitivity but may not 
be cost-effective and is not as sensitive as PCR (Nastouli et al, 2009). This delay in the 
formation of antibodies may result in significant delay in diagnosis of HCV in HIV-positive 
individuals and patients may lose the opportunity to have their infection treated 
successfully. An accurate estimate of seroconversion time (time of infection to the 
development of antibodies) in this group of patients is limited by the 3 monthly sampling 
window, and therefore, a subgroup of eight patients who had been sampled at monthly 
intervals (<30 days) were identified, allowing a more precise assessment of seroconversion 
time. In this group, the median time from infection to the development of antibodies was 
estimated as 158 days (IQR 47–209 days). Factors found to correlate with a prolonged 
seroconversion time included low ALT level and low HCV viral load at baseline, perhaps 
reflecting reduced B cell recognition and lower antigenic load, respectively. The CD4 cell 
count at the time of HCV infection was not associated with seroconversion time, although 
patients with a lower nadir CD4 cell count had a slightly increased likelihood of a delayed 
antibody response, suggesting that prolonged CD4 dysfunction may occur, despite an 
increased CD4 cell count following HAART.  Delayed anti-HCV antibody responses have also 
been reported in other immunosuppressed groups, such as solid-organ transplant and 
haemodialysis recipients (David-Neto et al, 1997; Schroeter et al, 2005; Preiksaitis et al 
1997). The phenomenon has also been described previously in a case series of three 
immunosuppressed HIV-infected individuals (CD4 cell counts 14–266 cells/μl; John et al, 
1998), with formation of anti-HCV antibodies following treatment with HAART and resultant 
immune restoration. This phenomenon was not observed in our cohort of patients, perhaps 
because of the higher median CD4 cell count in this patient population (Table 2.7). Thus, 
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delayed anti-HCV seroconversion may also occur frequently in HIV-positive patients who 
have normal CD4 cell counts. The association between nadir CD4 cell count and delayed 
seroconversion time, as well as likelihood of clearing HCV spontaneously, is likely to reflect 
impaired CD4 function, despite the restoration of absolute counts. The role of T cell function 
during acute disease is explored further in Chapter 4 of this thesis.  
 
In conclusion, elevated ALT levels in at-risk HIV-positive patients should indicate testing 
for HCV by PCR in order to diagnose infection early. Furthermore, HIV-infected patients 
diagnosed with acute HCV should have a preceding negative HCV RNA test (performed 
retrospectively) to accurately establish the timing of infection. 
 
2.6.2 Predicting spontaneous clearance of acute HCV in HIV-positive men based on 
viral dynamics, liver function and other clinical measures   
 
Three courses of infection were observed, based on VL changes over time (Figure 2.3). 
Spontaneous clearance (SC; 14%) was associated with a rapid decrease in VL. Patients who 
progressed towards chronicity exhibited 2 patterns of viraemia; the majority (48%) had an 
initial rise in VL followed by a plateau viraemia phase (PV), analogous to that seen in other 
chronic viral infections when the rate of viral clearance equilibrates with the rate of viral 
production. Some patients, however, developed a pattern of fluctuating viraemia (FV; 38%) 
characterized by an initial decline and subsequent rise in VL (>1log10). This pattern of 
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viraemia has been observed in HIV-negative individuals and chimpanzees but has not 
previously been correlated with outcome in a longitudinal study.     
 
 
We aimed to employ the viral kinetics of early HCV infection to predict subsequent 
outcome. SC patients had a 1.7log10 VL drop versus a 0.001log10 drop in PV and 0.57 log10 
drop in FV within 100 days of infection (OR=2.76, p=0.001; Table 2.6), increasing to a 4.03 
versus 0.13(PV)/0.85(FV) log10 drop by 200 days (OR=2.48, p<0.0001). While the likelihood 
of clearance is low if a 1log10 drop is not achieved by 100 days, some patients will not 
subsequently clear the virus even if they do achieve this, and therefore require careful 
ongoing monitoring. Such patients fall by definition into the fluctuating pattern of 
progression towards chronicity.   
A difficulty encountered in predicting the outcome of infection is in distinguishing between 
those who will develop a fluctuating viraemia and those who will go on to spontaneously 
clear infection, particularly those patients who become transiently RNA negative. 
Examination of the VL gradient in such patients (the FV group) revealed a slower decline in 
VL (median 129 versus 27 days to a 1.7log10 drop; p=0.009); thus the rate of decline of 
viraemia is key in predicting outcome. 
Other clinical measures were also predictive of outcome; an elevated serum bilirubin level 
of ≥40µmol/l was associated clearance with a hazard ratio of 5.04 while elevated ALT also 
predicted outcome (≥1000IU/l HR 2.62; Table 2.7). This may reflect the presence of a 
protective immune response in the liver. Finally, a higher CD4 count at the time of infection 
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was also associated with a higher likelihood of spontaneous clearance (≥650cells/mm3 HR 
2.66, p=0.045). The role of the CD4 response in controlling acute HCV is discussed further in 
Chapter 4.  
 
 
2.6.3 Predicting spontaneous clearance of acute HCV in HIV-positive men based on 
sequence analysis 
A detailed phylogenetic and genetic sequence analysis of 2295 longitudinally-acquired 
clonal E2 HVR-1 sequences allowed us to track the impact of superinfection, and to assess 
whether measurements of viral diversity and selection had predictive value. Several 
monophyletic clusters were present (Figure 2.4), in keeping with multiple transmission 
events in the MSM population, as previously described (Danta et al, 2007; van de Laar et al, 
2009).  
 
2.6.3.1 Superinfection with new strains of HCV 
Within individuals, the presence of superinfection was suggested by marked non-linear 
variation in genetic distance over time (Figure 2.5). In order to investigate if this variation 
was the result of superinfection events, neighbour-joining phylogenetic analyses of all 
longitudinally acquired E2 HVR-1 sequences (n=2295) were next carried out, revealing 3 
groups of patients (Figure 2.3); those who spontaneously cleared infection (n=10; 20%), 
those who progressed to chronicity with increasing quasispecies diversity but no evidence of 
superinfection (n=20; 40%) and those who progressed to chronicity with evidence of 
superinfection events (n=20; 40%). The introduction of new infecting strains occurred in 
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40%, both of the same genotype (30%) and with new genotypes (10%).  This high rate of 
superinfection is in keeping with the likely ongoing high risk behaviour of this group of 
patients (Danta et al, 2007) and the observation of reinfection events in other cohorts 
(Herring et al, 2004).  The majority of patients with fluctuating viraemia had evidence of 
reinfection and superinfection with new strains of HCV (63%).  
 
This observation could be explained in 3 other ways. Firstly, the observation could be 
artefactual as a result of PCR contamination error or Taq polymerase-related error 
introduction. Secondly, the phenomenon could be explained by the resurgence of minority 
quasispecies, present in plasma at baseline but undetected by clonal sequencing (<5%). 
Thirdly, unique strains could have been compartmentalised in the liver, PBMCs or the brain 
at the time of initial infection. The technicalities of reducing PCR-related error are discussed 
in the next section, and the possibility of undetected minority variants in Chapter 3 of this 
thesis. 
 
The presence of superinfecting strains was a confounding factor when analysing the 
evolution of HCV strains over time, producing wide variations in genetic diversity and dN/dS 
ratios (Figure 2.5). A correction was therefore introduced to investigate the evolution of 
related strains by calculating the average diversity/dN/dS ratio over branches of the 
phylogenetic trees separated by >10% variation.  
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2.6.3.2 Viral diversification within the E2 HVR-1 is predictive of spontaneous 
clearance  
In order to determine which genetic factors predicted spontaneous clearance, mean 
intrastrain Hamming distance (diversity), number of quasispecies and dN/dS ratios were 
calculated in 50 patients (40 progressors and 10 clearers) at multiple (median=3) time points 
(Table 2.8). Genetic diversity did not correlate with VL but was found to be significantly 
higher in progressors (both FV and PV) by 150 days of infection compared with SC patients, 
consistent with similar observations in HIV-negative individuals (Farci et al, 2000). In the 
main, a gradual increase in viral diversity and dN/dS ratio was observed over time in PV 
patients as a result of generation of positively-selected variants. In contrast, viral diversity 
and dN/dS ratio decreased gradually in SC patients ( Figure 2.7). We hypothesised that this 
would be likely to occur in association with a strong, multi-specific T cell response (Chapter 
4).   
 
2.6.3.3 Fluctuating Viraemia; superinfection versus recrudescence 
In the FV group, when patients with superinfection were excluded from the analysis, genetic 
diversity at baseline was greater than the PV group (Hamming distance 2.84 versus 0.49; 
p=0.04), possibly suggesting a more diverse infecting inoculum. The dN/dS ratio in FV 
patients with single strain infection was <1 suggestive of purifying selection at this stage. 
However, by 150 days, positive selection was evident, with a significantly higher median 
dN/dS ratio in FV than PV patients (1.78 versus 0.76; p=0.02).  One unusual case within the 
cohort suggested that reactivation of HCV may rarely occur in immunosuppressed 
individuals after successful treatment. This patient had evidence of reactivation of HCV 2 
110 
 
years after successful treatment for acute disease (Figure 2.6d). This coincided with a period 
of severe immunosupression and hospitalization and may have been the result of loss of T-
cell control of a virus present in the liver but not in the bloodstream or extremely low level 
viraemia below the limit of detection. Such cases are rare but have been previously 
reported in the literature (Kim et al, 2006).  
 This characteristic variation in viral diversity and VL in FV patients would be in keeping with 
a model of partial immune control and may reflect within some individuals a delayed 
partially effective immune response and in others the emergence of escape variants or an 
unsustained protective immune response due to B or T-cell failure, for example, as a 
consequence of PD-1 receptor upregulation (a marker of T-cell exhaustion and disease 
progression both in HIV-positive individuals and in acute HCV infection (Day et al, 2006; 
Urbani et al, 2006).  Alternatively, it could represent reinfection with the same strain of 
virus, which has been artificially demonstrated in the chimpanzee model (Bukh et al, 2008).  
A third explanation would be the persistence and re-emergence of virus from sites outwith 
the bloodstream e.g. the liver, PBMCs or the central nervous system (Maggi et al, 1997; 
Forton et al, 2004). These possibilities are investigated further in Chapters 3 and 4. 
 
2.6.4 Predicting SVR in HIV-positive men with acute HCV 
Patients with acute HCV are usually offered early antiviral treatment. This is known to be 
more effective than treatment given in the chronic phase, reaching success rates of 98% 
(Jaeckel et al, 2001) versus 54-56% (Manns et al, 2001; Fried et al, 2002) in HIV-negative 
individuals. Co-infection with HIV results in lower success rates; 59%-70% in the acute phase 
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versus 40% in chronic infection (Gilleece et al, 2005; Serpaggi et al, 2006, Dominguez et al, 
2006; Torriani et al, 2004 ). In this study, patients who did not achieve spontaneous 
clearance 12 weeks following diagnosis were offered treatment with 48 weeks of IFNα and 
ribavirin and 70% achieved an SVR. We hypothesized that those who had accumulated a 
higher diversity over time would be less likely to respond to treatment. In keeping with this 
hypothesis, an SVR was associated with lower viral diversity as early as the baseline sample, 
increasing in significance with successive measurements. Thus it is possible that the diversity 
within the initial inoculum may partially define the likelihood of SVR. A gradual increase in 
diversity over time may also explain the disparity between treatment during the acute and 
chronic phases of HCV infection. Once a threshold diversity has been reached, the likelihood 
of SVR is markedly reduced (Hamming distance at 150 days 2.05 in responders versus 7.82 in 
relapsers/non-responders and dN/dS 0.76 versus 4.76; p=0.004 and 0.007 respectively). It 
remains to be seen if patients with high viral diversity at baseline would benefit from very 
early anti-viral therapy. 
The mechanism of resistance to IFNα and ribavirin is not known, but a trend towards 
increased variation in the ISDR region of NS5A in patients with an SVR has been described in 
patients with chronic genotype 1a, 1b and 3a infections (MacQuilan et al, 2004; Pascu et al, 
2004). In this study, there was a trend towards greater variation in this region in treatment 
responders also, with a highly significant p value (<0.0001). If sequences were present with 
≤1 amino acid difference from the prototype reference strain, the SVR was 0%. Further work 
to identify variation in this region and SVR is indicated.    
 
 
112 
 
2.6.5 Artefactual error during PCR and clonal sequence analysis 
In order to reduce the likelihood of PCR contamination occurring, samples were processed 
in strict aseptic conditions as detailed in the methods section and a negative control was 
always included.  Variation in genotype or HCV strain was noted on multiple occasions, in 
multiple specimens from the same patients and by the clinical laboratory in separately 
processed samples. Another cohort (of IDUs), tested separately in another laboratory using 
the same primers also revealed evidence of multiple circulating HCV strains over time (Smith 
et al, 2010). Amplification of a region of NS5B was next carried out as a control experiment 
to verify these results. Although shorter branches were observed secondary to lower 
genetic diversity within NS5B, similar phylogenetic trees were produced, confirming that the 
appearance of new strains was unlikely to be secondary to contamination error.  
 
Nucleotide error may occur during PCR amplification (up to 2x10-4 errors/bp/cycle; Tindall et 
al, 1988) due to the lack of 3’ to 5’ exonuclease activity of Taq polymerase and to a lesser 
extent during RNA reverse transcription (6.4 x 10-5 nucleotide substitutions/site). Proof-
reading enzymes such as Tgo DNA polymerase or Pfu DNA polymerase are superior with 
error rates in the 10-6 range (Cline et al 1996), but are significantly more expensive than Taq-
containing preparations.   
In order to calculate the actual PCR error rate, the 5’UTR was subcloned following end-point 
dilution PCR and 1.9x10-5 errors occurred/bp/cycle (0.3 errors/sequence). This is likely to 
reflect the upper end of possible error, as PCR saturation is likely to have prevented the 
incorporation of as many errors due to higher starting concentrations of DNA pre-
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amplification. If errors are incorporated early on in the PCR reaction, the error rate could be 
much higher. Thus the error range lies between 0.14-1.3% per sequence. We used a cut-off 
of 10% for defining different strains, well above this level. Phylogenetic trees and sequence 
analyses were compared with a control experiment following amplification of NS5B using 
the proof-reading enzyme Tgo DNA polymerase with comparable results.  
 
2.7 Conclusions 
This study is the first longitudinal and detailed analysis of clinical outcome of acute HCV in a 
large cohort of HIV-positive patients, incorporating viral dynamics and detailed viral 
sequence evolution. Acute HCV infection is an emerging global epidemic in HIV-infected 
men and requires new public health planning and treatment strategies. These data suggest 
that the outcome of infection can be predicted by viral kinetics, CD4 count, liver function 
and genetic diversity. Diversification of HVR-1 of the E2 protein, which contains both B and 
T-cell epitopes was associated with progressive disease, while a narrowed quasispecies 
repertoire occurred in patients who subsequently spontaneously cleared infection. SVR was 
also related to viral diversity at baseline and over time. Targeting of high risk patients e.g. 
with no evidence of rapid decline in VL and higher viral diversity at baseline may increase 
the efficacy of treatment while those more likely to clear infection spontaneously could be 
monitored for a longer period of time thus avoiding a rigorous and expensive treatment.   
 
The study has a number of limitations. Firstly, it is restricted to an HIV-positive population, 
although patterns of evolution during early infection may also apply to those with HCV 
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monoinfection. Steps were taken to minimise error rates attributable to PCR contamination 
and clonal analysis, as detailed above. In order to overcome the problem of delayed HCV 
seroconversion in HIV-positive individuals (to avoid the inclusion of chronically infected 
patients), we used retrospective PCR testing on stored HIV VL samples to date the time of 
infection.  More work is needed to further define specific T cell targets and Class I/II 
restriction of these responses, as well as the impact of viral escape. The role of the immune 
response in containing HCV infection is discussed in detail in Chapters 3 and 4.  
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Chapter 3: The viral evolution of acute HCV 
3.1 Background 
3.1.1 Evolutionary theory  
The observation of variation in the phenotypic characteristics of animals and plants led 
Charles Darwin to conclude that speciation was not a fixed but a dynamic process (Darwin, 
1859). He realised that this variation occurred with the generation of progeny displaying 
new characteristics by observing the breeding of pigeons and other animals (variation under 
domestication) and subsequently under the forces of nature, a process he named natural 
selection. Charles Darwin argued that the mechanism for variation in species was a tree-like 
branching process, with each new generation diverging from the previous, which he 
illustrated with a diagram remarkably similar to current phylogenetic trees, constructed on 
the basis of sequence data. Nearly 100 years later, the discovery of the genetic code in 1953 
(Watson & Crick) paved the way towards a deeper understanding of genetic variation and 
new theories of evolution based on genotypic rather than phenotypic observations. 
The dynamic nature of variation in genetic sequences is now clearly apparent and a number 
of evolutionary forces have been defined all of which have been identified in observations 
of viral evolution.  The first, positive (Darwinian) selection reflects change in the phenotype 
of an organism as a result of environmental positive pressure. Purifying selection is the 
selection of genes with a structure essential to survival and the favouring of the status quo. 
Neutral selection is the continued generation of variants in a population with no selection 
pressure. These 3 models can be defined in mathematical terms by examining the ratio of 
non-synonymous to the number of synonymous substitutions.  
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Synonymous substitutions (those that do not result in a change in amino acid) are neutral 
and a measure of random genetic drift while non-synonymous substitutions (resulting in a 
change in amino acid sequence) are subject to positive or negative selection pressures.  A 
comparison of the rate of nonsynonymous (rN) to synonymous (rS) substitutions may 
indicate whether or not a region of interest is under positive selection pressure (rN>rS) or 
negative selection pressure (rS>rN) (Hughes and Nei, 1988, 1989). Both rN and rS can be 
estimated by comparing two nucleotide sequences and the number of synonymous 
substitutions per synonymous site (dS) compared with the number of non-synonymous 
substitutions per non-synonymous site (dN); the dN/dS ratio; Figure 3.1. 
Figure 3.1: Models of evolution 
                   
  
  
                                        
  
  
                                 
  
  
   
 
Figure 3.1: Models of evolution: positive, purifying and neutral selection are displayed as 
ratios of dN to dS 
 
These models rely on the assumption that silent synonymous mutations are not subject to 
selection pressure. While they do not result in amino acid changes, it is highly likely that 
variations in synonymous regions of genes have secondary structural functions. HCV core 
and NS5B RNA, for example, contain multiple stem–loops that are found in all HCV 
genotypes throughout both regions, as well as several strikingly conserved single-stranded 
regions, one of which coincides with a region of the genome to which ribosomal access is 
required for translation initiation (Tuplin et al, 2004).  The impact of variation in RNA 
structure is one which is relatively unexplored at the present time. 
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3.1.2 The evolution of HCV  
The red queen hypothesis of evolution is based on Lewis Carroll’s quotation that "it takes all 
the running you can do, to keep in the same place1.". As a model of evolution this refers to 
the continued struggle between host and virus to maintain fitness over time.  A 
characteristic feature of RNA viruses is their ability to diversify rapidly; 1012 HCV particles 
are produced every day in an infected individual due to the lack of proof-reading function of 
viral RNA polymerase (Neumann et al, 1998). This presents the immune system with an 
immense task; a host-virus arms race which in the majority of cases continues without 
resolution for the lifetime of the host. The evolution of the viral quasispecies is emerging as 
key in defining the outcome of infection and response to treatment (Chapter 2; Farci et al 
2000; Sheridan et al 2004).  
Variation within the 28-amino acid structure of the HCV E2 HVR-1 is extensive (Weiner et al 
1991) and contains both antibody (Farci et al 2000) and T cell epitopes (Sarobe et al 2006).  
As discussed in Chapter 2, evolution of HVR-1 is associated with progressive disease, while a 
narrowed quasispecies repertoire occurs in patients who subsequently spontaneously clear 
infection (Farci et al 2000; Sheridan et al 2004). Agammaglobulinaemic patients (who cannot 
form antibodies) with HCV develop chronic infection with a narrow repertoire of 
quasispecies (Gaud et al 2003) suggesting that this diversification of virus arises at least in 
part as a result of antibody-mediated immune pressure.  Detailed studies of longitudinal 
evolution in this region and outside it during acute infection (Farci et al 2000; Sheridan et al 
2004) have been limited by small sample size and have not previously been carried out in 
HIV-positive patients. The point at which such diversity arises after acute infection has not 
                                                          
1
 Exert from “Through the Looking Glass” by Lewis Carroll 
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previously been fully established. We discussed in Chapter 2 that the emergence of 
divergent strains correlates with progression to chronicity by 150 days of acute infection 
and also with the likelihood of treatment success. A number of factors may impact this 
diversification of virus over time. We aimed to investigate the impact of transmission 
diversity, superinfection with new viral strains and of the adaptive immune response on 
viral diversity in further detail. 
 
3.1.2.1 Transmission diversity 
A gradual accumulation of viable viral strains within an infected individual over time 
correlates with a decreasing likelihood of response to treatment (Chapter 2). The diversity 
at the onset of infection is also predictive of outcome. While all patients in this cohort were 
exposed to HCV by the sexual route, a significant minority also used intravenous or 
intramuscular drugs (most commonly crystal methamphetamine). We hypothesised that the 
route of transmission would impact on viral diversity and final outcome (spontaneous 
clearance or SVR) due to the likelihood of high diversity within the infecting inoculum in 
IDUs. Initially, a phylogenetic analysis of IDUs within the cohort was carried out to see if 
they represented a distinct population or were dispersed throughout the cohort. Measures 
of viral diversity were next compared in IDUs and non-IDUs. Finally, molecular clock 
techniques were used to reconstruct phylogeny within individual patients and 2 transmitting 
couples (both with dual genotype infection) to identify possible population bottlenecks at 
the time of transmission.    
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3.1.2.2 Superinfection or recrudescence  
A major confounding factor in this cohort was the appearance of new dominating 
quasispecies populations at different time points in individual patients (Figure 2.6). While a 
compelling explanation for this is reinfection or superinfection with other strains, there are 
other alternative explanations. The analysis of variant strains using clonal sequencing was 
limited to 20 per time point. As the mean number of viral copies at any time point in this 
cohort was 3x106/ml, each sample of 140µl of plasma could be expected to contain 
approximately 20,000 viral copies. This ratio of sampled viral strains was thus approximately 
1:1000 of the viral population present in each sample and 1:511 produced within the host in 
a single day (20 per 1012 viral copies). A minority variant present and amplified by PCR could 
thus remain undetected using the clonal sequencing technique. We aimed to investigate 
this possibility further by designing strain-specific primers for the superinfecting strain to 
test on the baseline sample to see if the majority quasispecies present at a later time point 
originated from the minority acquired during initial infection. Another approach would be to 
use ultra-deep pyrosequencing which can detect tens of thousands of sequences within a 
single cDNA sample.  
This problem of detection within the bloodstream is compounded by fact that viral strains 
may also be compartmentalised within the liver (Sobesky et al, 2007), PBMCs (Maggi et al, 
1997; Roque Alfonso, 1999) or the central nervous system (Forton et al, 2004). The role of 
compartmentalised virus acting as a reserve for future viral recrudescence is controversial 
and relatively unexplored. One patient in this cohort who denied reinfection risk had 
evidence of reactivation of HCV 2 years after successful treatment (Figure 2.6d). This 
coincided with a period of severe immunosupression and hospitalization and may have been 
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the result of loss of T-cell control of a virus present in the liver but not in the bloodstream or 
extremely low level viremia below the limit of detection.  We aimed to examine the case in 
more detail by looking for evidence of viral strains present in an archived paraffin-
embedded liver biopsy taken prior to viral recrudescence and in PBMC samples taken just 
after the re-emergence of infection. We also looked for evidence of viral 
compartmentalisation in PBMC samples in another 27 patients, including a transmitting 
couple with dual genotype infection. 
 
3.1.2.3 The adaptive immune response 
In Chapter 2, we attempted to correct for the impact of superinfection in each patient by 
using the mean intrastrain diversity in order to assess the impact of the immune response 
on viral populations. A number of more sophisticated techniques have been designed to 
overcome this problem by calculating the dN/dS ratio firstly over the entire phylogenetic 
tree and then for each branch of the tree. It is therefore possible to identify specific codons 
under positive, negative or neutral selection pressure. Several population-based tests may 
be used to ascertain if sequences are evolving due to random genetic drift (neutrality) or are 
under positive selection. Taijma's Test of Neutrality (Tajima, 1989) compares the number of 
segregating sites with nucleotide diversity.  Fu and Li's related neutrality test (1993) 
compares segregating sites with singletons (D test) or average pairwise divergence versus 
singletons (F test). Both the D test and dN/dS ratio can be averaged over a stretch of 25-100 
nucleotide sequence in a sliding window thus reducing the calculation to a smaller length 
and providing a visual assessment for sections of the alignment in a sliding window.   
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3.2 Hypotheses 
The diversification of viral quasispecies predictive of final outcome is defined by  
H1 ,Transmission diversity as a consequence of the route of transmission 
H2, Superinfection events  
H3 ,Positive or negative selection pressures as a consequence of the adaptive 
immune response, or  
H0, Chance 
3.3 Aims 
1. To identify epitopes under selection at the codon-specific level during early HCV 
infection 
2. To determine if superinfection contributes to viral diversity using PCR and clonal 
sequence analysis 
3. To compare viral diversity over time in patients depending on route of transmission  
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3.4 Methods used to analyse viral sequence diversification 
3.4.1 Measuring nucleotide diversity (π) 
Nucleotide diversity (π) in a population is defined as the number of nucleotide substitutions 
per site between sequences and may be calculated as follows:  
π = jj i
ij
ixx     
where xi=frequency of i
th type of sequence and πij=proportion of nucleotide differences 
between the ith and jth type of sequences. 
The evolution of viral diversity can be measured using a variety of phylogenetic and 
statistical techniques based on RNA or DNA sequence differences. Kimura (1968) introduced 
the theory of "neutral evolution" following the observation that many genetic mutations are 
random events and may not confer phenotypic change. This model may be applied to the 
analysis of variation in HCV viral quasispecies which occur largely as stochastic (random) 
events due to the lack of proof-reading function of the RNA-dependent RNA polymerase. 
Provided the population size is large enough, some mutations may occur which are 
beneficial and increase in frequency in a population as a result of natural selection. Others 
may be neutral and persist due to random genetic drift - these changes however take longer 
to arise than adaptive mutations. This phenomenon may be measured by comparing genetic 
sequences and taking into account whether or not RNA sequence changes encode changes 
in the translated amino acid sequence.  
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3.4.2 Inferring phylogeny 
This section on the construction of phylogenetic trees is a summary of information obtained 
from Felenstein Inferring Phylogenies 2004, The Phylogenetic Handbook 2nd edition 2009 
and Phylogenetic Trees Made Easy, Hall, 3rd edition, 2008). 
 
3.4.2.1 Nucleotide substitution models 
Phylogenetic tree analysis may be carried out using a variety of models. Sequences are 
compared and the genetic distance between them (represented by branch length) used to 
construct a tree. The observed number of nucleotide substitutions between sequences is 
called the p distance. Substitution of nucleotides was originally assumed to be an entirely 
random (stochastic) process and thus the first nucleotide substitution model introduced by 
Jukes and Cantor in 1969 (the JC69 model) was based on the assumption that all nucleotides 
have the same likelihood of being replaced by any other (that the nucleotide frequencies *π+ 
are equal and that πA =πT =πC =πG). A second assumption made was that substitutions only 
occur once at each site, when in fact multiple substitutions at the same site may occur 
(multiple hits), a substitution may revert to the original nucleotide (back mutation) and 
parallel substitutions may occur in two or more sequences. Lastly, in an open reading frame, 
third nucleotide substitutions in a codon are more likely to become fixed as they are less 
likely to result in an amino acid substitution than first or second nucleotide substitutions 
due to the redundancy of the genetic code. The observed genetic distance p may therefore 
differ substantially from the true genetic distance (d). 
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In order to correct for this difference, newer model systems introduce a formula which 
takes into account the frequency of transitions (TS) (purine purine or pyrimidine
pyrimidine) which is usually greater than the frequency of transversions (TV)(purine
pyrimidine) due to steric hindrance. The ratio of TS to TV (κ) and the ratio of purine 
transitions (TSR) to pyrimidine transitions (TSY), denoted by γ, and may also be incorporated 
into the equation as in the Tamura-Nei (TN93) model (Tamura & Nei, 1993). If γ=1 and the 
base frequencies are uniform (πi = 0.25), the TN93 model reduces to the Kimura 2-
parameter (K80) model (Kimura, 1980). When κ=1, the F81 model is generated (Felenstein, 
1981). Choosing an appropriate model is essential as inappropriate models may produce 
inaccurate tree topologies.  
 
3.4.2.2 Methods for the construction of phylogenetic trees 
Phylogenetic trees may be produced using exhaustive search methodology or stepwise 
clustering. Exhaustive search methods evaluate all possible tree topologies and apply 
criteria to select the most likely candidate. However, with increasing numbers of sequences, 
increasingly large numbers of possible trees may be produced, resulting in a lengthy 
analysis. Stepwise clustering methods overcome this problem by grouping sequence data 
together to form clusters with each new sequence compared to a cluster, thereby reducing 
computing time. Examples of exhaustive search methods are maximum parsimony (selects a 
tree with the smallest number of mutations required to generate internal nodes for each 
sequence) and maximum likelihood.  
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3.4.2.3 Stepwise methods 
In order to reduce computation time, stepwise clustering methods do not compare every 
possible tree phylogeny, but instead reconstruct phylogenies in a stepwise manner. 
The unweighted pair group method with arithmetic means (UPGMA) is the oldest technique 
developed for inferring phylogeny. A distance matrix is constructed, quantifying differences 
between pairs of operational taxonomic units (OTU; each representing a sequence). OTU 
clusters are constructed based on similarity within the distance matrix. The remaining OTUs 
are then sequentially paired with the cluster. This method assumes a constant evolutionary 
rate between OTU cluster pairs and does not identify different rates of evolution along 
different branches.  
The neighbour-joining (NJ) method also uses a distance matrix to identify similarity between 
sequences. However, instead of clustering OTUs, it involves the calculation of distance from 
OTUs to each internal node. The distance from each paired OTU to the internal node need 
not be the same and thus different rates of evolution along the branches of the tree are 
incorporated. A tree is constructed sequentially by the introduction of OTUs based on 
minimisation of the length of internal branches.  
The accuracy of trees may be evaluated by conducting a bootstrap analysis. This is a 
resampling technique and is carried out by constructing a new hypothetical alignment based 
on resampling of columns from the original alignment and reconstructing phylogenetic trees 
for each. The proportion of each clade among the bootstrap replicates is provided as a 
measure of the validity of each branch of the tree. 
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3.4.2.4 Exhaustive methods  
Maximum parsimony and maximum likelihood phylogenetic methods are exhaustive 
methods in which multiple tree topologies are constructed and the best tree selected from 
all calculated trees. Maximum parsimony finds the tree which is constructed with the 
smallest number of nucleotide substitutions. For each tree topology, a score called the 
parsimony length is calculated as the sum of all substitutions required to construct the tree. 
The tree with the lowest parsimony length is selected as the best tree.  
Maximum likelihood involves the construction of multiple phylogenetic trees and the 
calculation of likelihood based on all possible nucleotide or amino acid states in the 
hypothetical internal nodes. As well as the number of substitutions required to construct 
the tree, the validity of a particular evolutionary model is applied to the data.  
 
3.4.2.5 Bayesian analysis 
Bayesian analysis incorporates the principle of accommodation of previous evidence 
(posterior distribution) based on Bayes theorem (Figure 3.2) into the phylogenetic modelling 
process. The prior probability (or prior) is the likelihood before the posterior distribution 
was known. In phylogenetic analysis, posterior distributions may be obtained using Markov 
Chain Monte Carlo (MCMC) sampling. In mathematical modelling, a Markov chain is a 
discrete random process which depends only on the current state of the system and not on 
the probability distribution of the system at previous steps. Monte Carlo methods are 
computational algorithms (finite sequence of instructions) reliant on repeated random 
sampling to compute results. A domain of inputs is defined and generated randomly, given a 
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specified probability distribution. A deterministic computation is performed thereafter using 
the inputs and these computations are aggregated into the final result. 
Figure 3.2: Bayes theorem 
a) Bayes theorem 
                                     
                                                             
                      
 
 
       
          
    
 
b)  The Monty Hall problem solved using Bayes theorem 
The Monty Hall problem was published in 1975 (Selvin, 1975) and takes the form of a TV games show. There 
are 3 doors—red, green, and blue, one of which has a prize hidden behind it. The contender guesses the red 
door. The presenter (who knows where the prize is) opens the blue door which is empty. He then asks if the 
contender wishes to change his choice from the initial selection of red. Thus, the Monty Hall question is which 
choice is better; to choose the green or the red door? Intuitively, the answer may seem to be either, with a 
0.5/0.5 chance of each. However, following the application of Bayes theorem, this is not the case where 
P(Ar)=likelihood of the prize being behind the red door, P(B)=presenter opens the blue door = 0.5 (one of two 
doors without the prize), P(B Ar)=if the prize is behind the red door, the likelihood of picking green or 
blue=0.5, P(B Ag)=if the prize is behind the green door, the presenter must pick the blue door=1, P(B Ab)=if 
the prize is behind the blue door=0. Thus, 
        
            
    
  =  
          
   
  =  0.33 
 
        
            
    
  =  
        
   
  =  0.66 
 
        
            
    
  =  
        
   
  =  0 
The contender should always choose the green door, doubling the chance of winning. 
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3.4.2.6 Application of the molecular clock hypothesis to the 
evolution of HCV 
In 1962 and 1965, Zuckerkandl and Pauling published 2 papers revealing that the coding 
sequence for the same protein varied over time; showing a gradual linear increase in genetic 
diversity between species over time. They then hypothesised that this linear increase in 
genetic diversity with time could be used to estimate a molecular clock model of divergence 
times between species, with different proteins displaying different but constant genetic 
variation over time. This molecular clock hypothesis fits with the neutral theory of evolution 
described by Kimura in 1963 and 1983. Although a linear increase in sequence variation 
occurs in some proteins, it does not occur in a linear fashion in others (Jenkins et al, 2001). 
“Relaxed” models based on a non-linear accumulation of genetic mutations have been 
designed to overcome this problem (Pybus, 2006).   Both relaxed and strict (linear) 
molecular clock models can be incorporated into a Bayesian analysis (Figure 3.4)  
Using the clock-like theory of sequence evolution, it is estimated that HCV diverged from a 
common ancestor shared with GB Virus-B (GBV-B); a virus found in tamarins and 
chimpanzees (Ohno et al, 1996; Adams et al, 1998) between 500 and 2000 years ago (Smith 
et al, 1997). Within the last 300 years, six genotypes have evolved and within the last 100 
years, multiple subgenotypes emerged. This reconstruction of the history of HCV must 
however be interpreted with caution (Simmonds, 2001) as ancestral viral sequences have 
not been identified from more than 50 years ago, thus the reliability of the molecular clock 
model has not been verified. The diversity of HCV in westernised countries is considerably 
less than that in sub-Saharan Africa and South-East Asia. This would suggest that the 
variation seen in HCV in western countries is an example of founder effect and that HCV 
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originated either in sub-Saharan Africa or South East Asia (Simmonds, 2001). Expansions of 
transmission and evolution of the virus have occurred at various key historical time points; 
the onset of the industrial revolution coincides with an increase in diversity of genotype 1b 
HCV, likely to be related to urbanisation and the use of parenteral therapies on an extensive 
basis. While this hypothesised expansion is based on theoretical mathematical techniques, 
assuming rates of evolution based on sequence data obtained within the last 30 years, other 
expansions have been well-documented in real-time. Two notorious well-documented 
transmissions of HCV in recent years occurred in North Africa.  The first occurred in Egypt, 
where a genotype 4a epidemic paralleled an ambitious project to eradicate schistosomiasis 
using intramuscular and intravenous treatment in the 1960s and 1970s (Frank et al, 2000). 
Another outbreak in hospitalised Libyan children was investigated by the use of molecular 
phylogenetic techniques, revealing using Bayesian inference that spread of viral strains of 
HCV and HIV had occurred prior to the arrival of foreign nursing staff who stood accused of 
deliberately infecting the children (de Oliveira et al, 2006). 
 
3.4.2.7 Estimating effective population size 
Using Bayesian analysis, an estimate may be made of effective population size (Ne). This is 
the estimated size of a regenerating population with a variation rate equal to the studied 
sample. It becomes smaller than the overall population size (N) when some strains do not 
replicate and when natural selection is operating. When Ne is small, the rate of 
diversification reduces also. A decrease in Ne is known as a genetic bottleneck and may 
occur at the time of viral transmission, as a result of the immune response or as a result of 
treatment. 
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3.5 Laboratory methods  
3.5.1 Extraction of viral RNA from formalin-fixed, paraffin-
embedded (FFPE) liver biopsy specimens 
Liver biopsy specimens stored in paraffin blocks were obtained retrospectively from the 
clinical pathology department. RNA was extracted using the RNeasy FFPE kit (Qiagen). 
Freshly cut sections (5-10μm thick) of FFPE liver tissue were provided by Dr Rob Goldin (St 
Mary's Hospital Pathology Department) and placed immediately into a sealed 
microcentrifuge tube. Xylene (1ml) was added to the sample which was vortexed vigorously 
for 10 seconds and centrifuged at 13,000g for 2 minutes. The supernatant was then 
removed using a pipette and 1 ml of 100% ethanol was added to the pellet in order to 
remove excess xylene, mixed by vortexing and centrifuged at 13,000g for 2 minutes. The 
supernatant was again removed by pipetting and the pellet allowed to air dry. The pellet 
was then resuspended in 150μl of Buffer PKD and 10μl Proteinase K, and incubated at 55ºC 
for 15 minutes, then at 80ºC for 15 minutes. 320μl of Buffer RBC was added and the sample 
transferred to a spin column and centrifuged for 30 seconds at 8,000g.  A volume of 720μl of 
100% ethanol was added to the flow-through and the sample added to an RNeasy spin 
column and centrifuged for 15 seconds at 8,000g. 500μl of Buffer RPE Wash Buffer was 
added and centrifuged for 15 seconds at 8,000g. The RNA was eluted using 30μl of RNase-
free water. 
3.5.2 Extraction and concentration of RNA from PBMCs 
RNA was extracted from PBMCs was carried out using the QIAgen RNA Blood Minikit with a 
modified protocol. 2x106 cells were centrifuged at 300g and the supernatant removed by 
aspiration. 350µl of buffer RLT containing 10ul/ml of β-mercaptoethanol was added to each 
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sample. This was then vortexed and added to a QIAshredder spin column in a 2ml collection 
tube and centrifuged at full speed for 2 minutes. The column was then discarded and the 
lysate added to 350µl of 70% ethanol and then placed in a QIAamp spin column and 
centrifuged for 15 seconds at 8000g. The lysate was then discarded and 700µl of buffer RW1 
added to the column which was inverted and then centrifuged for 15 seconds at 8000g. 
500µl of buffer RPE was then added to the spin column and centrifuged for 15 seconds at 
8000g. A further 500µl of buffer RPE was added and centrifuged at 20000g for 2 minutes. 
This step was repeated with a further centrifuge step of 1 minute carried out prior to elution 
with 30µl of RNase-free water. The RNA concentration and 260:230 and 260:280 
absorbance ratios were then measured using a nanodrop machine. 
3.5.3 Strain-specific PCR  
Semi-nested strain-specific PCR was carried out using primers designed to amplify specific 
HVR-1 sequences in order to determine if low copy numbers of virus (not detected by clonal 
analysis) were present in preceding plasma samples of 11 patients thought to be 
superinfected with new strains and used to amplify HCV RNA baseline samples. PCR 
products were sequenced in order to rule out non-specific primer-binding.  
 
3.6 Computer-based methods for viral sequence analysis 
3.6.1 Program for cropping sequence files using Python 
Primer sequences were produced in separate sequence (.seq) files. A computer program 
was designed using the programming language Python to crop primers and vector sequence 
leaving the desired sequence behind in the correct orientation in fasta format (Appendix 2).  
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3.6.2 Sequence alignment 
Sequences were next translated and aligned in Fasta format in an open reading frame using 
Clustal W (www.ebi.ac.uk/Tools/clustalw) and MUSCLE www.ebi.ac.uk/muscle).  
Chromatograms were visualised and sequences edited manually using BioEdit.  
 
3.6.3 Construction of neighbour-joined phylogenetic trees 
Phylogenetic and molecular evolutionary analyses were conducted using MEGA version 4 
(Tamura et al 2007) and the Kimura-2 parameter (K80). All trees were inferred using 1000 
bootstrap replicates. Branches with bootstrap values > 70 were considered to be reliable. 
3.6.4 Construction of maximum likelihood trees 
Data files were converted from MEGA format to nexus format and imported into Phylip 
v3.68 and Garli v0.96 for the calculation of maximum likelihood trees. 
3.6.5 Path-O-Gen v1.2 
Path-O-Gen is a tool designed for analysing trees that have not been inferred under a 
molecular-clock assumption to see how valid this assumption may be. It can also root the 
tree at the position that is likely to be the most compatible with the assumption of the 
molecular clock. Maximum likelihood trees were constructed using GARLI and then analysed 
using this tool in order to assess their suitability for application in a molecular clock model. 
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3.6.6 Estimating tree topologies using a molecular clock model   
Initially sequences aligned in nexus format were uploaded to the data manipulation and 
model selection programme BEAUTI v1.4.8. Sequences were assigned a number in days 
based on the number of days from the earliest detected sequence. Initially a strict molecular 
model was implemented (less computationally intensive) and subsequently 2 relaxed 
models (exponential and logarithmic) applied to sequences derived from each patient at a 
minimum of 3 time points. The resulting xml programme file was implemented in BEAST 
v1.4.8 for a predetermined number of MCMC analyses. Two files were then produced – a 
log file and a tree file. The log file was examined in Tracer v1.4.1 in order to analyse the 
output to check performance and accuracy. An appropriate burn in was selected on the 
basis of the trace file (Figure 3.3) and effective sample size scores (ESS) of >100 were 
considered to be reliable. 
 
Each phylogenetic reconstruction was repeated twice and uploaded into Tracer and LogCombiner 
v1.4.8  to maximise accuracy.  Finally a consensus tree was created in TreeAnnotator v1.4.8. The 
resulting consensus tree was then viewed and edited in FigTree v1.2.2. 
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Figure 3.3 Tracer file output 
 
Figure 3.3 Tracer file output A trace file is shown with each variable tested against the length of 
MCMC. The excluded burn in region (highlighted) was highly variable while the selected region 
illustrated adjacent regions of similarity 
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3.6.7 Detecting evidence of purifying or positive section by 
pairwise comparison of sequences using the codon-based Z 
test 
In order to identify sequence pairs under positive selection or purifying selection pressure, 
the codon=based Z test was implemented using MEGA 4.0. Two hypotheses were tested: 
                          
       
               
 
 
                         
       
               
 
 
                           
 
If Z>1 for the purifying selection hypothesis H1 (dS>dN), this indicates evidence of purifying 
selection, where amino acid changes to the sequence have been eliminated. If Z>1 for the 
positive selection hypothesis H1 (dS>dN), this indicates evidence of positive selection, 
where amino acid changes to the sequence have been selected. The variance of the 
difference between these two quantities is estimated by the bootstrap method. In MEGA, a 
matrix is constructed and p values obtained for each pair of sequences indicating which are 
under purifying or positive selection respectively. 
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3.6.8 Testing for neutrality using Tajima and Fu and Li’s D test in 
DNAsp v5 
In order to test for neutrality, sequences were opened in nexus format in DNAsp v5. A 
sliding window was created for sequence alignments from each patient in order to view the 
d score across 50 nucleotide stretches with a corresponding p value for each region 
examined. 
 
3.6.9 Codon-specific models of positive, neutral or purifying 
selection 
3.6.9.1 Detecting codon-specific selection using HyPhy 
In order to identify specific regions of the genome under positive or negative selection, 
initially, sequences obtained from patients over time were examined using HyPhy 
(Kosakovsky et al, 2005) on the server located at www.datamonkey.org. Sequence 
alignments were entered in adjusted MEGA format. Three different codon-based maximum 
likelihood methods, SLAC, FEL and REL, can be used estimate the dN/dS (ω) ratio at every 
codon in the alignment. Each model involves the construction of a nucleotide model 
maximum likelihood (ML) fit, then the construction of a codon model ML fit and codon 
ancestral sequences are next reconstructed site by site using maximum likelihood by using 
the data generated from both ML models. Finally, for every variable site, the expected and 
observed dN and dS values are compared and codons under selection identified by a variety 
of statistical modelling techniques. In this study, the REL method was used. 
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3.6.9.2 Detecting codon-specific selection using CODEML 
The computer software package PAML may be used to produce evidence of codon based 
selection (using CODEML). Sequences alignments were converted to interleaved Phylip 4.0 
format from MEGA 4.0 (.phy). Maximum likelihood trees were constructed using the PHYLIP 
dnaml programme and saved in Phylip format (.tree). The CODEML control file which 
contains the specified model script was adjusted for each set of sequences analysed in order 
to identify the input Phylip sequence alignment, the input Phylip ML tree and the output 
file. The model was next selected. Initially, Model 0 was used, which calculates a dN/dS ratio 
averaged across the whole tree (each branch is assigned the same ratio). Next, Model 1 was 
used which calculates an independent dN/dS ratio for each branch of the tree. The log 
likelihood of the 2 models was next compared, to see if the variation in Model 1 was >Model 
0 indicating that variation was not the same across the phylogenetic tree. The likelihood 
ratio test is next carried out using a chi square analysis by comparing the log likelihoods (lnl) 
for each model. The chi square value is taken as 2*(lnl1-lnl2). The degrees of freedom are 
calculated as the number of parameters estimated under the 2 models -1. Under model 0, 1 
parameter is measured (the mean dN/dS ratio) while under model 1, each branch is counted 
and the degrees of freedom are the number of branches-1. 
 
3.7 Results 
3.7.1 The impact of transmission diversity on outcome 
In order to address the hypothesis that route of transmission impacts diversity and final 
outcome, we constructed a neighbour-joined phylogenetic tree using majority quasispecies 
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from the entire cohort in order to identify if IDU patients were dispersed throughout the 
cohort or were represented by one or several monophyletic lineages (Figure 3.4). This 
revealed that IDU patients were dispersed throughout the cohort. 
 
Figure 3.4: Neighbour-joined phylogenetic tree by route of exposure 
 
 
 
Figure 3.4 Neighbour-joined phylogenetic tree identifying patients by route of exposure: A 
neighbour-joined phylogenetic tree (K80 model) was constructed using 95 majority quasispecies 
strains from IDU patients (red squares) and non-IDU patients (black squares) and 214 reference 
sequences derived from patients from Europe and the USA available on the Los Alamos database.   
 
139 
 
Sequence diversity was next compared in the IDU and mucosal exposure populations (Table 
3.1).   
Table 3.1 Clinical and virological measures and route of exposure 
Transmission route IDU + mucosal   95% CI Mucosal   95% CI P value 
Number of patients 
 
29 - 69 - - 
Baseline HCV VL (log10) 
 
6.39             5.97, 6.89 5.79             5.24, 6.08 0.05* 
Peak HCV VL (log10) 
 
6.91 6.49, 7.22 6.22  5.82, 6.45 0.001** 
Baseline ALT 
 
68 42, 149 86 48, 140 0.57 
Peak ALT 
 
585         
  
401, 1480 
 
311        234, 467 
 
0.03* 
Baseline bilirubin 
 
9                6, 12 12         9, 16 0.05* 
Peak bilirubin 
 
17            15,  19 15.50            14, 20 0.84 
Baseline quasispecies 
 
4 3, 5 4 3,6 0.55 
Total quasispecies (all samples 
combined) 
10 7, 14 11 8, 14 0.75 
      
Baseline Hamming  
distance 
 
3.38 0.28 ,11.28 0.49 0.36, 1.16 0.05* 
Hamming distance  
at 3 months 
 
1.89             0.31, 15.32 1.95              0.94, 4.94 0.26 
Mean Hamming distance 12.29 2.67, 17.08 2.52 1.41, 9.33 0.03* 
Spontaneous clearance 
 
3/30 
(10%) 
 9/64 
(14%) 
 0.75 
SVR 2/9  
(22%) 
- 18/21 
(86%) 
- 0.002* 
 
In order to further investigate diversity at the time of transmission, Bayesian phylogenetic 
trees were constructed using a molecular clock model in 22 patients (Figure 3.5). Patients in 
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the IDU group had a higher viral diversity at the time of transmission (transmission window 
highlighted in blue) than patients in the mucosal exposure group showing that although the 
number of quasispecies was not significantly different in the 2 groups, patients were 
infected with more diverse quasispecies; each of the IDU patients is infected with 2 groups 
of quasispecies which originate from 2 different branches, while the quasispecies in patients 
with mucosal exposure derive from the same branch, suggesting that a bottleneck at the 
time of transmission occurs in this group of patients.   
 
Two transmitting couples within the cohort were identified. Both had dual infection with 
genotypes 1a and 4d. Bayesian phylogenetic trees were constructed for each pair using a 
logarithmic relaxed molecular clock model. Both showed multiple probable transmission 
events over time. 
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Figure 3.5 Bayesian phylogenetic trees: a) IDU exposure and b) Mucosal exposure 
a) IDU exposure (Subjects 11 and 34) 
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b) Mucosal exposure (Subjects 5 and 14) 
 
 
Figure 3.5: 4 Bayesian phylogenetic trees illustrating 2 IDU (Figure 3.5a) and 2 mucosal exposure 
patients (Figure 3.5b). Trees were constructed using a strict molecular clock with a fixed rate across 
all branches in BEAST v1.4.8. The blue shading indicates the transmission window (time from last 
negative PCR to first positive PCR). 
Day 0
Day 99
Day 310 
Patient 69
Strict clock 8e-4
GTR + γ
LCA =  416.673 days
Day 389
143 
 
Figure 3.6 Bayesian phylogenetic tree analysis of transmitting couples (TC): a) TC1 and b) TC2 
a) TC1        b)   TC2 
  
 
Figure 3.6: Bayesian phylogenetic trees from TC1 and TC2 constructed using a logarithmic relaxed 
molecular model and 120x106 and 10x106 MCMC respectively in BEAST v1.4.8. Branches derived from 
each patient are coloured red and blue (Figure 3.6.a TC1: Subjects 13 [red] and 34 [blue]; Figure 3.6b 
Subjects 9 [red] and 45 [blue]). In addition, in Figure b, PBMC-derived sequences were analysed (light 
blue; patient 45, pink patient 9). The length of each branch is given in days. 
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3.7.2 The impact of superinfection and recrudescence of minority strains on viral diversity over 
time 
In order to investigate whether new viral strains were being introduced into individual patients as a 
result of superinfection or as the result of recrudescence of minority variant strains, PCR primers 
were designed to specifically identify the introduced strains. These were used in a third semi-nested 
PCR step to amplify the cDNA obtained from the first positive (baseline) sample. 15 patients had 
sequences sufficiently divergent to design primers to detect the new strain exclusively (Figure 3.7) 
and PCR product was amplified successfully in 11/15 of these.  
Figure 3.7: Strain-specific PCR: a) Primer sequences, b) Alignment of old and new strains detected 
with strain-specific primer sequences for subject 13, and c) PCR gel electrophoresis image. 
a) Primer sequences 
Primer name Patient number Primer Sequences 
ET26643 2 ATGCTTAGTCCGGGCGCC 
ET4485 3 GGCCGCGTTTGGTCTC 
ET7609 6 CGGGCCGCGTTTGCTC 
ET22503 8 CTGCGAATAGCCTTGCC 
ET1117 12 CTTCACCTCACTGTTCAA 
ET5322_4 13 GACCACGTCTGCTGTCG 
ET5322_1 13 TGGTGCCAATGCTATAACTG 
ET55108 18 CGCCCGCACTGTGAATAG 
ET25196 21 AAGTGCTGCTAAGACCACGTC 
ET55427 27 CTGAGACCATGTCTGGTCTCG 
ET8438 28 GCCGGGCTTGTCGATCTC 
ET21754 29 GGCGCGTTGGGAATTAG 
ET5645 31 GGTGCCAATGCTATAACTGG 
ET21860 37 GCTATTGCCAAATCCGCATTC 
ET27758 39 AAGTGCTGCTCGGACCATG 
ET2387 44 CCGCTGGATTTGCCAGCTTCAG 
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a) Alignment of old and new strains detected with strain-specific primer sequences in patient 13 
 
b) Amplified strain-specific PCR products run on a 2% agarose gel 
 
Figure 3.7: Strain-specific PCR: a) Primer sequences, b) Alignment of old and new strains detected 
with strain-specific primer sequences for subject 13, and c) PCR gel electrophoresis image. 
HVR-1 amplicons obtained using strain-specific primers in a third semi-nested PCR round. from 
subjects 13 and 37 at 2 time points. A strain-specific product is present as expected at the second 
time point in subject 13, but not at the first, while a strain-specific product is detected at both time 
points in subject 37  
 
Negative              6/1/4        14/8/3                     6/3/6   13/11/6 
control                      Patient 13                                  Patient 37 
200 bp 
ladder 
100 bp 
product 
Sample 2 
sequences 
Sample 1 
sequences 
Primer specific to 
sample 1 strains 
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Of the 11 patients who had successful amplification of a strain-specific product, sequences 
characteristic of the new majority strain were identified in baseline samples in 4 patients 
(36%) by strain-specific PCR. Thus 64% of patients demonstrating evidence of new strains 
were likely to have been superinfected. The experiment was repeated to exclude 
contamination and the products were gel extracted and sequenced in order to confirm that 
non-specific amplification had not occurred.  
 
3.7.3 The impact of compartmentalisation on recrudescence of minority strains 
over time 
3.7.3.1 Compartmentalisation within PBMCs 
In order to assess whether sequence strains were archived within PBMCs or the liver, RNA 
was extracted from PBMCs derived from 20 patients and a paraffin-embedded liver biopsy 
taken for investigation of deranged liver function in subject 1 during early infection with 
HCV. 
Of 20 patients tested, 11 had a positive PCR result (61%). This was strongly associated with 
outcome; no SC patients had detectable virus within PBMCs (Table 3.2). 
Table 3.2 HCV detection within PBMCs and outcome 
 Spontaneous clearance Plateau progression Fluctuating viraemia p value 
PBMC PCR positive 0% 
0/4 
100% 
6/6 
60% 
6/10 
0.011* 
 
Median HCV VL 
(IU/ml) 
0 
(0, 27) 
1260734     
(9143, 1731309) 
151166  
(0, 1002869) 
 
0.02* 
PCR positive and  
VL< 50  
0% 
0/4 
0% 
0/6 
100% 
3/3 
0.02* 
 
147 
 
In order to determine if the presence of HCV within PBMCs had an effect on T cell function, 
flow cytometry was carried out as described in Chapter 4 in order to determine IFNγ, IL-2, 
IL-17 and TNFα expression in HCV+ and HCV- PBMCs in response to pooled HCV peptides 
and PMA/ionomycin. Expression of IL-2, IL-17 and TNFα did not differ between groups. 
However, a significant difference in IFNγ production was noted between the groups 
stimulated with HCV peptides (Table 3.3). No difference was noted between PBMC total 
IFNγ production in response to PMA/ionomycin but CD4 IFNγ production was slightly 
reduced in PBMCs of the HCV+ group (p=0.05).   
Table 3.3: IFNγ expression in HCV+ and HCV- PBMCs following stimulation with pooled 
HCV peptides 
 PBMC HCV+ PBMC HCV- p value  
Total IFNγ 0 
(0, 0.44) 
1.48 
(0.58, 9.48) 
0.002** 
CD4 IFNγ 0 
(0, 0.01) 
0.47 
(0, 1.48) 
0.01* 
CD8 IFNγ 0 
(0, 0.07) 
0.45 
(0, 1.95) 
0.02* 
 
 
3.7.3.2 Compartmentalisation within the liver 
One patient (subject 1) had a liver biopsy at the time of acute HCV infection. He had had 
acute HCV infection (genotype 1a) in January 2004. His viral load initially descended to 
undetectable in February 2004 despite deranged liver function tests, but became positive 
again within 1 month. He was subsequently treated with pegIFNα and ribavirin for one year. 
Six months after completion of treatment, the HCV RNA was undetectable by PCR (detection 
limit <12 IU/ml) and the ALT was normal. In May 2006 his CD4 count dropped to 106 x106 
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cells/mm3 and he required treatment for Pneumocystis jeroveci pneumonia. In October 
2006, his previously normal ALT rose to 133 IU/l and HCV-RNA was detectable once again. 
He denied any episodes of unprotected sex or contact with his previous partner, or any 
other high- risk exposure to HCV. We aimed to investigate whether this was due to 
reinfection or reactivation of virus, and to see if variation in strains was present in PBMCs 
obtained in April 2007, the liver biopsy from February 2004 (taken when the plasma HCV VL 
was negative) and a blood sample taken prior to this, during detectable viraemia. No virus 
was detected within PBMCs from April 2007. However, PCR for HVR-1 was successful 
following RNA extraction from a 1mm section of paraffin embedded liver biopsy. A 
neighbour-joined phylogenetic tree was constructed revealing that sequences derived from 
all three samples were derived from the same branch   
  
149 
 
Figure 3.8: Neighbour-joined circular phylogenetic tree of subject 1 and reference sequences 
 
Figure 3.8: Neighbour-joined circular phylogenetic tree of subject 1 and reference 
sequences. Kimura’s two-parameter model was implemented using MEGA 4. An unrooted circular 
neighbour-joined tree (Kimura two-parameter distance) was constructed using HVR-1 sequences 
(n=442).   Branches derived from patient HVR-1 sequences (n=56) are coloured in yellow (February 
2004), green (April 2007) and red (liver biopsy, February 2004) and compared with genotype 1a 
sequences derived from ten similar HIV and HCV positive patients seen at St Mary's Hospital (n=386) 
and reference strains  (n=6; black diamonds) from the Los Alamos database. Sequences derived from 
the patient cluster together, indicating they are closely related. The relevant branch was supported 
by a bootstrap value of 85 (1000 replicates). 
 
3.7.4 The impact of positive or negative selection pressure on viral diversification   
A number of techniques were used to investigate the impact of the adaptive immune response on 
viral evolution. As described in Chapter 2, higher genetic diversity and dN/dS ratios within the HCV E2 
HVR-1 region occurred in progressors by 150 days of infection.  These increased with time in PV 
patients, fluctuated in patients with FV and decreased in the SC group. We aimed to identify further 
85 
150 
 
evidence of selection within each individual patient (or transmitting pair) and over the population 
sampled over multiple time points. This was carried out using the codon-based Z test implemented in 
MEGA 4.0, neutrality testing using a sliding window analysis and finally using codon-based selection 
methods (HyPhy and CODEML). 
 
3.7.4.1 Codon based z test 
The codon based Z test provides evidence of positive or negative selection by comparing multiple 
paired sequences and providing a model to test for either positive or negative (purifying) selection.  
 
In Figure 3.9, a matrix is displayed showing pairwise comparisons between sequences obtained from 
transmitting couple 2. The majority of sequences are under purifying selection although a smaller 
number show evidence of positive selection. This was the most common picture within all progressor 
patients sampled. No sequences derived from SC patients were subject to positive selection, while 
the majority showed evidence of negative selection.  
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Figure 3.9: Evidence of selection using the codon-based Z test: a) Positively selected 
sequences and b) Negatively selected sequences. 
a)  
b)  
 
Figure 3.9: Evidence 
of selection using the 
codon-based Z test: 
a) Positively selected 
sequences and b) 
Negatively selected 
sequences. Matrices 
are displayed showing 
pairwise comparisons 
between sequences 
obtained from a 
transmitting couple 
with acute HCV (TC2). 
The Z score for each 
pairwise comparison 
is shown above the 
diagonal, with values 
of dN-dS>1 in 
sequences under 
positive selection 
(Figure 3.9a) and 
values of dS-dN>1 in 
sequences under 
negative selection 
(Figure 3.9b). 
Sequence pairs with 
statistical evidence of 
positive or negative 
selection (p<0.05) are 
highlighted in yellow. 
 
152 
 
3.7.4.2 Neutrality testing 
In order to identify regions of the E2 HVR-1 under neutral selection pressure, Fu and Li’s neutrality 
test was implemented using DNAsp v5. The null hypothesis in this test is that the sequences are 
under neutral selection pressure. Thus a negative d test statistic with a significant p value is 
suggestive of positive selection or population expansion with a large number of minority 
polymorphisms, while a positive d test statistic is suggestive of balancing selection. 
For sequences derived from the whole population (patients 1-10), Fu and Li's D test was negative 
(p<0.02) suggesting positive selection. In order to pinpoint which areas of the E2 HVR-1 were under 
positive selection, a sliding window analysis was performed in SC and FV/PV patients. Positive 
selection was evident at several sites at both 5’ and 3’ ends of the E2 HVR-1 region in progressor 
patients, while only a small region was targeted in SC patients (Figure 3.10).  
 
Figure 3.10: Fu and Li's D test in a) clearers and b) PV/FV patients  
a)                                                     b) 
  
Figure 3.10: Fu and Li's D test in a) clearers and b) PV/FV patients. Fu and Li's neutrality 
test was carried out using a sliding window analysis of 424 sequences from subjects 1-10. A 
window length of 25 nucleotides was used. Positive selection was evident at nucleotide 
positions 1-25 (p<0.02), 26-51 (p<0.02), 26-77(p<0.02), 130-180 (p<0.05) and 155-180 
(p<0.02) in chronically infected patients (highlighted in red) but did not reach statistical 
significance in SC patients. 
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3.7.4.3 Codon-specific selection  
In order to identify evidence of codon-specific selection, 2 methods were employed. Both 
methods are similar and involve calculating a dN/dS ratio across all branches of a maximum 
likelihood phylogenetic tree and comparing this ratio with ratios derived from each branch 
on the tree. Initially each method was compared and found to be broadly similar. As 
CODEML was found to be the slightly more conservative method, HyPhy was used to 
identify possible codons under selection. A Bayes factor result of >50 was considered to be 
statistically significant (equivalent to p<0.02). 
 
Table 3.4 Number of codons under positive and negative pressure by group. 
 Cleared PV FV p value 
Negatively  
selected 
0 
(0, 0.9) 
0 
(0,0) 
0 
(0,0) 
0.65 
Positively  
selected 
0 
(0,0) 
0 
(0, 4.7) 
0 
(0,1) 
0.05* 
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Figure 3.11: Frequency of positively selected codons within the E2 HVR-1 region. 
 
Figure 3.11: Frequency of positively selected codons within the E2 HVR-1. The most 
frequently recognised codon (39) corresponds to amino acid position 13 of E2 of the H77 
reference sequence and lies within a previously defined antibody and DRB1*1101 restricted T 
helper cell epitope. The arrowed area corresponds to the HVR-1 within E2. 
 
 
3.8 Discussion 
The central aim of this chapter was to investigate in further detail the mechanisms involved 
in defining viral diversification of early HCV infection in HIV-positive individuals. In 
particular, the roles of transmission diversity, superinfection and the adaptive immune 
response were addressed. 
 
3.8.1 Transmission diversity 
IDU patients were dispersed throughout the cohort (Figure 3.4) and could therefore 
represent a high-risk reservoir of infection. It is compelling to hypothesise that the 
emergence of acute HCV within this cohort may be related to multiple introductions via the 
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IDU route into the MSM population. Patients using parenteral drugs were found to differ 
from mucosal exposure patients in a number of significant ways. Firstly, both the baseline 
and peak HCV VL and the baseline ALT were significantly higher, strongly suggesting a higher 
inoculating dose. Furthermore, as might be expected, the diversity at baseline was also 
significantly higher as HCV acquired via the IDU route is not subject to mucosal immunity. 
The rate of spontaneous clearance in IDUs was lower than that of non-IDU patients, but this 
observation did not reach statistical significance. Strikingly, however, the SVR rate in IDU 
patients was markedly lower than that seen in mucosal infection; 20% versus 86%; p=0.002. 
This could, in part, account for higher SVR rates seen in cohorts of MSM with acute HCV 
(Gilleece et al, 2005) when compared with studies carried out in chronic HCV and HIV co-
infection which included significant number of IDU patients (Torriani et al, 2004) and must 
be a significant confounding factor. The increased diversity observed at transmission in IDUs 
was illustrated with the use of Bayesian inference showing that infecting diversity in IDUs is 
higher. These trees should be regarded with a degree of caution as they were carried out 
using samples obtained over a relatively short period of time, during acute infection and 
were constructed using relatively short PCR fragment sequences. They did however, 
coalesce easily and all had ESS values of >100.   
Two transmitting couples, both with dual genotype 1a and 4d infection were analysed in 
detail using the molecular clock model (Figure 3.6b). Multiple probable transmission events 
can be seen on the tree with the appearance and disappearance of strains acquired and re-
acquired from each partner. TC2 illustrates the same phenomenon, and PBMC samples were 
also available for analysis from this couple. A large amount of genetic diversity is apparent 
within both patients, some of which is specific to the PBMC compartment of each patient. 
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Within the genotype 1a region, it is apparent that PBMC specific strains in subject 9 have 
resulted in infection of the plasma and subsequently the PBMCs of patient 45. A similar 
phenomenon is seen within genotype 4 with transfer of infection from the PBMCs of patient 
9 to the PBMCs of patient 45.  This appearance is strongly suggestive that PBMC-specific 
strains of HCV exist and may act as a reservoir for future recrudescence of virus; a 
phenomenon that has been reported previously (Maggi et al, 1997; Roque Alfonso, 1999). 
 
3.8.2 Compartmentalisation 
We next aimed to investigate whether compartmentalisation of HCV occurred within PBMCs 
and the liver. Interestingly, this was the case in 61% of patients and correlated with 
outcome (p=0.01); None of the SC patients had HCV within PBMCs, while plateau 
progressors exhibited 100% positivity. FV patients had 60% infection of PBMCs. Initially, we 
considered that this could be secondary to passive adsorption of virus from the plasma and 
that the presence of HCV within PBMCs could simply reflect higher viral load within each 
outcome group. As predicted, viral load and the presence of HCV within PBMCs did correlate 
(p=0.02). However, when PBMCs were examined in SC and FV patients following the first 
VL<50 IU/ml in plasma after infection, 100% of FV patients had HCV within their PBMCs, 
while 0% of spontaneous clearers had virus present (p=0.02). Thus, compartmentalisation of 
HCV in PBMCs appears to be a significant occurrence in HIV positive MSM and the presence 
of HCV within PBMCs could help to predict the outcome of acute infection. Furthermore, 
flow cytometry revealed that IFNγ expression in HCV+ PBMCs was virtually undetectable 
when compared with HCV- PBMCs (p=0.002). This effect was seen most strongly in CD4+ 
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cells but also significantly affected the CD8+ response to HCV. It appeared to be a general 
effect, as the CD4+IFNγ response to PMA/ionomycin was also low in HCV+ PBMCs. 
As well as examining PBMCs, we aimed also to investigate the role of the liver as a 
compartment. As liver biopsies are not carried out routinely during acute HCV infection, 
only one patient had a liver biopsy available for retrospective analysis. RNA was 
retrospectively extracted from a paraffin-embedded section obtained during early HCV 
infection and compared with sequences derived from blood. At the time of the biopsy, the 
plasma HCV VL was undetectable (<12IU/ml). However, the liver contained virus which was 
closely related to the original infection prior to transient aviraemia. Subsequently, the 
patient developed severe CD4+ cell deficiency secondary to HIV and the HCV infection re-
emerged. Thus the quality of the CD4 response is highly likely to be central to the control of 
HCV. 
 
3.8.3 Superinfection 
While it initially appeared likely that the above patient had superinfection with HCV, the 
likelihood is that he developed a recrudescent viraemia due to loss of CD4 control. Many 
patients, however, had evidence of the introduction of new strains of HCV after their initial 
infection. This initial conclusion, described in Chapter 2, has some limitations. Clonal 
sequencing was limited to the analysis of only 20 variant strains at a time – a tiny fraction of 
the actual circulating virus population. A strain-specific PCR was therefore designed to 
improve the sensitivity of detection of minority variants possibly present at the first point of 
infection. Interestingly, although the majority of patients initially identified as being 
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superinfected had no evidence of dual infection at the outset, a significant minority (36%) 
had evidence of a small population which later became dominant in the plasma. Thus what 
appears to be superinfection following the detection of divergent viral strains may not be, 
either as a result of lack of detection by clonal analysis or compartmentalisation within the 
PBMCs or liver. 
 
3.8.4 Adaptive immunity 
We originally hypothesised that adaptive immunity would define viral diversification and the 
final outcome of infection. To investigate this, a number of computational predictive 
experiments were carried out. Firstly, the codon-based Z test was used to compare 
sequence pairs. This revealed strong evidence of both purifying and positive selection 
pressures operating within each patient over time. We next applied Fu and Li’s neutrality 
test using DNAsp v5 software. This revealed that the null hypothesis of neutral evolution 
was invalid when applied to sequences obtained from 10 representative patients from the 
cohort (424 sequences from subjects 1-10). A statistically significant negative d score at 
multiple time points in progressor patients, but not SC patients was highly suggestive that 
positive selection pressure was operating during the evolution of viral chronicity. A sliding 
window analysis provided some insight into which parts of the E1/E2 fragment were being 
targeted. In order to investigate this further, patient sequences from 50 subjects within the 
cohort were analysed using CODEML and HyPhy in order to detect evidence of codon-
specific immune selection. A number of significantly selected epitopes were identified 
(Figure 3.11), many within the HVR-1, a well-recognised site of immune selection. Codon-
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specific positive selection within the HVR-1 was associated with progression to chronicity 
(p=0.05). 
3.9 Conclusions 
In summary, viral diversification is significantly related to route of transmission, probably as 
a result of infecting dose and viral diversity. Compartmentalisation and lack of detection of 
minority quasispecies can result in overestimation of superinfection although this is also an 
extremely common event in HIV positive MSM. Based on predictive modelling, the adaptive 
immune response is likely to play a significant role in limiting viral diversity and is the 
subject of the next chapter of this thesis. 
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Chapter 4: Cellular immune responses to HCV in HIV-positive individuals                                           
 
4.1 Introduction 
4.1.1 T cells and their role in the adaptive immune response 
Added together, the total mass of lymphocytes in the human body (2 × 1012 cells) make the 
immune system comparable in size to the liver or brain and their function is as vital in 
maintaining life. In the adult, between 25 and 100 million distinct naive T cell clones exist 
(Arstila et al, 1999). The response to foreign antigens is initiated by the innate immune 
system following the recognition of pathogen-associated molecular patterns (PAMPs) via 
toll-like receptors (TLRs) and other receptors present on antigen presenting cells such as 
dendritic cells.  Recognition of pathogens by dendritic cells is central to the control of 
infection and, in part, governs the type of immune response produced by the adaptive 
immune system; for example, the release of interleukin-12 (IL-12) by antigen-presenting 
cells polarises CD4+ cells towards a Th1 profile and increases IFNγ production.  
 Following recognition of foreign material by cells expressing MHC class 1 (most nucleated 
cells) or class 2 (antigen-presenting cells), the cellular immune response is initiated. Peptides 
are processed within cells, bound to the MHC in the cytosol and expressed on the cell 
surface. T cell receptors then recognise the MHC-antigen complex and a signalling cascade is 
initiated. MHC class I molecules bind antigen in a longitudinal conformation within the 
peptide-binding cleft and present the complex to CD8+ cells. Both ends of this cleft are 
closed and therefore only short peptide fragments are usually expressed at the cell surface 
(8-10 amino acids). Longer fragments may bind, but are cleaved by exopeptidases within the 
endoplasmic reticulum prior to transport to the cell surface. MHC class II molecules are 
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different in structure to MHC I and have a longitudinal binding cleft with open ends. Thus 
longer peptide fragments may bind and be expressed at the cell surface (usually >13 amino 
acids in length). The interaction is stabilised by CD4 and CD8 which act as co-receptors and 
enhanced by co-stimulatory molecules such as CD28, which is present on naive T cells. After 
stimulation, T cells enter a process of maturation, characterised by the expression of a 
variety of cell surface receptors (Table 4.1). 
Table 4.1: Protein expression during T cell maturation in naive, effector and memory T 
cells (adapted from Janeway, 7th edition, 2008). 
 
Receptor Naive Effector Memory  
CD44 + +++ +++ Cell-adhesion molecule 
CD45RO + +++ +++ Involved in TCR signalling 
CD45RA +++ + +++ Involved in TCR signalling 
CD62L +++ - +++ Lymph node homing 
CCR7 +++ +/- +++ Lymph node homing 
CD69 - +++ - Early activation 
IFN - +++ +++ Effector cytokine 
Granzyme 
B 
- +++ +/- Effector molecule in cell killing 
Fasl - +++ + Effector molecule in cell killing 
CD122 +/- ++ ++ IL-2/IL15 receptor 
CD25 - ++ - IL-2 receptor 
CD127 ++ - +++ IL7 receptor 
Ly6C + +++ +++ GPI-linked protein 
CXCR4 + + ++ CXCL12 receptor; tissue migration 
CCR5 +/- ++ +++ CCL3 and CCL4 receptor; tissue migration 
 
After stimulation, CD4+ T cells mainly secrete cytokines while CD8+ T cells act as cytotoxic 
killer cells. The elimination of cells infected with virus is mediated by CD8+ cytotoxic T 
lymphocytes (CTL). Following recognition of peptides derived from intracellular viral 
proteins bound to class I MHC molecules, CTLs insert perforins into the target-cell 
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membrane creating pores through which granzymes enter into the target cell with resultant 
activation of caspase enzymes and apoptosis. CD8+ cytotoxic cells can also bind Fas 
molecule via Fas ligand (FasL), a process that also activates caspases and results in 
apoptosis.  In addition to killing infected cells directly, CD8+ T cells also produce cytokines, 
including tumour necrosis factor (TNFα) and IFNγ.  
CD4+ cells act as either effector cells (Th1, Th2 and Th17 subsets) or as regulatory cells 
expressing FoxP3 and CD25 markers.  CD4+ effector T cells are characterised by polarisation 
into 3 main groups based on cytokine expression profile. Th1 CD4+ cells [Mosmann et al, 
1986] are associated with IFNγ production, while Th2 CD4+ cells *Romagnani, 1991] produce 
IL-4, IL-5, IL-9, IL-10 and IL-13. Th1 cells are formed following exposure to IL12 produced by 
myeloid dendritic cells (DCs) as well as IFNγ produced by NK cells and plasmacytoid DCs. Th1 
responses occur in response to a variety of viral infections as well as intracellular bacteria 
e.g. Mycobacterium and protozoan parasites such as Leishmania. Th2 polarisation occurs in 
the presence of IL4, and Th2 predominant responses occur in the presence of allergic 
inflammatory disorders and helminth infections. Some CD4+ cells are able to produce both 
IFNγ and IL4 and are designated Th0 cells [Mosmann & Sad, 1996]. Another group of CD4+ 
cells; Th17 cells have recently been described in mice and in humans and are characterised 
by their ability to secrete IL-17A. IL-17A release may result in massive tissue inflammation as 
a result of neutrophil activation.  Such cells may also secrete IL-17F, IL-21, IL-22, IL6 and 
TNFα. Th17 cells may share a developmental origin with Th1 cells (Annunziato et al, 2007) as 
both lineages produce IFNγ and express IL12 and IL-23 receptors and the transcription factor 
T bet. Th17 cells express the receptor CD161 (Cosmi et al, 2008) which is also expressed on 
NKT cells. CD161+CD4+Th17 cells may interact with a number of ligands, including lectin-like 
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transcript 1 (LLT1), C-type lectin domain family 2A (CLEC2A) and proliferation-induced 
lymphocyte-associated receptor (PILAR; Huarte et al, 2008). Th17 CD161+ cells are 
concentrated in the liver and the intestine and have been associated with increased 
evidence of liver damage in chronic hepatitis B infection (Zhang et al, 2009) and alcoholic 
liver disease (Yasumi et al, 2007; Lemmers et al, 2009).  In the mouse model, Th17 cells may 
upregulate the expression of antiapoptotic molecules and could therefore increase the 
survival of virus-infected cells (Hou et al, 2009). 
 
4.1.2 The adaptive immune response to HCV 
Although most patients infected with HCV develop chronic infection, a significant proportion 
of individuals spontaneously control virus after acute infection, with the accompanying 
emergence of adaptive immune responses. Further studies to define these protective 
immune responses are critical for future vaccine development and immunotherapies. While 
the phenomenon of resistance to HCV is well recognised, the mechanism is not clear.  
Much work on the mechanisms underlying spontaneous control of HCV has been carried 
out, but this has typically been based on small patient groups. The reason for this is that 
acute HCV virus infection rarely presents clinically, so the time-course of spontaneous 
clearance has not been extensively studied. However, we do know from small human (Cox 
et al 2005; Kantzanou et al 2003; Gruner et al 2001, Thursz et al 1999) and animal (Harcourt, 
2001) studies that both CD4+ and CD8+ T cell immune responses are highly active during 
acute-phase disease. It is thought that such responses are central to acute control of virus, 
and that failure of such responses is accompanied by progression to chronic infection.   
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CD8+ T cell responses are of key importance in the control of HCV infection. MHC class 1 
associations (particularly HLA B27) with spontaneous clearance provide evidence of this 
(McKiernan et al, 2004; Neumann-Haefelin et al, 2007). In the chimpanzee model, a 
reduction in viraemia coincides with the onset of T cell responses at weeks 6 and 8 post-
infection.  A rapid (10-fold) decrease in VL occurs around week 8, following the emergence 
of IFNγ-producing HCV-specific CD4+ and CD8+ T cells (Woollard et al, 2003). Escape from 
such responses by viral mutation in key CD8+ T cell epitopes is accompanied by progression 
to chronicity, and depletion of CD8+ T cells leads to a prolonged course of viraemia (Cooper 
et al 1999). In humans, acute CD8+ T cell responses may be substantial (up to 8% of total 
CD8+ T cells), and are activated during acute infection (Cox et al 2005), targeting a wide 
range of viral epitopes (Table 4.1).  Many of these HCV-specific CD8+ cells express the liver 
homing markers CXCR6 and CD161 (Northfield et al, 2008). These CD161+ cells are made up 
largely of CCR7- effector memory T cells that produce IFNγ and TNFα but contain scanty 
amounts of cytolytic molecules (granzyme B and perforin) and proliferate poorly in vitro.   
 
The emergence of HCV-specific CD8+ IFN+ T cells are associated with viral clearance (Grüner 
et al, 2000; Cox et al, 2005). A number of epitopes are recognised by CD8+ cells within the 
HCV structural and NS proteins (Cox et al, 2005) including a number of immunodominant 
epitopes such as NS3 1073-81 which is commonly recognised in individuals with the HLA A2 
allele and is particularly targeted by SC patients.  In prospective human studies of acute 
infection, immune escape has been observed in a subset of targeted epitopes (Cox et al 
2005) although this is not the only way in which HCV evades the immune response, as 
mutations within NS3 and other regions often do not occur, despite resurgence of viraemia 
(Kantzanou et al, 2003). The necessity of a sustained CD8+ response is key in self-limiting 
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infection. Many patients who eventually progress to chronicity exhibit an initially robust but 
non-sustained T cell response in the absence of immune escape with eventual 
downregulation of markers of activation such as CD38 (Lechner et al, 2000). The mechanism 
for this is not yet fully understood. T cells extracted from patients with acute HCV evolving 
towards chronicity commonly express the negative T cell regulator and exhaustion marker 
PD-1, and blockade  of PD-1 or its receptor PD-L1 is associated with the restoration of 
functional T cell responses both in HIV infection (Day et al, 2006) and in acute HCV infection 
(Urbani et al, 2008). However, while restoration of T cell responses occurs in HCV-infected 
patients following blockade of PD-1 and PDL1, high levels of PD-1 expression have been 
observed to occur early in acute infection during both resolved and chronic stages of 
infection, irrespective of clinical outcome (Kasprowicz et al, 2008). Thus analysis of PD-1 
expression alone is not sufficient to predict infection outcome.  
 
Once chronicity is established, while CD8+ T cell responses are weak or undetectable by 
standard screening methods, they can still be detected using enhanced tetramer staining 
and magnetic bead enrichment (Komatsu, 2003; Barnes et al, 2004).  Cells present in chronic 
infection function poorly and are of an immature phenotype, having failed to express 
markers of T cell maturation, such as perforin (Gruener et al 2001). In contrast, CD8+ T cell 
responses in those who have spontaneously resolved infection are readily detectable, and 
may target a broad range of antigens (Cooper et al 1999; Cox et al 2005). Escape from such 
responses can occur, and may be central to progression to chronicity (Timm et al, 2004; Cox 
et al, 2005; Guglietta et al , 2005). Polyfunctional CD8+ T cell responses (characterised by 
both IFNγ and IL2 secretion) have been observed to correlate with an increased likelihood of 
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spontaneous clearance of HCV and may be restored after early treatment with IFNα and 
ribavirin (Badr et al, 2008) although this has not yet been confirmed in a large study. 
 
In addition to CD8+ T cell responses, CD4+ T cell responses are important in resolution of 
infection (Thursz et al 1999; Harcourt et al 2001; Zajac et al 1998). Indeed, strong 
multispecific CD8+ responses in isolation may not be sufficient to control HCV (Lauer et al, 
2005). Longitudinal and cross-sectional studies of immune responses, as well as genetic 
evidence, support the key role of CD4+ cells in the control of infection. HLA types 
DRB1*0101, DR1B1*1101 (OR=2.14) and DQB1*0301 (OR=2.22) are associated with 
spontaneous resolution of acute HCV (Thursz et al, 1999) and an improved immune 
response (Harcourt, 2001) while HLA-DRB1*0701 is associated with viral persistence 
(Fanning et al, 2001).  
 
In chimpanzees, depletion of CD4+ T cells in immune animals results in persistent infection 
following re-exposure to HCV (Grakoui et al, 2003). CD4+ T cell responses in humans 
predominantly target a variety of regions within core and the non-structural genes 
(Appendix 3).  Targeting of NS proteins has been associated with spontaneous clearance in 
HIV-negative individuals, while responses to core are commoner in chronically evolving 
infection (Gerlach et al, 2005; Aberle et al, 2006; Ruys et al, 2008). The same may be the 
case in HIV-positive patients; in a small study of HIV-positive individuals (n=4), individuals 
with resolved infection or temporary suppression of HCV-RNA had HCV-specific CD4+ T cell 
responses directed predominantly against the NS proteins while an individual with high HCV 
RNA plasma concentrations had CD4+ T cell responses predominantly directed against core 
(van den Berg, 2009).  Thus CD4+ responses to core may not be protective. HCV infection is 
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associated with an increase in core-binding protein (gC1qR) expression on CD4+ T cells, 
which may increase the susceptibility to core-mediated immune dysregulation and facilitate 
the establishment of HCV persistence (Cummings et al, 2009). Further characterisation of 
the epitopes targeted by CD4+ cells has yet to be carried out. Particular conserved epitopes 
have been suggested as protective targets (Appendix 3), but the true nature of any single 
protective epitope has yet to be confirmed in larger studies. This has been in part because 
CD4+ T cell responses are difficult to detect during chronic infection and cohorts of acutely 
infected individuals have been limited in size. A recent study investigated the role of specific 
mutations in core protein in association with CD4+ responses. Viral sequence analysis 
revealed sequence mutation in 2 of 21 individuals and in both of these cases, the circulating 
sequence variant was poorly recognised by host CD4+ T cells (Fleming et al, 2010). IFNγ 
responses were present, however, in the majority of donors, often targeting multiple 
epitopes, and a new immunodominant peptide in core was identified. Although the NS 
proteins might be a better region to examine for immune escape, responses to these 
proteins are often only weakly detectable.   
 
It is likely that CD4+ cells have an effect both directly and indirectly by providing support for 
CD8+ T cells. In animal models, CD4+ T cell help is critical in maintaining long term 
protective CD8+ T cell immunity (Zajac et al 1998). This appears to be the case also in 
humans with maturation of CD8+ responses following on from a protective strong, broad 
CD4+ response (Urbani et al, 2006). All patients (n=16) in this study were found to have 
weak and narrow CD8+ responses at the onset of infection while CD4 responses were found 
to be weak and narrow in patients with a chronic outcome but strong and broad with a Th1 
type profile in resolving infection. This was shown to be followed by a progressive expansion 
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and maturation of CD8+ cells to a CD127+ memory phenotype in SC patients but not those 
progressing to chronicity.  Thus CD4+ responses may contribute to the control of HCV by 
promoting maturation of protective memory CD8+ responses. The IL7 receptor CD127 is 
required for the establishment and maintenance of memory CD4+ and CD8+ T lymphocytes, 
and cells lacking it demonstrate impaired IL-2 secretion and have a short life-span (Golden-
Mason et al, 2006).  Thus, evolution to chronic HCV is characterized by T cells that are 
functionally impaired and exhibit an immature phenotype.  
Both IFNγ and IL-2 production are associated with self-limiting infection and the priming of 
CD8+ T cells following the production of IL-2 by CD4+ cells in response to HCV may influence 
outcome in acute disease (Smyk-Pearson et al, 2008). During chronic infection, some HCV 
specific CD4+ populations are maintained but that they are low in both IL-2 production and 
proliferative capacity (Semmo et al, 2005, Semmo et al, 2007). This profile is similar to that 
seen in CD4+ T cell responses to HIV (Day & Walker, 2003).  In one study, the lack of 
sustained cell mediated immunity which had been observed during early infection (10% of 
chronically infected individuals compared with 70% of subjects who had cleared HCV) was 
accounted for by an impaired ability to proliferate that could be rescued in vitro by 
concomitant exposure to IL-2 (Folgori et al, 2006). 
 
Regulatory CD4+ T cells (FoxP3+CD25+) are present in higher numbers in patients with 
chronic HCV than those with acute HCV. However, during acute HCV infection, while 
maintenance of the CD4+ anti-HCV response is key to clearance of infection (Gerlach et al, 
1999), there is no evidence of a clear relationship between the presence of HCV-specific 
regulatory T cells and the evolution of self-limiting or chronic infection (Heeg et al, 2009).  
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While a Th1 type CD4+ response is associated with spontaneous clearance, it may also be 
associated with increased levels of fibrosis during chronic infection. HCV-specific Th2 type T 
cell responses with increased IL-10 expression may play a dual role in HCV infection, 
dampening effector T-cells to promote viral persistence in acute infection but also 
protecting against progressive fibrosis in chronic disease (Kaplan et al, 2008). Administration 
of IL-10 to HCV-infected patients results in improved necroinflammatory and fibrosis scores, 
but is associated also with an increase in HCV VL (Nelson et al, 2003). 
 
The role of CD4+ T cells is likely to be of particular relevance in patients who are HIV-
infected. In a study of acute HCV with and without HIV coinfection, significantly reduced 
CD4+ IFN responses were observed in HIV positive patients (n=14) versus those in HCV-
monoinfected individuals (n=8), especially those directed against NS3-5 (1/10 vs. 5/8; p = 
0.008; Danta et al, 2008). This could explain in part the reduced rate of spontaneous 
clearance observed in cohorts of HIV-positive individuals with acute HCV. 
 
While providing important insights into the pathogenesis of HCV infection and how the 
immune system may successfully counter infection, there are a number of limitations to 
many of the above studies. Firstly, the cross-sectional design of the majority of these studies 
mean that the timing of immune responses has not been fully explored, particularly 
observations in differences in immune response prior to changes in VL. Furthermore, the 
preclinical phase is under-researched due to lack of presentation.  The assessment of T cell 
responses in blood may not reflect the situation in the liver which is likely to be the main 
site of immunological attack. These drawbacks do not apply to the animal model of disease, 
although extensive studies in chimpanzees have not been carried out because of ethical 
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concerns. We do know however,  that in the chimpanzee model, while intrahepatic 
responses have been observed to correlate most strongly with outcome (Thimme et al, 
2001), responses in the blood do reflect those seen in the liver (Shin et al, 2008). Another 
problem in many studies is that of superinfection which is common in some cohorts 
(Chapter 2; Herring et al, 2004). If T cell responses are assessed against peptides from a 
historical infection e.g. against genotype 1 with a dominant genotype 3 superinfection, then 
the true breadth and vigour of responses may be missed (Harcourt et al, 2003). 
 
In summary, both CD4+ and CD8+ responses are important in resolution of acute HCV 
infection. CD8+ responses are largely associated with responses directed against a broad 
range of viral epitopes. CD4+ responses with a Th1 type cytokine profile directed against the 
NS proteins are protective but must be sustained to achieve clearance of HCV. 
 
The role of innate immune responses in directing an appropriate immune response is still an 
area of uncertainty. Dendritic cells may direct the course of T cell response towards a Th1 or 
Th2 profile and it has been suggested that inhibition of IL-12 by HCV may favour a Th2 
response with resultant persistence of infection (Bain et al, 2001; Fowler et al, 2003). 
 
The role of antibody responses in the control of HCV is also poorly understood as the 
neutralising capacity of such responses has been difficult to define. Viral evolution in 
envelope genes may lead to rapid generation of escape mutants (Farci et al 2000) and 
absence of antibody response may result in a less varied population of HCV quasispecies and 
persistence of infection (Gaud et al 2003). In the chimpanzee model, antibodies limit 
viraemia (Farci et al, 1996). However, the presence of neutralising antibodies is not likely to 
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be central to acute HCV resolution; HCV pseudoparticle-specific neutralising antibodies are 
readily detected in vitro in patients with chronic evolution and impaired virus-specific CD4+ 
T-cell responses but not in patients who clear infection with a robust virus-specific CD4+ T-
cell response (Kaplan et al, 2007).  Interestingly, after long term clearance of virus, antibody 
responses to HCV may be lost, but cellular immune responses maintained (Takaki et al 
2004).  
 
4.1.3 The adaptive immune response to HIV-1 and 2 
Untreated, HIV-1 and 2 infections result in a profound depletion of CD4+ cells, leading to 
severe immunodeficiency and death as a result of opportunistic infection or malignancy. 
Paradoxically, during this time, strong CD8+ cytotoxic T cell responses evolve and are clearly 
involved in the control of HIV VL. In monkeys with experimental simian immunodeficiency 
virus (SIV) infection, depletion of CD8+ cells results in higher levels of HIV VL.  In humans, 
the role of CD8+ cells is clearly implicated by the strong association of MHC class 1 alleles 
with limited and progressive disease. HLA B57 and B27 are over-represented in elite 
controller and long-term non-progressor (LTNP) groups (B57 in around 50%; B27 in around 
20%; Walker et al, 2007). In particular, HLA type B5701 is strongly associated with long-term 
non-progression (Migueles et al, 2000).  HLA B35, in contrast, is associated with more rapid 
progression toward AIDS (Jin et al, 2002). 
 
Following initial infection with HIV and a peak in HIV VL, the acquired immune response 
results in a reduction in VL and plateau viraemia phase. During acute HIV infection, the time 
at which the peak VL descends correlates with the point of peak CD8+ T cell response 
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(Wilson et al, 2000). The final “set-point” or VL level at which this plateau phase settles 
relates directly to the rapidity of progression to AIDS. Some patients are able to control 
infection for many years with very low or undetectable levels of HIV and are known as 
LTNPs (HIV VL<2-5000 copies/ml) or “elite controllers” (<50 copies/ml). A number of 
mechanisms may be responsible in such individuals, but the CD8+ response appears to be 
particularly important with more than 10% of circulating CD8+ cells in individual patients 
targeted against HIV epitopes during the acute phase of infection (reviewed in McMichael & 
Rowland-Jones, 2001). Unlike the situation in HCV infection, it seems that CD8+ responses in 
HIV remain highly activated and are of a more mature phenotype (although effector 
function may still be defective). While the breadth and strength of CD8+ responses as 
measured by ELISpot do not show a clear relationship with viral load or clinical presentation, 
targeting of certain regions of the virus and the production of multiple cytokines do 
correlate with outcome. 
 
Many epitopes are recognised during HIV infection. However, preferential targeting of gag is 
associated with viral control, while decoy targeting of HIV envelope is associated with a 
higher VL (Kiepiela et al, 2007; Peut & Kent, 2007).  HIV-specific CD8+ cells may lyse CD4+ 
cells by perforin and granzyme release and CD4+ cells expressing gag protein are particularly 
susceptible to cell lysis.  CD4+ responses to gag also correlate with outcome, with higher 
levels of IFNγ (Lo-Caputo et al, 2003) and IL-2 (Eyeson et al, 2003) expression in LTNPs.    
Lower levels of IL-10 expression is associated with a protective response (Clerici et al, 1996). 
Thus Th1 responses appear to be more protective than Th2. 
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Another correlate of protective immunity in HIV infection is T cell polyfunctionality. Dual 
production of both IL2 and IFNγ  by CD8+ T cells is associated with reduced viral load in elite 
controllers  (Zimmerli et al, 2005). Furthermore, the production of IFNγ, MIP-1β, IL-2 and 
TNF-α production as well as the expression of CD107a (which is a marker of CD8+ 
degranulation) correlate even more strongly with viral control (Betts et al, 2006).  
Production of IL2 by this population of CD8+ cells may result in T cell proliferation in the 
absence of CD4+ T cell help, likely to be of particular significance in HIV-infected individuals. 
Polyfunctional CD8+ T cell responses occur with increased antigen sensitivity (measured by 
calculating the activation threshold in response to defined concentrations of exogenous 
peptide; Almeida et al, 2009). 
 
4.1.4 Cellular immune responses during co-infection with HCV and HIV 
As described above, the role of a persistent CD4+ response to acute HCV infection is strongly 
linked to resolution of infection. This might be expected to be particularly important in 
individuals also infected with HIV. In patients with chronic HCV, both the prevalence and 
breadth of CD4+ and CD8+ responses are lower in co-infected patients (Capa et al, 2007). 
A recent study of 38 HIV-positive patients with acute HCV found that rare spontaneous 
clearance (n=5) correlated with weak but significant CD4 T-cell responses (Schnuriger A et 
al, 2009). Proliferative responses were observed in 35% of cases and were associated with a 
lower HCV VL (p = 0.04) and spontaneous clearance (p = 0.02). Anti-NS4 responses were 
found to be particularly prominent in SC patients (p = 0.03).  Interestingly, although IFNγ-
producing T cells were detectable ex vivo in 81% of cases, they were found to be 
independent of HCV outcome in this study. 
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CD4+ cell dysfunction may also impact on CD8+ responses during HIV infection, both in 
chimpanzees and humans. In chimpanzees, depletion of CD4+ cells results in impairment of 
CD8+ responses and immune escape (Grakoui et al, 2003). In human, a cross-sectional 
analysis of HCV-specific CD8+ cells responses during chronic HCV and HIV infection revealed 
that HIV-related CD4 cell depletion was associated with significantly lower HCV-specific 
CD8+ cells (p<0.0001; Kim et al, 2005).   
 
While the immune response to HCV is clearly affected by the presence of HIV infection, the 
immune response to HIV may also be altered. In one study, HLA A2-restricted responses to 
the HIV-immunodominant gag epitope SLYNVATL were different in HCV-infected children 
and adolescents with haemophilia with a shift towards a more immature phenotype, more 
typical of HCV and a reduction in perforin and the senescent cell marker CD57 characteristic 
of HIV (Harcourt et al, 2005).  
 
In this study, we aimed to characterise the T cell response in a large cohort of HIV-infected 
patients with acute HCV infection to see if associations could be made with the type of 
response and the likelihood of spontaneous clearance. 
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4.2 Hypotheses 
The early detection of strong multispecific CD4+ and CD8+ T cell responses determines 
outcome in acute HCV in HIV positive individuals 
4.2.1 Spontaneous clearance is associated with a strong multispecific (broad) T cell 
response 
4.2.2 Plateau viraemia is associated with a weak and narrow T cell response 
4.2.3 Fluctuating viraemia in patients without evidence of superinfection may be 
due to variation in T cell function over time 
4.2.4 Use of intravenous methamphetamine may impair the cell-mediated 
response to acute HCV  
 
4.3 Aims 
4.3.1 To characterise T cell responses in this cohort using IFNγ detection by ELISpot 
and multichannel flow cytometry in spontaneous clearance, plateau viraemia and 
fluctuating viraemia  
4.3.2 To assess the effect of IV methamphetamine use on T cell function using by 
ELISpot and multichannel flow cytometry 
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4.4 Methods 
4.4.1 Separation of peripheral blood mononuclear cells (PBMCs) 
Blood samples were obtained using vacutainer tubes containing ethylenediamine 
tetraacetic acid (EDTA). Each sample was added slowly to a 50 ml tube containing 7.5 ml of 
Ficoll-Paque solution and centrifuged at 800g for 20 minutes with no brake. The white blood 
cell fraction was transferred to a new 50 ml tube using a sterile Pasteur pipette, made up to 
15ml using phosphate buffered saline (PBS) and centrifuged for 5 minutes at 400g. The 
supernatant was discarded and the pellet resuspended in 5ml of PBS. 100μl trypan blue dye 
(0.5%) was added to 100μl of solution and the cells were counted by direct microscopy. A 
further centrifugation step was carried out for 5 minutes at 400g. The cells were then 
resuspended in heat-inactivated foetal calf serum (FCS) at a concentration of 5 million cells/ml 
FCS. A 20% solution of dimethyl sulphoxide (DMSO) in Roswell Park Memorial Institute 
(RPMI) medium was prepared and 1ml added to each ml of resuspended cells.  The PBMCs 
were placed in 2ml NUNC tubes, insulated, frozen overnight at -800C and then stored in 
liquid nitrogen. 
 
4.4.2 Thawing of PBMCs 
Thawing medium (TM) was made by diluting CTL Wash supplement medium 1:10 in RPMI, 
with 1:100 L-glutamine and 50U/ml Benzonase. DNAse was added at 1:100. TM and R10 
medium [RPMI 1640 (Sigma-Aldrich), 10% foetal calf serum (Sigma-Aldrich), and 10 mM 
HEPES buffer (Sigma-Aldrich)] were prewarmed in a 37oC (+/- 1oC) waterbath. Cells were 
thawed quickly with gentle agitation in a 37oC (+/- 1oC) water bath and transferred using a 
sterile 1 ml pipette to a 50ml tube. TM was added to each tube drop wise in 1-2 minutes of 
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dispensing/mixing cycles diluting to 10x the original volume.  Cells were then centrifuged at 
18-20oC at 250g for 10 minutes.  The supernatant was aspirated, the cells resuspended in 
1ml RC lysis buffer (Gibco) with 4 ml/thawed vial of R10 medium and transferred to a 37°C 
incubator in a 5% CO2 atmosphere overnight. Cell viability was assessed using flow 
cytometry (Guava) and cell numbers included in each assay were determined as the total 
number of live cells (range 70-96%).  
 
4.4.3 HLA typing 
Genomic DNA was extracted from 200µl whole blood or 1x106 PBMCs using the QIAamp 
DNA Blood Mini Kit (Qiagen) and the concentration calculated using a nanodrop machine or 
spectrophotometer. HLA typing was then carried out at the Anthony Nolan Institute, Royal 
Free Hospital. 
4.4.4 Ex-vivo IFN ELISpot assay 
Polyvinylidene plates (96-well; Millipore) were coated with 100µl 1:200 dilution of mouse anti-human 
gamma interferon (IFNγ) antibody (MAbTech) in sterile phosphate-buffered saline at 4°C overnight. Thawed 
PBMCs were added at 200,000 live cells/well in 100µl of R10 medium containing 2mM glutamine and 50U 
of penicillin-streptomycin/ml. Samples obtained from 5 patients were analysed using 100,000 live cells/well 
due to limited availability of cells. Genotype-specific peptides (genotypes 1a, 1b and 3a) were added directly 
to the wells at a final concentration of 6µg/ml (Table 4.2). Genotype 1b peptides were used for patients 
with genotype 4d infection. The plates were incubated for 18 hours at 37°C in 5% CO2. Plates were then 
washed, labelled with a 1:2000 dilution of biotinylated mouse anti-human IFN monoclonal antibody 
(MAbTech), and developed by incubation with alkaline phosphatase-conjugated anti-biotin monoclonal 
antibody (Vector Laboratories), followed by incubation with 5-bromo- 4-chloro-indolylphosphate (BCIP)–
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nitroblue tetrazolium (NBT) (Pierce) in Tris buffer (pH 9.5). The reaction was stopped by washing with tap 
water, and the plates were dried overnight, prior to counting. The numbers of spots per well were counted 
using an automated Elispot plate reader (AID, Germany) and results expressed as spot-forming cells 
(SFCs)/million PBMCs after subtracting the negative well from test well values. All plates were read using 
the same calibration settings. If the negative control (DMSO) background was greater than 55 spot-forming 
cells (SFC)/106 PBMC, the sample was retested.  Responses were considered positive if the number of spots 
per well minus the background was at least 25 SFC/106 PBMC according to an established laboratory 
protocol at the University of Oxford ; concavalin A stimulated cells served as a positive control.  
Table 4.2: Peptide pools 
a) Genotype 1a peptides 
Peptide Pool  Abbreviation a.a. range  Peptide at Start of Pool Peptide at End of Pool 
HCV H77 Peptide 
Pool A 
Core 1-191 MSTNPKPQRKTKRNTNRR LALLSCLTVPASA 
HCV H77 Peptide 
Pool B 
E1  192-383  
YQVRNSSGLYHVTNDCPN 
WAKVLVVLLLFAGVDA 
HCV H77 Peptide 
Pool C 
E2 384-746 ETHVTGGNAGRTTAGLV CLWMMLLISQAEA 
HCV H77 Peptide 
Pool D 
p7 + NS2 747-1026 ALENLVILNAASLAGTH PADGMVSKGWRLL 
HCV H77 Peptide 
Pool E 
NS3p 1027-1353 APITAYAQQTRGLLGCII AETAGARLVVLATATPPG 
HCV H77 Peptide 
Pool F 
NS3h 1343-1657 LVVLATATPPGSVTVSH ITKYIMTCMSADLEVVT 
HCV H77 Peptide 
Pool G 
NS4 1658-1972 STWVLVGGVLAALAAYCL HQWISSECTTPC 
HCV H77 Peptide 
Pool H 
NS5A 1973-2420 SGSWLRDIWDWICEVL VSSGADTEDVVCC 
HCV H77 Peptide 
Pool I 
NS5BI 2421-2718 SMSYSWTGALVTPCAA ASGVLTTSCGNTLTCYIK 
HCV H77 Peptide 
Pool J 
NS5BII 2708-3011 SCGNTLTCYIKARAACRA LLAAGVGIYLLPNR 
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b) Genotype 1b peptides 
 
c)  
 
 
 
 
 
 
 
  
 Peptide Pool   Abbreviation a.a. range  
of pool 
 Peptide at Start of Pool  Peptide at End of Pool 
HCV J4 Peptide 
Pool A 
Core 1-191 MSTNPKPQRKTKRNTNRR LALLSCLTIPASA 
HCV J4 Peptide 
Pool B 
E1  192-383 YEVRNVSGIYHVTNDCSN WAKVLIVALLFAGVDG 
HCV J4 Peptide 
Pool C 
E2 384-746 ETHTTGRVAGHTTSGF RVCACLWMMLLIAQAEA 
HCV J4 Peptide 
Pool D 
p7 + NS2 747-1026 ALENLVVLNAASVAGAH ADSLEGQGWRLL 
HCV J4 Peptide 
Pool F 
NS3p 1027-1353 APITAYSQQTRGVLGCII AETAGARLVVLATATPPG 
HCV J4 Peptide 
Pool G 
NS3h 1343-1657  LVVLATATPPGSVTVPH ITKYIMACMSADLEVVT 
HCV J4 Peptide 
Pool H 
NS4 1658-1972 STWVLVGGVLAALAAYCL HQWINEDCSTPC 
HCV J4 Peptide 
Pool I 
NS5A 1973-2419  SGSWLRDVWDWICTVL TVSEEASEDVVCC 
HCV J4 Peptide 
Pool L 
NS5BI 2420-2717 SMSYTWTGALITPCAA ASGVLTTSCGNTLTCYLK 
HCV J4 Peptide 
Pool M 
NS5BII 2707-3010 SCGNTLTCYLKATAACRA LLSVGVGIYLLPNR 
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d) Genotype 3a peptides 
 
Peptide Pool  Abbreviation  a.a. Range 
of pool 
  
 Peptide at Start of 
Pool 
Peptide at  End of Pool 
HCV NS3 Peptide 
Pool A 
Core 1-191 MSTLPKPQRKTKRNTIRR  LALFSCLIHPAAS 
HCV NS3 Peptide 
Pool B 
E1  192-383 LEWRNTSGLYVLTNDCSN WAKVAIIMVMFSGVDA 
HCV NS3 Peptide 
Pool C 
E2 384-752  STHVTAGQAARNAYGI ARVCVALWLILTISQAEA 
HCV NS3 Peptide 
Pool D 
p7 + NS2 753-1032 ALENLVTLNAVAAAGTH ADDYREMGWRLL 
HCV NS3 Peptide 
Pool F 
NS3p 1033-1359 APITAYAQQTRGLLGTIV AETAGVRLTVLATATPPG 
HCV NS3 Peptide 
Pool G 
NS3h 1349-1663 LTVLATATPPGSITVPH ITKYVMACMSADLEVTT 
HCV NS4 Peptide 
Pool H 
NS4 1664-1978 STWVLLGGVLAAVAAYCL RRLHQWINEDYPSPC 
HCV NS5a Peptide 
Pool I 
NS5A 1979-2430 SGDWLRIIWDWVCSVV TVSDSEEQSVVCC 
HCV NS5b Peptide 
Pool L 
NS5BI 2431-2726 SMSYSWTGALITPCSA CRASGVLPTSFGNTITCY 
HCV NS5b Peptide 
Pool M 
NS5BII 2716-3021 PTSFGNTITCYIKATAAA  LLTVGVGIFLLPAR 
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4.4.5 Flow cytometry 
PBMCs were thawed and 100µl containing 1x106 live cells added to a 96 well plate and left 
in an incubator for 2-4 hours prior to stimulation. Peptides formed 3 antigen pools 
(corresponding to combined pools used for ELISpot analysis) as shown in Table 4.3. 
 
Table 4.3: Peptide pools used for flow cytometry 
 Stocks Final conc. 
P1  Pools ABCD  
Core, E1, E2, p7, 
NS2 
(0.3mg/ml)  
1ug/ml 
P2  Pools EFG 
NS3HP, NS4AB 
(0.3mg/ml)  
1ug/ml 
P3   Pools HIJ 
NS5A, NS5BI and 
II 
(0.3mg/ml)   
1ug/ml 
 
Cells to which 1µl DMSO or 1µl PMA and ionomyosin were added instead of peptide pools 
served as negative and positive controls respectively. The samples were then incubated for 
2 hours at 37C. 2µl of brefeldin A was next added at a concentration of 10ug/ml and the 
samples were incubated overnight at 37C. The next day, 100µl PBS was added to each well 
with a multichannel pipette and the plates were spun at 1500rpm for 5 minutes. The 
supernatant was discarded and 50 µl of a mastermix containing 1:50 live/dead dye, 1:50 
CD19-Pacific Blue (Invitrogen) and 1:100 CD14-Pacific Blue (Invitrogen) antibodies was 
added and incubated for 20-30min in the dark at room temperature. CD14, CD19 and live 
dead dye were used to reduce the likelihood of non-specific background staining. 150µl PBS 
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was next added to wash the cells and the plates spun at 1500rpm for 5minutes. The 
supernatant was discarded and the cells incubated in 100 µl 1% FACS fix (1ml formaldehyde 
+ 36ml PBS) for 20 minutes. 100µl of Foxp3 Perm buffer was added followed by 
centrifugation at 1600rpm for 5 minutes and the supernatant discarded. The cells were then 
incubated in 200µl of a 1:10 dilution of FoxP3 Perm buffer for 20 minutes. The cells were 
spun at 1600rpm for 5minutes and the supernatant discarded, then resuspended in an 
antibody cocktail made in FoxP3 Perm buffer (50µl per well; Table 4.4) and incubated for 30 
minutes. 
 
Table 4.4: Antibodies used for flow cytometry 
Antibody Manufacturer Concentration 
Anti-IL-17-PE eBiosciences 1:25 IL-17-PE 
Anti-Human CD8 PerCP-
Cy5.5 
BD 1:100 CD8-PerCP 
Cy5.5 
Anti-Human IFN Alx700 BD 1:50 IFNg-
AlexaFluor700 
Anti-IL-2-APC BD 1:25 IL-2-APC 
Anti-human TNF BD 1:25 TNFa-PE-Cy7 
Anti-CD3 Pacific Orange Invitrogen 1:50 CD3-Pacific 
Orange 
Anti-human CD4 QDot605 Invitrogen 1:200 CD4-Qdot 605 
 
The cells were next washed in 150µl of buffer and 200µl of PBS, centrifuged at 1600rpm for 
5 minutes and resuspended in 200µl PBS. Cells were analysed using an LSRII flow cytometer. 
Prior to analysis of samples, compensation controls were set up on ice with 4 µl of each 
antibody using compensation beads and a compensation matrix set up using FACS Diva 
software. A negative control sample was used to adjust voltage thresholds for forward and 
side scatter and each antibody.  Gates were created to select for lymphocytes, single cells, 
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live CD3 positive cells and then CD4/CD8, IFN, TNF, IL-2 and IL-17 (Figure 4.1).  Lymphocyte 
gates were adjusted as necessary to include the appropriate cells for each sample, but all 
other gates remained unchanged. Data was analysed using FlowJo v7.5 software (Tree Star). 
 
Figure 4.1 Flow cytometry analysis 
a. FSC vs SSC plot for PBMCs 
 
 
b. Gates used to select for live CD3+ T cells 
 
Side scatter 
(SSC) 
 
 
Forward scatter (FSC) 
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c. Selection of CD4+ and CD8+ populations 
 
d. Single cytokine stains for IL2, TNFα, IFNγ and IL17 in CD4+ cells   
 
 
 
 
Positive  
control 
Negative 
control 
IL2 IL17 IFNγ TNFα 
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e. Dual cytokine gates for IFN, IL2, IL17, and TNF in CD4+ cells   
 
 
Positive  
control 
Negative 
control 
Figure 4.1 Flow cytometry 
analysis a) FSC vs SSC plot for 
PBMCs The lymphocyte 
population was selected as 
illustrated b) Gates used to 
select for live CD3+ T cells c) 
Selection of CD4+ and CD8+ 
populations d) Single 
cytokine stains for IL2, TNFα, 
IFNγ and IL17 in CD4+ The 
same gates were used in the 
analysis of CD8+ cells 
e) Dual cytokine gates for 
IFN, IL2, IL17, and TNF in 
CD4+ cells  The same gates 
were used in the analysis of 
CD8+ cells 
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4.5 Results 
4.5.1 HLA typing 
After HLA typing, patients were initially grouped into those with a favourable or 
unfavourable HLA type, based on previous studies. HLA B27, DRB1*0101, DRB1*1101 and 
DQB1*0301 were considered to be protective and assigned a score of +1, while DRB1*0701 
was considered unfavourable and assigned a score of -1. Other HLA types were assigned a 
score of 0. Fisher’s exact test with the Bonferroni correction for multiple comparisons was 
used to analyse the data. Initially, MHC class appeared to be weakly associated with 
outcome (p=0.07). However, when the associations were divided into classes I and II, while 
class I MHC was not associated with outcome (p=0.54), class II alleles were strongly 
associated (p<0.0001). Specific new HLA associations were not investigated due to sample 
size. 
4.5.2 ELISpots 
Interferon gamma (IFNγ) production in response to pooled peptides spanning the entire 
viral genome were measured by ELISpot at 2 time points in 40 patients with genotype 1a 
infection (Figure 4.2). Total responses at baseline were significantly higher in SC versus PV 
(p=0.006) and FV (p=0.01) patients while responses were not significantly different by 3-6 
months. Spontaneous clearance was associated with significantly increased early responses 
to p7/NS2, NS3 protease and NS5A when compared with both PV and FV progressors. SC 
patients also had significantly increased responses to NS3 helicase and NS5B than PV 
patients but not FV patients. 
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Figure 4.2 Ex vivo IFNγ ELISpot results by group over time a) Total T cell responses b) T cell 
responses across the HCV genome c) T cell responses to individual peptide pools 
a) Total T cell responses at baseline and 3-6 months   
 
b) T cell responses across the HCV genome at baseline and 3-6 months 
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c) T cell responses to individual peptide pools at baseline and 3-6 months 
 
 
Time  Cleared  
Median spots/10
6
 cells  
(95%CI)  
[% with positive well]  
Plateau  
Median spots/10
6
 cells  
(95%CI)  
[% with positive well]  
Fluctuating 
Median spots/10
6
 cells  
(95%CI)  
[% with positive well] 
p value  
Cleared vs Plateau 
Cleared vs Fluctuating 
(Median  
spots)  
Baseline  (0-3 months)   
Core  18 (0, 25)  
[14%]  
0 (0, 13)  
[9%]  
5 (0, 8) 
[10%] 
0.36  
0.49 
E1  20 (0, 35)  
[43%]  
5 ( 0    11)  
[9%]  
4 (0, 5) 
[10%] 
0.28 
0.38  
E2  10 (0, 28)  
[29%]  
5 ( 0        17.5)  
[9%]  
9 (3,13) 
[15%] 
0.45 
0.91  
p7/NS2  20 (8, 33)  
[29%]  
0 (0, 11)  
[9%]  
1 (0, 10) 
[10%] 
0.006* 
0.005*  
NS3p  28 ( 13.14286    62.9)  
[71%]  
3 ( 0    23)  
[18%]  
14 (5, 22) 
[25%] 
0.007* 
0.05* 
NS3h  25 ( 1.571429    58.)  
[56%]  
0 ( 0    15.9)  
[9%]  
6 (3, 33) 
[30%] 
0.02* 
0.42  
NS4A and B  20 ( 1.571429    43.4)  
[43%]  
10 ( 0    30.7)  
[27%]  
8 (5, 18) 
[15%] 
0.14 
0.35 
NS5A  30 ( 1.571429          64)  
[57%]  
10 ( 0    25.7)  
[18%]  
0 (0, 10) 
[10%] 
0.24 
0.03*  
NS5BI  38 (3, 68)  
[71%]  
0 (0, 18)  
[18%]  
7 (0, 21) 
[26%] 
0.02* 
0.08  
NS5BII  5 ( 0    77)  
[29%]  
0 (0, 10)  
[9%]  
0 (0, 9) 
[16%] 
0.22 
0.46  
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Figure 4.2: T cells responses to pooled peptides spanning the entire HCV genome were assessed by 
ELISpot in 40 patients with genotype 1a infection at 2 time points. Significant results (p<0.05) are 
highlighted with asterisks.  a) Total T cell responses b) and c) T cell responses to individual peptide 
pools across the HCV genome    
 Cleared  
Median spots/10
6
 cells  
(95%CI)  
[% with positive well]  
Plateau  
Median spots/10
6
 cells  
(95%CI)  
[% with positive well]  
Fluctuating 
Median spots/10
6
 cells  
(95%CI)  
[% with positive well] 
p value  
Cleared vs Plateau 
Cleared vs Fluctuating 
(Median  
spots)  
3-6 months     
Core  16 (1, 31)  
[17%]  
5 (3, 20)  
[0%]  
10 (0, 22) 
[13%] 
0.43  
0.53 
E1  1 (0, 23)  
[17%]  
8 (0, 18)  
[0%]  
10 (0, 34) 
[21%] 
0.50 
0.24  
E2  3 (0, 26)  
[17%]  
3 (0, 8)  
[0%]  
5 (0,17) 
[7%] 
0.89 
0.53  
p7/NS2  6 (0, 19)  
[0%]  
3 (0, 8)  
[0%]  
13 (5, 26) 
[21%] 
0.51 
0.21  
NS3p  19  (1, 76)  
[33%]  
18 (8, 23)  
[0%]  
5 (0, 23) 
[27%] 
0.90 
0.37  
NS3h  15  (0, 56)  
[17%]  
8  (8, 20)  
[0%]  
10 (1, 47) 
[21%] 
1.00 
0.79  
NS4A and B  16 (0, 85)  
[33%]  
5 (0, 8)  
[0%]  
10 (0, 14) 
[14%] 
0.24 
0.42  
NS5A  5 (0, 81)  
[33%]  
0 (0, 28)  
[33%]  
8 (0, 14) 
[14%] 
0.57 
 0.93 
NS5BI  14 (1, 22)  
[0%]  
0 (0, 13)  
[0%]  
3 (0, 30) 
[21%] 
0.15  
0.23 
NS5BII  0 (0, 0)  
[0%]  
8 (0, 15)  
[0%]  
0 (0, 8) 
[14%] 
0.03* 
0.06  
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Within individual patients, T cell responses were variable over time, particularly in the FV group 
(Figure 4.3).  
Figure 4.3 ELISpot responses in representative patients from each group  
 
 
Figure 4.3: T cells responses were assessed by IFNγ ELISpot. Spot forming cells (SFCs) represent cells 
expressing IFNγ.  SC patients had significantly higher responses at baseline than PV patients. FV 
patients displayed a non-sustained response. 
 
 
 
 
 
 
 
  
191 
 
 
4.5.3 Flow cytometry 
 
4.5.3.1 Flow cytometry results by outcome group 
In order to correlate outcome with cytokine expression, 50 patients had PBMC samples available for 
flow cytometry analysis. Initially, total T cell responses to peptides from across the genome were 
measured and subsequently, the response to each peptide pool was assessed after gating for CD4 or 
CD8 expression (Tables 4.5-4.10). All results are shown after subtraction of the DMSO negative 
control result.  
4.5.3.1.1 CD4+ responses by outcome group 
Production of IFNγ by CD4+ cells was higher in SC patients, reaching a statistically significant 
difference following stimulation with peptide pool 3 (containing peptides derived from NS5A and 
NS5B; p=0.04; Table 4.6). While IFNγ expression was also higher following stimulation with peptide 
pools 1 and 2, this did not reach statistical significance (Appendix 4). 
 
Table 4.5: Total CD4+ cell responses: all peptide pools 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFNγ 0.45 0.08,1.24 0.01 0, 0.27 0.02 0, 0.12  0.05* 
IL-17  0 0,0.08 0.02 0,0.07 0 0,0.03  0.54 
TNFα  0.05 0,0.23 0.21 0,0.89 0 0,0.11  0.83 
IL-2 0.04 0,0.19 0 0,0.01 0.02 0,0.04  0.82 
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Table 4.6: CD4+ cell responses  following stimulation with peptide pool 3 
 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFNγ 0.58 0,2.73 0 0,0 0 0,0.05  0.04* 
IL-17  0.04 0,0.63 0.02 0,0.09 0 0,0.05  0.51  
TNFα  0.1 0,3.4 0.02 0,0.94 0 0,0.6  0.65 
IL-2 0.02 0,0.22 0 0,0.03 0.02 0,0.1  0.60 
 
 
Within the CD4+ IFN+ population, dual expression of IFN+TNF+ and IFN+IL17+ were also significantly 
higher in the SC group than in progressors (p=0.01 and p=0.006 respectively; Table 4.7).  
 
Table 4.7 Dual cytokine expression in CD4+ cells to all peptides 
 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN+ve TNF+ve   0.15 0.01,0.39 0 0,0.04 0 0,0  0.01* 
IFN+ve IL-17+ve   0.01 0.01,0.03 0 0,0 0 0,0 0.006** 
IFN+ve IL-2+ve   0 0,0.02 0 0,0 0 0,0  0.40 
 
These IFN+TNF+ and IFN+IL17+ populations were evident following stimulation with peptide pool 3 
but not 1 or 2 (Table 4.8; Figure 4.4; Appendix 4). 
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Table 4.8 Dual cytokine expression in CD4+ positive cells stimulated with peptide pool 3 
 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN+ve TNF+ve   0.37 0,2.67 0 0,0.04 0 0,0.03  0.03* 
 IFN+ve IL-17+ve   0.03 0,0.12 0 0,0 0 0,0  0.0007** 
 IFN+ve IL-2+ve   0 0,0.03 0 0,0.01 0 0,0.01  0.68 
 
 
Figure 4.4: IFNγ and IL-17 expression in CD4+ cells stimulated with peptide pool 3.  
 
                        Clearer      Plateau   
  
Figure 4.4: IFNγ and IL17 secretion in 2 representative patients with spontaneous clearance 
and plateau progression. The small population of IFN+IL17+ CD4+ cells highlighted in red in 
the SC patient is not observed in the PV patient. 
 
4.5.3.1.2 CD8+ responses by outcome group 
Production of IFNγ by CD8+ cells was higher in SC patients but this difference was not statistically 
significant (p=0.75; Appendix 4). However, dual expression of IFNγ and TNFα by CD8+ cells was 
increased in the SC group (p=0.04; Table 4.9; Appendix 4).   
IL-17  
(PE) 
 
IFNγ (AF700) 
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Table 4.9 Dual cytokine expression in CD8+ cells to all peptides 
 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN+ve TNF+ve   0.14 0.01,0.38 0 0,0.05 0 0,0.01 0.04* 
IFN+ve IL-17+ve   0 0,0.01 0 0,0.01 0.01 0,0.02 0.33 
IFN+ve IL-2+ve   0 0,0.02 0 0,0.01 0 0,0.01 0.50  
 
 
4.5.3.1.3 Fluctuating viraemia 
 
As with ELISpot analyses, patients with fluctuating viraemia were noted to have marked variation in T 
cell response over time, in association with changes in HCV viral load (Figure 4.5). 
Figure 4.5: CD4+ IFNγ and IL-17 expression in a FV patient.  
      
Figure 4.5: This is the same FV patient as illustrated in Figure 4.3 at 2 time points, 3 months 
apart, revealing variation in IFNγ expression from CD4+ cells. The CD4+IFNγ+IL-17+ 
expression seen in spontaneous clearers is absent at both time points.  
  
IFNγ (AF700) 
 
IL-17 
(PE) 
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4.5.3.2 Flow cytometry results by route of infection 
 
In order to investigate if T cell responses were significantly different in patients who used 
intravenous or intramuscular drugs (IDUs), T cell responses were compared between the 
groups as above (Tables 4.10-4.16).  
 
4.5.3.2.1 CD4+ responses in IDUs versus non-IDUs 
IDUs were significantly more likely to have low levels of IL-2 expression by CD4+ cells 
(p=0.0004; Table 4.10).  
Table 4.10: Total responses in CD4+ cells to all pools 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0.01 0,0.1 0 0,0.04  0.26 
IL-17  0 0,0.02 0 0,0.04  0.90 
TNFα  0.01 0,0.14 0 0,0.99  0.67 
IL-2 0.01 0,0.03 0 0,0 0.0004**  
 
Lack of IL-2 expression by CD4+ cells in the IDU population was particularly marked in response to 
stimulation with the NS proteins (pools 2 and 3; Table 4.11).  
  
196 
 
 Table 4.11: CD4+ cell responses by peptide pool a) Peptide pool 2 b) Peptide pool 3 
 
a) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B) 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0.01 0,0.6 0 0.16,  0.37 
IL-17  0 0,0 0 0,0.07 0.49  
TNFα  0 0,0.19 0 0,2.94 0.86  
IL-2 0.06 0.02,0.63 0 0,0.01  0.002** 
 
b) Peptide pool 3 (NS5A, NS5BI and II) 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0 0,0.19 0 0,0.49 0.77  
IL-17  0 0,0.1 0.01 0,0.1 0.80 
TNFα  0.01 0,0.32 0.1 0,4.38 0.38  
IL-2 0.01 0,0.03 0 0,0  0.05* 
 
A difference in dual expression of IFNγ and IL-2 in the CD4+ population in IDUs was also evident 
(p=0.0003; Table 4.12; Figure 4.6). 
 
Table 4.12 Dual cytokine expression in CD4+ cells to all peptides 
Cytokine No IDU 95% CI IDU 95% CI P value 
 IFN+ve TNF+ve   0.01 0,0.04 0 0,0.04 0.83 
 IFN+ve IL-17+ve   0 0,0.01 0 0,0.01 0.71  
 IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.0003**  
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This loss if IFN+ IL2+ population was most evident following stimulation with the NS proteins (pools 2 
and 3; Table 4.13).  
Table 4.13 Dual cytokine expression in CD4+ positive cells by peptide pool a) Peptide pool 1 b) 
Peptide pool 2 c) Peptide pool 3 
 
a) Peptide pool 2  
Cytokine No IDU 95% CI IDU 95% CI P value 
 IFN+ve TNF+ve   0 0,0.14 0 0,0.38 0.86  
 IFN+ve IL-17+ve   0 0,0.01 0 0,0.02 0.92  
 IFN+ve IL-2+ve   0.01 0,0.02 0 0,0 0.01*  
 
b) Peptide pool 3 
Cytokine No IDU 95% CI IDU 95% CI P value 
 IFN+ve TNF+ve   0 0,0.05 0 0,0.42 1.00  
 IFN+ve IL-17+ve   0 0,0 0 0,0.03 0.70  
 IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.04*  
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Figure 4.6: Dual secretion of IL2 and IFNγ from CD4+ cells in HIV-positive IDUs versus non-
IDUs.  
    
 
 
Figure 4.6: Expression of CD3+CD4+ cells secreting IL-2 and IFNγ in a patient with acute HCV 
following mucosal exposure versus a patient with both mucosal (intranasal drug use/sexual 
exposure) and IDU exposures. 
 
4.5.3.2.2 CD8+ responses in IDUs versus non-IDUs 
IFNγ release from CD8+ cells was significantly lower in IDUs than non-IDUs (p=0.05; Table 
4.14). IL2 secretion was also lower.  
Table 4.14: Total CD8+ cell responses to all peptide pools 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0.06 0,0.34 0 0,0.06  0.05* 
IL-17  0 0,0 0 0,0.06  0.65 
TNFα  0.05 0,0.19 0 0,0.79  0.88 
IL-2 0.01 0,0.07 0 0,0  0.01* 
 
This was most apparent in response to stimulation with peptide pools 2 and 3 although only 
IL2 secretion reached statistical significance when individual peptide pools were examined 
(Table 4.15).  
IFNγ (AF700) 
IL-2 (APC) 
IDU Mucosal 
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Table 4.15: CD8+ cell responses by peptide pool a)  Peptide pool 2  b) Peptide pool 3 
 
a) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0.09 0,0.89 0.01 0,0.36  0.28 
IL-17  0 0,0.03 0.03 0,0.14 0.72  
TNFα  0.11 0,0.68 0 0,4.6 0.88  
IL-2 0.12 0.04,1.25 0 0,0.25 0.01*  
 
 
b) Peptide pool 3 (NS5A, NS5BI and II). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFNγ 0.08 0,0.55 0 0,0.54  0.22 
IL-17  0 0,0.1 0 0,0.09 0.79  
TNFα  0.01 0,0.21 0.15 0,6.18 0.31  
IL-2 0.01 0,0.11 0 0,0 0.08 
 
 
Dual secretion of IFNγ and IL-2 from CD8+ positive cells was significantly lower in IDU 
patients despite the fact that the cell populations examined were a small percentage of total 
CD8+ cells (Table 4.16). 
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Table 4.16 Dual cytokine expression in CD8+ positive cells by peptide pool a) Peptide pool 1 b) 
Peptide pool 2 c) Peptide pool 3 
 
a) Peptide pool 2 
Cytokine No IDU 95% CI IDU 95% CI P value 
 IFN+ve TNF+ve   0 0,0.14 0 0,0.38 0.86  
 IFN+ve IL-17+ve   0 0,0.01 0 0,0.02 0.92  
 IFN+ve IL-2+ve   0.01 0,0.02 0 0,0 0.01*  
 
 
b) Peptide pool 3 
Cytokine No IDU 95% CI IDU 95% CI P value 
 IFN+ve TNF+ve   0 0,0.05 0 0,0.42 1.00  
 IFN+ve IL-17+ve   0 0,0 0 0,0.03 0.70  
 IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.04*  
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4.6 Discussion 
4.6.1 The evolution of cellular immune responses  in spontaneous clearance and 
progression to chronicity 
This study is currently the largest longitudinal study of cellular immune responses during 
acute HCV infection in HIV-positive patients. The results indicate that CD4+ responses are 
central to the control of acute HCV in HIV-positive individuals and reveal the role of newly 
described HCV antigen-specific immune responses which are associated with clinical 
outcome.  
Protective immunity in HIV-negative individuals is known to be associated with broad and 
multi-specific CD4+ and CD8+ T-cell responses (Cooper et al, 1999; Lechner et al, 2000; 
Harcourt et al, 2001; Cox et al, 2005). We therefore aimed to ascertain if the decreased 
dN/dS ratios and viral diversity observed within HCV E2 and NS5B in SC and FV patients in 
this HIV-positive cohort (Chapters 2-3) were related to a protective T-cell response, using 
ELISpot and flow cytometry to measure responses to overlapping pooled peptides spanning 
the entire HCV genome.  While variation within the HCV E2 protein is largely antibody driven 
(Farci et al, 2000; Gaud et al, 2003), it does contain T cell epitopes (Appendices 3 and 4) and 
also indirectly reflects the T-cell responses to other parts of the genome such as the non-
structural proteins through a genetic hitchhiking effect (Klenerman et al, 2000). 
We found, as in other studies in HIV-negative populations, that SC patients exhibited 
significantly stronger and broader (multispecific) IFNγ responses than either progressor 
group (PV p=0.006; FV p=0.01, Figure 4.2). In particular, significant differences in response 
to NS2/p7, NS3 protease and NS5A were detected (SC versus FV and PV progressor groups).  
SC patients also had significantly increased responses to NS3 helicase and NS5B than PV 
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progressors. These responses were significantly different within the first 3 months of 
infection. The possibility of overestimation of statistical significance due to multiple 
comparisons is a limitation of the identification of specific regions in this study although the 
significance of the total breadth and strength of the response is robust. Further work to 
identify immunodominant regions at the epitope level is indicated.  
Using flow cytometry, the phenotype of the IFNγ-producing cells observed with ELISpot 
analysis  
was found to be mainly CD4+ and predominantly directed against the non-structural 
proteins (especially against NS5A and NS5B). As in other studies, although responses to core 
protein were detected, they were not significantly associated with a beneficial outcome 
(Gerlach et al, 2005; Aberle et al, 2006; Ruys et al, 2008). The impact of the CD4+ response 
in controlling HCV is highly likely to be prominent in this cohort, at least in part because of 
co-infection with HIV. While only a trend was observed when comparing absolute CD4 count 
with outcome (Chapter 2), CD4 cell function was clearly different between patient groups. 
This was found to be a main determining factor in another recent study of HIV-positive 
patients with acute HCV (Schnuriger et al, 2009). In this study, although CD4+ T cell 
responses were generally weak (<150 SFC)/106 PBMCs) as in the Schnuriger study, they 
were a major determining factor of self resolving or chronically progressing infection. 
Interestingly, of the IFNγ-secreting CD4 cells, a significant larger proportion dually expressed 
IL-17 or TNFα also (p<0.006; p=0.03 respectively) in response to stimulation with NS5A and 
NS5B peptides in SC patients versus progressors. While the percentage of these cells was 
small, a distinct CD4+IL-17+ population could be visualised in SC patients with a small 
increase in CD4+IL-17+IFNγ+ cells (Figure 4.4). Such cells are known to belong to the CD161+ 
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population (Cosmi et al, 2008). As HIV-1 infection is associated with a marked depletion of 
CD161+ Th17 cells, occurring before the onset of clinically apparent HIV-related disease 
(Prendergast et al, 2010), this group might be expected to impact on outcome in this group 
of HIV-infected individuals. CD161 is associated with liver homing and therefore recognition 
of NS5A and NS5B within the liver may be central to mounting a successful immune 
response.  Th17+CD161+ cells have been associated with a higher histological activity index 
after liver biopsy in patients with chronic hepatitis B virus (HBV) infection, possibly as a 
consequence of the release of proinflammatory cytokines (Zhang et al, 2009). Whether the 
situation is similar in HCV infected patients is not yet known. 
While CD4+ phenotypic and functional differences between patient groups were most 
marked, CD8+ responses were also significantly different. Of note, although total CD8+ 
IFNγ+ responses were not markedly different between groups, dual expression of IFNγ and 
TNFα in response to the NS5A/NS5B pool was significantly higher in SC patients. It is likely 
that these CD8+ responses are governed by the CD4+ response. 
While most studies indicate that cellular immunity is the main determinant of acute HCV 
outcome, spontaneous clearance may also occur in the absence of strong multispecific 
responses. This has been reported in chimpanzees (Thomson et al, 2003) and in humans 
during enhanced screening of high-risk individuals, for example in the prison setting (Meyer 
et al, 2007). One patient in this human cohort developed a transient low-level viraemia and 
rapidly cleared HCV in the absence of elevation in LFTs with a weakly detectable ELISA 
response which later disappeared. Innate immune mechanisms are likely to have played a 
role in eliminating infection in this case and more research is indicated in this area. Another 
area warranting further exploration is the role of polyfunctional HCV-specific T cells. These 
204 
 
are better correlates of clinical outcome in HIV infection and their role in HCV is as yet 
unexplored. The advent of sophisticated computer programmes such as PESTLE and SPICE 
designed to analyse such responses make this a realistic prospect. 
 
4.6.2 Fluctuating viraemia 
As expected from the variation in dN/dS ratios over time in the FV group (Chapter 2), T cell 
responses were noted to vary significantly over time (Figures 4.3, 4.5). Despite early strong 
and multispecific IFNγ responses in many FV patients, this was often not sustained. This 
could reflect the increased expression of inhibitory molecules such as the exhaustion marker 
PD-1 (Day et al, 2006; Urbani et al, 2008). As the majority of patients with FV were found to 
be superinfected with new HCV strains, the immune response to the circulating strain may 
be weak while the eliminated strain remains strong. Further experiments using autologous 
peptides could help to delineate this problem. More work is also required to characterise 
the inhibitory and activation marker expression in this group. Another possibility is that 
although FV patients are able to eliminate virus in the periphery, the appropriate cells may 
not home efficiently to the liver. This would be in keeping with the significantly lower 
NS5A/NS5B CD4+ IL-17 responses observed in FV patients when compared with SC patients 
at all time points. This could indicate that although virus is targeted in the periphery, 
intrahepatic responses may be lower in this group. Compartmentalisation of virus in the 
liver appears to occur in some patients in the absence of viraemia (Chapter 3). 
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4.6.3 Cellular immune responses in intravenous methamphetamine users 
Unexpectedly, route of transmission resulted in a different profile in HCV-specific CD4+ and 
CD8+ responses. Patients were divided into those who had a possible intramuscular or 
intravenous injection (IDU) exposure to HCV versus those whose only risk factors were 
mucosal (unprotected sexual intercourse and/or intranasal use of cocaine or ketamine). The 
most commonly injected drug was crystal methamphetamine (Chapter 2). Patients using 
intravenous or intramuscular drugs are dispersed throughout the cohort, have higher viral 
diversity at baseline and lower SVR rates (Chapter 3). Thus although sexual transmission is 
the most frequent route of transmission within this patient population (Danta et al, 2007), a 
significant minority may also have been exposed to infection via the parenteral route. We 
aimed to investigate if T cell responses were different in these groups. 
Patients who injected methamphetamine had significantly different immune responses to 
those who did not. CD4+  IL-2 expression was significantly reduced in the IDU group and 
dual expression of IL2 and IFNγ by CD4+ cells was also significantly reduced.  CD8+ 
responses were also affected with a reduction both in IL2 and IFNγ expression including a 
reduction in dual expression of IFN+ IL2+ CD8+ cells. Thus proliferative responses are highly 
likely to be reduced in the IDU population. These CD8+ and CD4+ responses were directed 
primarily against the NS proteins. Thus the T cell response in patients using parenteral 
recreational drugs (mainly crystal methamphetamine) are suppressed in this cohort. 
Methamphetamine is associated with cellular immune dysfunction in mice and in humans 
(Yu et al, 2002; Martinez et al, 2009; Toussi et al, 2009). The mechanism for this is unclear 
and warrants further investigation. Another explanation for the reduction in T cell function 
could be exposure to a higher viral load and more diverse infecting inoculum in IDU patients 
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resulting in T cell exhaustion. More work is warranted to investigate these processes 
further. 
 
4.7 Conclusions 
In conclusion, the CD4+ response in HIV-positive individuals is central to the resolution of 
infection with HCV.  The evidence of this comes from class II MHC association and functional 
and phenotypic analyses. In particular, IFNγ+ CD4+ responses directed against the NS 
proteins are significantly stronger during self-limiting disease. Further work to map 
protective, cross-specific epitopes is urgently required. Patients with fluctuating viraemia 
have wavering T cell responses and further work on activation and inhibitory receptor 
expression over time in this group would provide insights into the mechanisms behind this 
phenomenon. Intravenous drug users have dysfunctional CD4+ and CD8+ T cell responses 
and this affects the specific response to HCV. More work to identify the mechanism for this 
is warranted.  
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Chapter 5: Final Discussion 
The natural history of acute HCV in HIV-positive MSM  
In this cohort of HIV positive MSM with acute HCV infection, three clinical courses of 
infection were observed; spontaneous clearance (14%), fluctuating viraemia (38%) and 
plateau progression (48%). These outcomes were strongly associated with viral 
diversification at transmission, superinfection and the evolution of the adaptive cellular 
immune response.  
 
5.1 Spontaneous clearance 
Patients with spontaneous clearance had an initial rise and rapid decline in HCV VL within 
100 days of infection. This coincided with a decline in viral diversity and a decreasing dN/dS 
ratio (<1), highly suggestive of purifying selection. Purifying selection was confirmed to be 
the main mechanism of viral evolution in these patients as defined by the codon-based z 
test, Fu and Li’s neutrality test and by identification of codons under selection pressure 
using HyPhy and CODEML-based analyses. An early CD4+ IFNγ+ response was associated 
with spontaneous clearance and was directed predominantly against the NS proteins. 
Interestingly, a slight but significant increase in the Th17 population of CD4+IFN+ cells 
responding to peptide pool 3 containing NS5A and B peptides was noted in resolving 
infection and may represent a liver-homing population of cells. Dual secretion of TNFα and 
IFNγ was also associated with clearance (p=0.006; p=0.03 respectively).  Importantly, PBMCs 
infected with HCV had very low levels of IFNγ expression. It is not clear if this is a direct 
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effect of HCV and HIV within the cell and it would be extremely interesting to investigate 
this further.   
 
5.2 Plateau viraemia 
Patients with plateau viraemia had a peak and then plateau HCV VL during acute HCV 
infection. In these patients, evidence of positive selection as a result of viral evolution was 
clearly evident. A high dN/dS ratio was characteristic and multiple positively selected 
codons were detected in this population within the HCV E2 HVR-1. The number of positively 
selected codons within this region in the presence of weak or absent CD4+ and CD8+ 
responses to the NS proteins was significantly associated with final outcome, suggesting 
that the HCV E2 HVR-1 region may act as an immunological decoy.  In the absence of clear 
CD4+ and CD8+ responses directed against these epitopes, it is likely that they were 
selected by the antibody-mediated response. Further work to clarify this would be 
worthwhile. 
 
5.3 Fluctuating viraemia 
A peak and subsequent slow decline in HCV VL occurred in FV patients who do did not clear 
the infection in the long term (p=0.001; OR 2.76). FV patients who became transiently PCR 
negative took a median of 154 days to reach negativity, while SC patients took a median of 
only 108 days (p=0.04). Furthermore, progressor patients were noted to take an average of 
129 days versus 27 days to reach a 1.7log10 drop in viraemia (p=0.009). The mechanism for 
this appears to be multi-factorial and includes superinfection with new viral strains, re-
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emergence of minority or compartmentalised variants and delayed onset or loss of CD4+ 
and CD8+ HCV specific responses. 
In order to ascertain whether the introduction of new viral strains (superinfection) defined 
this group, a phylogenetic analysis of 2295 sequences obtained from 50 patients within the 
cohort at a median of 3 time points was carried out. A large number of patients had 
evidence of the introduction of new viral strains both within the same strain (30%) and with 
new genotypes (10%). This was significantly more common in FV patients than SC or PV 
patients; 63% of FV patients had evidence of superinfection by clonal sequencing. A strain-
specific PCR later revealed however, that the new dominant quasispecies in 36% of these 
patients had in fact emerged from minority strains present at the onset of infection. Thus 
approximately 41% of FV patients had clear evidence of new superinfecting HCV infection. 
Some of the remainder may have been re-infected with the same strain of HCV, as 
previously described in the chimpanzee model, but the remainder developed recrudescent 
viraemia in the absence of reinfection. We hypothesised on the basis of clinical and 
virological data that partial immune control was responsible for this phenomenon. A 
common theme in studies investigating the T cell response to HCV in HIV-negative 
individuals is that protective CD4+ and CD8+ responses must be sustained over time. This is 
likely to be a particularly important factor in HIV-infected individuals, due to CD4 cell 
dysfunction. Loss of immune control during the first 150 days of infection in FV patients was 
predicted by initially low but increasing dN/dS ratios, rising from <1 (suggestive of purifying 
selection) to a median of 1.78 (highly suggestive of positive selection). The role of cellular 
immunity in defining this population was later established using flow cytometry and ELISpot 
analyses. Interestingly, all patients who became PCR negative in this group had evidence of 
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HCV within PBMCs (100% of FV versus 0% of SC patients with a negative HCV VL). 
Furthermore, PBMCs contained sequences not seen at the same time points in plasma, 
suggesting that this compartment may support independent replication of the virus at low 
level and therefore may act as a reservoir of infection. One patient with acute HCV had a 
liver biopsy carried out during early HCV infection (in the absence of detectable plasma HCV 
VL). This revealed HCV sequences from the initial infection. Following successful treatment, 
the patient developed a recrudescent VL following a period of severe immunosupression 
associated with a low CD4 count. Lack of CD4+ control of HCV present in the liver but not 
the blood is likely to have resulted in this phenomenon. In summary, FV occurs due to 
superinfection events, compartmentalisation of virus in PBMCs and the liver and due to loss 
of immune regulation by CD4+ and CD8+ T cells (Figure 5.1). 
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Figure 5.1 Model of viral evolution in FV patients  
 
 
 
5.4 Route of transmission and final outcome 
We found that route of transmission significantly impacted on the likelihood of response to 
treatment although not significantly on spontaneous clearance. Strikingly low SVR rates 
were observed in IDUs versus patients with mucosal exposure to HCV (20% versus 86%; 
p=0.002). This was significantly associated with higher viral diversity at baseline and pre-
treatment. Interestingly, both IL2 and IFNγ production was lower in IDUs, affecting both the 
CD4+ and CD8+ response. This could be due to higher diversity of the infecting inoculum and 
subsequent T cell exhaustion (Figure 5.2) or a direct effect of methamphetamine which has 
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been associated with immune toxicity in mouse models. Further work to explore the role of 
methamphetamine on control PBMCs would help to clarify this. 
 
Figure 5.2 Transmission diversity and outcome; route of transmission hypothesis 
 
 
 
5.5 Treatment outcome and viral evolution 
The response to treatment with pegIFNα and ribavirin was clearly related to viral diversity 
within the baseline and subsequent samples (p=0.008 and 0.004 respectively). An increasing 
dN/dS ratio was also strongly associated with outcome (p=0.007) and a higher number of 
mutations within the putative ISDR region of NS5A when compared with HCV-1 reference 
sequence. Although the p values comparing the number of amino acid changes suggested 
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that this is a real effect (p=0.00001), the overlapping confidence intervals and low number 
of actual deviations from the reference sequence were so small that it would be impractical 
to use this test as part of standard practice at the current time.  
 
5.6 Conclusions 
In this thesis, we aimed to investigate the following hypotheses:  
1. HCV diversification and evolution predicts the outcome of acute infection in a cohort 
of HIV-infected individuals 
2. Diversification occurs early during the course of infection and defines the later viral 
population and response to treatment 
3. The evolution of acute HCV in this cohort is defined by the adaptive cellular immune 
response  
Using a number of experimental techniques, including extensive longitudinal sequence 
analysis, computational prediction of positive or negative selection pressures and functional 
and phenotypic analyses, it is apparent that all of the above hypotheses are valid. The 
outcome of acute HCV infection in HIV-positive patients is defined by the rate of viral 
evolution within the first 150 days of infection. This is influenced by transmission diversity 
(and the route of infection), superinfection events, compartmentalisation of virus in the 
PBMCs and the liver and is governed by the T cell response. The CD4+ response is key in 
limiting infection as might be expected in an HIV-positive population and delayed or non-
sustained responses are associated with progression to chronicity. Further work is urgently 
required to identify specific and cross-protective epitopes (most likely within the non-
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structural proteins) which are recognized during acute HCV infection to progress the search 
for an effective vaccine against the virus.   
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Chapter 6: Future work 
Following on from this work, a number of further experiments are planned and in progress. 
1. Pyrosequencing analysis of cDNA amplicons using a nested PCR step with fusion 
primers in 20 patients in order to look for evidence of minority strains present within 
baseline samples. This will allow a depth of several thousand sequences and will add 
weight to superinfection being a major mechanism of diversification in progression 
to chronicity. 
 
2. Microarray analysis. A number of patients within the cohort belong to an HIV 
seroconverter study (SPARTAC) and have had PBMC samples taken both before and 
after acute HCV infection. A study has been designed to carry out a microarray 
analysis from these PBMCs, looking at mRNA expression across the whole genome. 
Interferon pathways will be of particular interest when analysing this data. 
 
3. In order to further prediction of spontaneous clearance and SVR, ideally a large 
multicentre cohort should be created. This would increase the statistical power of 
the study and create the possibility of a large scale multivariate analysis. A large 
cohort of such patients would also pave the way for new interventional treatment 
studies. 
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Appendix 1: Vector map TOPO-4 
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Appendix 2: Python programme for cropping sequences 
#!/usr/local/bin/python 
##################################################################################
#### 
# Sequence parsing module   
# 
# Crops sequence files in the following way:  
# 1) removes left and right primer portions 
# 2) copies "good" sequences  
# 3) output is three text files: 
#        a) cropped_sequences.fa (fasta file containing all cropped good sequences) 
#        b) list_good_sequences.log 
#        c) list_bad_sequences.log 
#        d) bad_sequences.fa (fasta file with all bad seqs) 
# must be run from the directory containing the sequence files. 
# 
# Sequence files must be recognizable by a unique extension, e.g. ".seq" 
#                       
# 2009 edition by e.thomson@imperial.ac.uk based on programme by p.cherepanov@imperial.ac.uk 
2007 
##################################################################################
#### 
 
print "sequence parsing module; will search through a list of sequence files, looking for forward and 
reverse primer seuences and count/crop them" 
print "requires sequence recognizable by a unique extention, for example:" 
print "sequence1.seq, sequence2.seq, run125.seq, blabla.seq, etc"  
 
import os, re, string 
from string import maketrans, translate, join 
 
seq_file_extention = raw_input('sequence file extension? For example, type seq for 
sequence.seq:\n') 
seq_file_extention = '.*' + seq_file_extention + '$'  
 
cropped_sequences = open('cropped_sequences.fa', 'w') 
bad_sequences = open('bad_sequences.fa', 'w') 
#primer_product_sequences = open('primer_product_sequences.fa', 'w') 
list_good_sequences = open('list_good_sequences.log', 'w') 
list_bad_sequences = open('list_bad_sequences.log', 'w') 
#list_primer_product_sequences = open('list_primer_product_sequences', 'w') 
list_good_sequences.write('list of good files:') 
list_good_sequences.write('\n') 
list_good_sequences.write('-'*60) 
list_good_sequences.write('\n') 
list_bad_sequences.write('list of bad files:') 
list_bad_sequences.write('\n') 
list_bad_sequences.write('*'*60) 
list_bad_sequences.write('\n') 
number_of_good_sequences = 0 
number_of_bad_sequences = 0 
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number_of_primer_product_sequences = 0 
 
seq_file_count = 0    #sequence counter  
 
trans = maketrans("acgttumrwsykvhdbnACGTTUMRWSYKVHDBN", 
"TGCAAAKYWSRMBDHVNTGCAAAKYWSRMBDHVN")  #reverse complement rules 
 
def reversecomp(sequence): 
 sequence_list = list(sequence) 
 sequence_list.reverse() 
 reversed_sequence = join(sequence_list, '') 
 reverse_complement_sequence = translate(reversed_sequence, trans) 
 return reverse_complement_sequence 
 
forward1 = 
re.compile('(ATGATGAACTGG)|(NTGATGAACTGG)|(ANGATGAACTGG)|(ATNATGAACTGG)|(ATGNTG
AACTGG)|(ATGANGAACTGG)|(ATGATNAACTGG)|(ATGATGNACTGG)|(ATGATGANCTGG)|(ATGATGAA
NTGG)|(ATGATGAACNGG)|(ATGATGAACTNG)|(ATGATGAACTGN)', re.IGNORECASE) 
forward2 = 
re.compile('(GTCCTGGCGGGC)|(NTCCTGGCGGGC)|(GNCCTGGCGGGC)|(GTNCTGGCGGGC)|(GTCNTG
GCGGGC)|(GTCCNGGCGGGC)|(GTCCTNGCGGGC)|(GTCCTGNCGGGC)|(GTCCTGGNGGGC)|(GTCCTGG
CNGGC)|(GTCCTGGCGNGC)|(GTCCTGGCGGNC)|(GTCCTGGCGGGN)', re.IGNORECASE) 
 
reverse1 = 
re.compile('(ACATCAA[CTN]AGCA)|(ANATCAA[CT]AGCA)|(ACNTCAA[CT]AGCA)|(ACANCAA[CT]AGCA)
|(ACATNAA[CT]AGCA)|(ACATCNA[CT]AGCA)|(ACATCAN[CT]AGCA)|(ACATCAA[CT]NGCA)|(ACATCAA[
CT]ANCA)|(ACATCAA[CT]AGNA)|(ACATCAA[CT]AGCN)', re.IGNORECASE) 
reverse2 = 
re.compile('(GGCATATAAATA)|(GNCATATAAATA)|(GGNATATAAATA)|(GGCNTATAAATA)|(GGCANAT
AAATA)|(GGCANATAAATA)|(GGCATNTAAATA)|(GGCATANAAATA)|(GGCATATNAATA)|(GGCATATAN
ATA)|(GGCATATAANTA)|(GGCATATAAANA)|(GGCATATAAATN)', re.IGNORECASE) 
 
 
for fname in os.listdir(os.getcwd()): 
 if re.compile(seq_file_extention).match(fname):  
  seq_file_count = seq_file_count + 1 
  current_seq_file = open(fname, 'r') 
  seq_dirty = current_seq_file.read()  
  oseq = seq_dirty.replace('\n', '')    #removing new line characters, if any; oseq = the 
original sequence 
  LTR_end = -99 
  LINKER_pos = -99 
  seq = oseq 
  rseq = reversecomp(seq) 
 
  if (forward1.search(seq) or forward2.search(seq) or forward1.search(rseq) or 
forward2.search(rseq)) and (reverse1.search(seq) or reverse2.search(seq) or reverse1.search(rseq) 
or reverse2.search(rseq)): 
   if forward1.search(rseq) or forward2.search(rseq): 
    seq = rseq 
   if forward1.search(seq): 
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    LTR_end = seq.find(forward1.search(seq).group()) + 96 
    print LTR_end 
   elif forward2.search(seq): 
    LTR_end = seq.find(forward2.search(seq).group()) 
   if reverse1.search(seq): 
    LINKER_pos = seq.find(reverse1.search(seq).group()) - 3 
   elif reverse2.search(seq): 
    LINKER_pos = seq.find(reverse2.search(seq).group()) 
 
   if LINKER_pos > 0 and LTR_end > 0 and (LINKER_pos - LTR_end > 40): #last 
cond removes primer product observed in some clones 
    right = LINKER_pos 
    left = LTR_end 
    number_of_good_sequences = number_of_good_sequences + 1 
    #print '>', fname, 'cropped', left+12, ':', right 
    cropped = seq[left+12:right] 
    fa_record= '>' + fname + '\n' + cropped +'\n' 
    cropped_sequences.write(fa_record) 
    list_good_sequences.write(fname) 
    list_good_sequences.write('\n') 
    print fname, 'good'  
   else: 
    number_of_bad_sequences = number_of_bad_sequences + 1 
    list_bad_sequences.write(fname) 
    bad_fa_record = '>' + fname + '\n' + oseq + '\n' 
    bad_sequences.write(bad_fa_record) 
    list_bad_sequences.write('\n') 
    print fname, 'baad' 
  else: 
   number_of_bad_sequences = number_of_bad_sequences + 1 
   list_bad_sequences.write(fname) 
   bad_fa_record = '>' + fname + '\n' + oseq + '\n' 
   bad_sequences.write(bad_fa_record) 
   list_bad_sequences.write('\n') 
   print fname, ' bad' 
 
print 'total files parsed: ', seq_file_count 
print 'number of potentially usable sequences:', number_of_good_sequences 
print 'number of bad sequences:', number_of_bad_sequences 
 
cropped_sequences.close() 
bad_sequences.close() 
list_bad_sequences.close() 
list_good_sequences.close() 
raw_input('Done! Press enter to exit...')  
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Appendix 3a: CD8+ restricted epitopes (adapted from the Los Alamos Immunology databse 
http://hcv.lanl.gov/content/immuno/tables/ctl_summary.html) 
Epitope Region HLA 
restriction 
Location 
MSTNPKPQK Core A11 1-9 
STNPKPQK Core A11 2-9 
STNPKPQKK Core A11 2-10 
GVYLLPRRGPRLGVR Core   33-47 
YLLPRRGPRL Core A2 35-44 
YLLPTTGPRL Core A2 35-44 
LLPRRGPRL Core A2 36-44 
GPRLGVRAT Core   41-49 
GPRLGVRAT Core B7 41-49 
GPRLGFRAT Core B7 41-49 
RLGVRATRK Core A3 43-51 
KTSERSQPR Core A3 51-59 
PLYGNEGCGWAGWLL Core   84-98 
NEGLGWAGW Core B44 88-96 
NEGCGWAGW Core B44 88-96 
NEGCGWMGW Core B44 88-96 
ADLMGYIPLV Core A2 111-119 
DPRRRSRNL Core B7 111-119 
GFADLMGYIPLVGAP Core   129-143 
ADLMGYIPLV Core A2 131-140 
DLMGYIPLV Core A2 132-140 
LPGCSFSIF Core B7 169-177 
LLALLSCLTV Core A*0201 178-187 
LLALLSCLTV Core A2 178-187 
CPNSSIVY E1 B35 207-214 
ILHTPGCV E1 A2 220-227 
NASRCWVAM E1 B35 234-242 
QLRRHIDLLV E1 A2 257-266 
QLRRIDLLV E1 A2 257-266 
VFLVSQLFTF E1   284-293 
QLFTFSPRR E1 A3 289-297 
SIYPGHITGH E1   307-316 
WDMMMNWSPTAALVV E1   320-334 
MMMNWSPTT E1   322-330 
LVMAQLLRI E1 A2 332-340 
SMVGNWAKV E1 A2 363-371 
SMVGNWAKVL E1 A2 363-372 
SLLAPGAKQNV E2 A2 401-411 
CRPLTDFDQGW E2 B53 459-469 
DFAQGWGPISYANGS E2   464-478 
246 
 
YPPKPCGI E2 B51 489-496 
GTTDKSGAPT E2   517-526 
TTDKSGAPTYSWGE E2   518-531 
GENDTDVFVL E2 B60 530-539 
VFVLNNTRPPLGNWF E2   536-550 
NTRPPLGNWF E2 B57 541-550 
CVIGGAGNNT E2 B50 569-578 
HYSYRLWHY E2   610-618 
DYPYRLWHY E2 Cw7 610-618 
YRLWHYPCTI E2 Cw7 613-622 
RLWHYPCTV E2   614-622 
TINYTIFK E2 A11 621-628 
RMYVGGVEHR E2 A3 630-639 
LEDRDRSEL E2 B60 654-662 
WAIKWEYVVLLFLLL E2   712-726 
EYVLLLFLL E2 A*2402 717-725 
FFCFAWYLKGRWVPG p7   771-785 
KWVPGAVYTFYGMWPLLLLL p7   781-800 
FYGMWPLL p7 Cw7 790-797 
FYGMWPLLL p7 A29 790-798 
LYGVWPLLL p7 Cw*0801  790-798 
MALTLSPY NS2 A29 827-834 
LSPYYKRYIS NS2 A25 831-840 
LSPYYKRYISW NS2 A25 831-841 
LSPYYKRYISWCLWWLQYFL NS2   831-850 
YISWCLWWL NS2 A23 838-846 
LTRVEAQLHVWVPPL NS2   850-864 
DAVILLMCAVHPTLVFDITK NS2   871-890 
HPALVFDITK NS2   881-890 
PYFVRAQGLI NS2 Cw*0303 910-919 
PYFVRAQGLI NS2 Cw*0304 910-919 
LGALTGTYVYNHLTPLRDWA NS2   941-960 
TYVYDHLTPL NS2 B*4002 947-956 
TYVYDHLTPL NS2 B*4006 947-956 
TPLRDWAHNGLRDLA NS2   954-968 
RDWAHNSL NS2   957-964 
RDWAHNGL NS2 B37 957-964 
INGLPVSARRGQEILL NS2   997-1012 
AYSQQTRGL NS3 A24 1031-1039 
VEGEVQIVSTAAQTF   NS3   1055-1069 
QTFLATCINGVCWTV NS3   1067-1081 
ATCINGVCWTVYHGAGTRTI NS3   1071-1090 
CINGVCWTV NS3   1073-1081 
KLVALGINAV NS3   1073-1081 
CINGVCWTV NS3 A2 1073-1081 
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CVNGVCWTV NS3 A2 1073-1081 
CINGVWCTV NS3 A2 1073-1081 
AGTRTIASPKGPVIQM NS3   1085-1100 
TRTIASPKGPVIQMY   NS3   1087-1101 
DLVGWPAPQGSRSLT   NS3   1107-1121 
RRRGDSRGSLLSPRP NS3   1143-1157 
LLCPAGHAV NS3 A2 1169-1177 
CPAGHAVGIFRAAVCTRGVA NS3   1171-1190 
HAVGLFRAA NS3 A68 1175-1183 
AYAAQGYKVL NS3 Cw*0303 1243-1252 
AYAAQGYKVL NS3 Cw*0304 1243-1252 
TLGFGAYMSK NS3 A11 1261-1270 
LGFGAYMSK NS3 A3 1262-1270 
GAYMSKAHGV NS3 A11 1265-1274 
TITTGAPVTYSTYGK NS3 A2 1284-1298 
TGSPITYSTY NS3 A2 1287-1296 
TGAPVTYSTY NS3 A2 1287-1296 
TYSTYGKFL NS3 A*2402 1292-1300 
CHAQDATTVL NS3 B38 1318-1327 
HPNIEEVAL NS3   1359-1367 
HPNIEEVAL NS3 B*3501 1359-1367 
HPNIEEVAL NS3 B35 1359-1367 
GEIPFYGKAI NS3   1371-1380 
FYGKAIPIEAI NS3   1375-1385 
LEVIKGGRHLIFCHSK NS3   1382-1397 
LIFCHSKKK NS3 A3 1391-1399 
LIFCHSKKKCDELAA   NS3   1391-1405 
HSKKKCDEL NS3   1395-1403 
ATDALMTGY NS3   1395-1403 
HSKRKCDEL NS3   1395-1403 
HSKKKCDEL NS3 B8 1395-1403 
ELAAKLVAL NS3 B8 1402-1410 
LAAKLVALGINAVAY   NS3   1403-1417 
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LAAKLVALGINAVAY NS3   1403-1417 
KLVALGINAV NS3 A2 1406-1415 
GDVVVVSTDALMTGY NS3   1430-1444 
DVVVVATDALMTGYT   NS3   1431-1445 
ATDALMTCY NS3 A1 1436-1444 
ATDALMTGY NS3 A1 1436-1444 
ALMTGYTGDFDSVI NS3   1439-1452 
GFTGDFDSV NS3 A*0206 1443-1451 
MFDSSVLCECYDAGC NS3   1511-1525 
VFTGLTHIDAHFLSQTKQSG NS3   1561-1580 
CLIRLKPTLHGPTPLLYR NS3   1610-1627 
DPRRRSRNL NS3   1610-1627 
LIRLKPTL NS3 B8 1611-1618 
EVTLTHPITKYIMTCMSA NS3 B8 1634-1651 
TLTHPITK NS3 A11 1636-1643 
TLTHPVTK NS3 A11 1636-1643 
STWVLVGGVLAALAA NS4a   1658-1672 
VLAALAAYCL NS4a A2 1666-1675 
IPDREVLY NS4a B35 1695-1702 
EVIAPAVQTNW NS4b   1744-1754 
VIAPAVQTNW NS4b A24 1745-1754 
ETFWAKHMW NS4b A25 1758-1766 
AFWAKHMWNF NS4b   1759-1768 
FWAKHMWNF NS4b A*2402 1760-1768 
GIQYLAGLSTLPGNPAIASL NS4b   1771-1790 
SLMAFTAAV NS4b A2 1789-1797 
LTTSQTLLF NS4b B57 1801-1809 
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LLFNILGGWV NS4b A2 1807-1816 
ILAGYGAGV NS4b A2 1851-1859 
GVAGALVAFK NS4b A3 1858-1867 
VAGALVAFK NS4b A3 1859-1867 
AARVTAIL NS4b   1941-1948 
SECCTPCSGSW NS4b B37 1966-1972 
SECTTPCSGSW NS4b B37 1966-1976 
VLSDFKTWL NS5a A2 1987-1995 
VLDSFKTWL NS5a A2 1987-1995 
DFKTWLQSKL NS5a   1990-1999 
LLREEVSFRV NS5a A2 2140-2149 
HEYPVGSQL NS5a B60 2152-2160 
PCEPEPDVAVL NS5a B35 2161-2171 
EPEPDVAVL NS5a B35 2163-2171 
ARGSPPSVASSSASQLSAPS NS5a   2191-2210 
SVASSSASQLSA NS5a   2197-2208 
QLSAPSLKATCTANH NS5a   2205-2219 
NHDSPDAEL NS5a B38 2218-2226 
SPDAELIEANL NS5a A2 2221-2231 
ELIEANLLW NS5a A25 2225-2233 
ILDSFDPLV NS5a A2 2252-2260 
REISVPAEIL NS5a B60 2266-2275 
KFPPALPIW NS5a A*2402 2280-2288 
VYSTTSRSASL NS5b   2457-2467 
TSRSACQRQKKVTFDRLQVL NS5b   2461-2480 
SLTPPHSAK NS5b A3 2510-2518 
QPEKGGRKPA NS5b B55 2568-2577 
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RLIVFPDLGV NS5b A2 2578-2587 
RVCEKMALY NS5b A3 2588-2596 
MALYDVVSKLPLAVM NS5b   2593-2607 
ALYDVVTKL NS5b A2 2594-2602 
KSKKTPMGF NS5b B57 2629-2637 
KSKKTPMGFSYDTRC NS5b   2629-2643 
GLQDCTMLV NS5b A2 2727-2735 
HDGAGKRVY NS5b A3 2794-2802 
HDGAGKRVYYL NS5b B38 2794-2804 
TARKTPVNSW NS5b A25 2819-2828 
TARHTPVNSW NS5b A25 2819-2828 
RMILMTHFF NS5b A*2402 2842-2850 
CYSIEPLDL NS5b A*2402 2871-2879 
SLHSYSPGEINRVAA NS5b   2893-2907 
SPGEINRVAA NS5b B55 2898-2907 
LGVPPLRAWR NS5b B57 2912-2921 
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Appendix 3b: CD4+ restricted epitopes (adapted from the Los 
Alamos Immunology databse 
http://hcv.lanl.gov/content/immuno/tables/ctl_summary.html) 
  
    
Epitope Protein HLA restriction Location 
MSTNPKPQIKTKRNTNRR Core DR 1-18 
MSTNPKPQRKTKRNTNRRQD Core   1-20 
DVKFPGGGQIVGGVYLLPRR Core   21-40 
DVKFPGGGQIVGGVYLLPRR Core DRB1*1101, DQB1*0301 21-40 
VGGVYLLPRRGPRLG Core   31-45 
VGGVYLLPRR GPRLG   Core DR11 31-45 
VGGVYLLPRRGPRLGVRATR Core   31-50 
RRRSRNLGKVIDTLT Core   113-127 
TLTCGFADLMGYIPL Core   125-139 
GAPLGGAARA LAHGV   Core DR11, DR12 141-155 
GAPLGGAARALAHGVRVLED Core   141-160 
APLGGAARALAHGVR Core   142-156 
SFSIFLLALLSCLTI Core   173-187 
LLSCLTIPASA Core   181-191 
HVTNDCPNSSIVYEA E1   202-216 
CPNSSIVYEAHDAIL E1   207-221 
SRCWVALTPTLAARN E1   236-250 
RCWVAMTPTVATRDG E1   237-251 
MTPTVATRDGKLPAT E1   242-256 
KLPATQLRRHIDLLV E1   252-266 
TIRRHVDLLVGAAAF E1   257-271 
GSATLCSALYVGDLC E1   267-281 
GSVFLIGQLFTFSPR E1   282-296 
TFSPRRHQTVQDCNC E1   292-306 
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SIYPGHITGHRMAWD E1   307-321 
HITGHRMAWDMMMNW E1   312-326 
HVSGHRMAWDMMMNW E1   312-326 
MMMNWSPTAALVMAQ E1   322-336 
SPTAALVVSQLLRIP E1   327-341 
QAILDMIAGAHWGVL E1   342-356 
HWGVLAGLAYYSMVG E1   352-366 
FSMVGNWAKVLVVLL E1   362-376 
NWAKVLVVLLLFAGV E1   367-381 
GFATQRLTSLFALGPSQK E2 DRB1*1101 393-410 
CLWMMLLIAQAEQALL E2   734-749 
AMDREMAASCGGAVF NS2   809-823 
RDAIILLTCAVHPEL NS2   870-884 
GPLMVLQAGIIRAPY NS2   897-911 
PVSARRGREILLGPADGMVS NS2   1001-1020 
GQGWRLLAPITAYSQ NS3   1020-1034 
GPVIQMYTNVDQDLV   NS3   1095-1109 
QGSRSLTPCTCGSSD   NS3   1115-1129 
SSDLYLVTRHADVIP   NS3   1127-1141 
YLVTRHADVIPVRRRGDSRG NS3   1131-1150 
SLLSPRPISYLKGSS   NS3   1151-1165 
CPAGHAVGIFRAAVC   NS3   1171-1185 
LETTMRSPVFTDNSSPPVVP NS3   1201-1220 
SPVFTDNSSP PAVPQ   NS3 DR11 1207-1221 
VPQSFQVAHLHAPTG   NS3   1219-1233 
FQVAHLHAPTGSGKS   NS3   1223-1237 
KVPAAYAAQGYKVLV   NS3   1239-1253 
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PAAYAAQGYKVLVLNPSVAA NS3   1241-1260 
AAKGYKVLVL NPSVA   NS3 DR11 1245-1259 
AQGYKVLVLNPSVAA NS3   1246-1260 
QGYKVLVLNPSVAAT   NS3   1247-1261 
GYKVLVLNPSVAAT NS3 DR 1248-1261 
GYKVLVLNPSVAAT NS3 DR4 1248-1261 
GYKVLVLNPSVAAT NS3 DRB1*1101,DRB1*1201,DRB1 
*0401,DRB1*1302,DRB1*1601 
1248-1261 
GYKVLVLNPSVAATLGFG NS3   1248-1265 
GYKVLVLNPSVAATLGFGAY NS3 DQB1*0301 1248-1267 
VLVLNPSVA NS3 DR 1251-1259 
VLVLNPSVA NS3 DRB1*1101,DRB1*1201,DRB1 
*0401,DRB1*1302,DRB1*1601 
1251-1259 
ITYSTYGKFLADGGCSGGAY NS3   1291-1310 
YSTYGKFLADAGCSGGAY   NS3   1293-1310 
TYGKFLADGGCSGGA   NS3   1295-1309 
LADAGCSGGAYDIIICDE   NS3   1300-1317 
LADAGCSGGAYDIIICDE NS3 DR 1300-1317 
GGAYDIIICDECHST   NS3   1307-1321 
DIIICDECHSTDATS   NS3   1311-1325 
TDATSILGIGTVLDQAETAG NS3   1321-1340 
ATSILGIGTVLDQAE   NS3   1323-1337 
VIKGGRHLIFCHSKKKCD NS3   1384-1401 
VIKGGRHLIFCHSKKKCD NS3 DR15 1384-1401 
VIKGGRHLIFCHSKKKCD NS3 DRB1*15 1384-1401 
VIKGGRHLIFCHSKKKCD   NS3 DRB1*15 1384-1401 
VIKGGRHLIFCHSKKKCD NS3 HLA-DR15 1384-1401 
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VIKGGRHLIFCHSHHHCD NS3 HLA-DRB1*15 1384-1401 
GGRHLIFCHSKKKCD   NS3   1387-1401 
GRHLIFCHSK NS3 DRB1*1501/DRB5*0501 1388-1397 
GRHLIFCHSKR NS3 DRB1*1502/DRB1*1104 1388-1398 
KCDELAAKLVALGIN   NS3   1399-1413 
LAAKLVALGINAVAY   NS3   1403-1417 
GINAVAYYRGLDVSV   NS3   1411-1425 
GINAVAYYRGLDVSVIPTSG NS3   1411-1430 
VAYYRGLDVSV NS3 DRB1*1501 1415-1425 
VAYYRGLDVSVIPTS   NS3   1415-1429 
IPTNGDVVVVSTDALMTG NS3   1426-1443 
ALMTGYTGDFDSVID   NS3   1439-1453 
DFDSVIDCNTCVTQTVDF NS3   1447-1464 
DFDSVIDCNTCVTQTVDF   NS3   1447-1464 
VIDCNTCVTQTVDFS   NS3   1451-1465 
NTCVTQTVDFSLDPT   NS3   1455-1469 
TQTVDFSLDPTFTIE   NS3   1459-1473 
EQYVDFSLDPTFSIE NS3   1459-1473 
PTFTIETTTLPQDAVSRT   NS3   1468-1485 
MFDSSVLCECYDAGC NS3   1511-1525 
YDAGCAWYELTPAETTVRLR NS3   1521-1540 
MPAETTVRLRAYMNTPG NS3   1531-1547 
MPAETTVRLRAYMNTPG NS3 HLA-DR 1531-1547 
TPAETTVRLRAYMNTPGLPV NS3   1531-1550 
TTVRLRAYMNTPGLP   NS3   1535-1549 
LRAYMNTPGLPV NS3 DRB1*1502/DRB1*1104 1539-1550 
LRAYMNTPGLPVCQD   NS3   1539-1553 
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RAYMNTPGLPV NS3 DRB1*0701 1540-1550 
AYMNTPGLPV NS3 DRB1*0101/DRB1*0701 1541-1550 
ESVFTGLTHIDAHFL NS3   1559-1573 
TGLTHIDAHFLSQTK   NS3   1563-1577 
ENLPYLVAYQATVCARAQAP NS3   1581-1600 
LPYLVAYQATVCARA   NS3   1583-1597 
NLPYLVAYQATVCA NS3 DRB1*0101/DRB1*0701 1585-1594 
YLVAYQATVC NS3 DRB1*0301/DRB1*1501 1585-1594 
YLVAYQATVCA NS3 DRB1*1501 1585-1595 
VAYQATVCARAQAPP   NS3   1587-1601 
TAYQATVCARAQAPP NS3   1587-1601 
AQAPPPSWDQMWKCL   NS3   1597-1611 
DQMWLKCLIRLKPTLH NS3   1605-1619 
PTPLLYRLGAVQNEITLTHP NS3   1621-1640 
PVTKYIMACSADLES NS3   1640-1655 
PITKYIMTCMSADLEVVT   NS3   1640-1657 
TSTWVLVGGVLAALA NS3   1657-1671 
NFISGIQYLAGLSTLPGNPA NS4   1767-1786 
TSTWVLVGGVLAA NS4a DRB1*0101/DRB1*0701 1657-1669 
STWVLVGGVLAALAA NS4a   1658-1672 
TWVLVGGVLA NS4a DRB1*0101/DRB1*1301 1659-1668 
AAYCLSTGCVVIVGRVVLSG NS4a   1671-1690 
VVLSGKPAIIPDREVLYREF NS4a DRB1*0301 1686-1705 
GKPAIIPDREVLYRE NS4a DRB1*0301 1690-1704 
IIPDREVLYR NS4a DRB1*0301/DRB1*1501 1694-1703 
IAPAVQTNWQKLETFWAKHM NS4b DRB1*16 or DRB3*0202 1746-1765 
NFISGIQYLAGLSTLPGNPA NS4b DRB1*1104 1767-1786 
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GIQYLAGLSTLPGNPAIASL NS4b   1771-1790 
QYLAGLSTLPG NS4b DRB1*1104 1773-1783 
YLAGLSTLPG NS4b DRB1*1502/DRB1*1104 1774-1783 
LAGLSTLPGNPAIASLMAFT NS4b DRB1*0402/DRB1*1101 1775-1794 
GLSTLPGNPAIASLMAFT NS4b DR 1777-1794 
LPGNPAIASLMAFTAAVTSP NS4b   1781-1800 
PAIASLMAFTA NS4b DRB1*1502/DRB1*1104 1785-1795 
IASLMAFTAA NS4b DRB1*0102 1787-1796 
LTTSQTLLFNILGGWVAAQL NS4b   1801-1820 
TQHTLLFNILGGWVA NS4b   1803-1817 
LFNILGGWVA NS4b DRB1*0101, DRB1*0102 1808-1817 
FNILGGWVA NS4b DRB1*0101/DRB1*0701 1809-1817 
FNILGGWVAAQL NS4b DRB1*0101/DRB1*1301 1809-1820 
LGKVLVDILAGYGAG NS4b   1844-1858 
IMSGEVPSTEDLVNLLPA NS4b DR 1868-1885 
GEVPSTEDLVNLLPAILSPG NS4b   1871-1890 
LVNLLPAILS NS4b DRB1*0101 1879-1888 
NLLPAIL NS4b DRB1*0101, DRB1*0701 1881-1887 
ALVVGVVCAAILRRHVGPGE NS4b   1891-1910 
GPGEGAVQWMNRLIAFASRG NS4b DRB1*1104, DQB1*0501 1907-1926 
EGAVQWMNRLIAFAS NS4b   1910-1924 
GAVQWMNRLIAFASRGNHVS NS4b   1911-1930 
NRLIAFASRGNHVSPTHY NS4b DR 1917-1934 
SQLSARSLKATCTANHDS NS5a DR 2204-2221 
IEANLLWRQEMGGNI NS5a   2227-2241 
VSVPAEILRK SRRFA   NS5a DR11 2268-2282 
VSVPAEILRK SRRFA   NS5a DR11 2270-2284 
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PAELRKSRFAQALPVWAR NS5a   2271-2290 
LRHHNLVYSTTSRSACQRQK NS5b   2451-2470 
KVTFDRLQVLDSHYQDVLKE NS5b   2471-2490 
SVWKDLLEDNVTPIDTTIMA NS5b   2541-2560 
KGGRKPARLIVFPDLGVRVC NS5b   2571-2590 
KPARLIVFPDLGVRVCEK NS5b DR 2575-2592 
KPARLIVFPDLGVRVCEK NS5b HLA-DR 2575-2592 
KLPLAVMGSSYGFQYSPGQR NS5b   2601-2620 
VEFLVQAWKSKKTPMGFSYD NS5b   2621-2640 
SDIRTEEAIYQCCDLDPQAR NS5b   2651-2670 
QCCDLDPQARVAIKSLTERL NS5b   2661-2680 
GYRRCRASGVLT NS5b   2695-2706 
CSSNVSVAHDGAGK NS5b   2786-2799 
SVAHDGAGKRVYYLTRDPTT NS5b   2791-2810 
RDPTTPLARAAWETA   NS5b   2806-2820 
NIIMFAPTLWARMILMTHFF NS5b   2831-2850 
ARMILMTHFFSVLIARDQLE NS5b   2841-2860 
LMIHFFSILAQEQLE NS5b   2845-2860 
INRVAACLRKLGVPPLRAW NS5b   2901-2920 
CGKYLFNWAV RTKLK   NS5b DR11 2941-2955 
CGKYLFNWAVRTKLKLTPIA NS5b   2941-2960 
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Appendix 4: Full flow cytometry results 
 
Table 1: Total T cell responses; all peptides 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN 0.58 0.09,1.25 0.1 0,0.5 0 0,0.06  0.06 
IL-17  0 0,0.09 0.15 0.09,0.26 0.04 0,0.43  0.02* 
TNF 0.02 0,0.42 0.35 0.07,1.17 0.12 0,0.78  0.14 
IL-2 0.02 0,0.29 0.03 0,0.1 0.05 0,0.17  0.85 
Table 2: Total T cell responses by peptide pool 
a) Peptide pool 1 (HCV core, envelope E1 and E2, p7, NS2) 
Cytokine Cleared 95% CI Fluctuating 95% CI Platea
u 
95% CI P value 
 IFN 0.54 0.08,1.28 0.11 0,1.92 0.03 0,0.08  0.14    
 IL-17  0 0,0.61 0.11 0,0.43 0.59 0.01,1.12  0.10 
 TNF 0.07 0,4.94 0.57 0.01,3.93 0.3 0,2.01  0.40 
 IL-2 0.02 0,0.64 0 0,0.04 0 0,0.11  0.41 
b) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B) 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.44 0,7.42 0.23 0.01,1.42 0 0,0.13  1.00 
 IL-17  0 0,0.07 0.14 0,0.35 0 0,0.29  0.05* 
 TNF 0 0,1.7 0.36 0.09,2.62 0.18 0,1.4  0.07 
 IL-2 0 0,12.12 0.18 0.03,1.08 0.12 0.01,1.74  0.31 
c) Peptide pool 3  (NS5A, NS5BI and II) 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.75 0.03,3.95 0 0,0.46 0.01 0,0.67  0.05* 
 IL-17  0.08 0,1.18 0.2 0.01,0.76 0 0,0.45  0.60 
 TNF 0.09 0,6.12 0.12 0,3.17 0.05 0,1.37  0.80 
 IL-2 0.08 0,1.91 0.01 0,0.15 0.11 0,0.51  0.85 
Table 3: Total CD4+ cells: all pools 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.45 0.08,1.24 0.01 0, 0.27 0.02 0, 0.12  0.05* 
 IL-17  0 0,0.08 0.02 0,0.07 0 0,0.03  0.54 
 TNF 0.05 0,0.23 0.21 0,0.89 0 0,0.11  0.83 
 IL-2 0.04 0,0.19 0 0,0.01 0.02 0,0.04  0.82 
 
Table 4: CD4 cell responses by peptide pool:  a) Peptide pool 1, b) Peptide pool 2, and c) Peptide 
pool 3 
a) Peptide pool 1 (HCV core, envelope E1 and E2, p7, NS2) 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.25 0,0.95 0.02 0,0.37 0.02 0,0.09  0.34 
 IL-17  0 0,0.09 0.01 0,0.1 0 0,0.3  0.37 
 TNF 0.07 0,2.75 0.1 0,1.42 0.03 0,0.44  0.71 
 IL-2 0 0,0.19 0 0,0 0 0,0.03  0.33 
b) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B) 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.26 0,2.3 0.01 0,0.55 0 0,0.03  0.79 
 IL-17  0 0,0.03 0 0,0.04 0 0,0.02  0.35 
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 TNF 0 0,0.68 0 0,0.18 0 0,0.48  0.66 
 IL-2 0 0,3.34 0.04 0,0.35 0.04 0,0.47  0.44 
c) Peptide pool 3  (NS5A, NS5BI and II) 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.58 0,2.73 0 0,0 0 0,0.05  0.04* 
 IL-17  0.04 0,0.63 0.02 0,0.09 0 0,0.05  0.51  
 TNF 0.1 0,3.4 0.02 0,0.94 0 0,0.6  0.65 
 IL-2 0.02 0,0.22 0 0,0.03 0.02 0,0.1  0.60 
Table 5: Total CD8+ cells: all peptide pools 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.11 0,0.67 0 0,0.13 0 0,0.06  0.75 
 IL-17  0 0,0.03 0.01 0,0.12 0 0,0.05  0.09 
 TNF 0 0,0.18 0.11 0,0.51 0.05 0,0.28  0.04* 
 IL-2 0.02 0,0.1 0 0,0.07 0 0,0.12 0.91 
Table 6: CD8 responses by peptide pool: a) Peptide pool 1, b) Peptide pool 2, and c) Peptide pool 3 
a) Peptide pool 1 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.11 0,0.74 0.04 0,0.81 0 0,0.12  0.63 
 IL-17  0 0,0.54 0 0,0.22 0.02 0,0.94  0.20 
 TNF 0 0,2.19 0.18 0,2.46 0.1 0,1.58  0.26 
 IL-2 0.02 0,0.45 0 0,0 0 0,0.08  0.33 
b) Peptide pool 2  
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0 0,5.12 0.05 0,0.81 0 0,0.42  0.74 
 IL-17  0 0,0.04 0.05 0,0.15 0 0,0.25  0.14 
 TNF 0 0,1.02 0.16 0,2.21 0.05 0,0.68  0.11 
 IL-2 0 0,8.78 0.13 0,0.75 0.12 0,1.47  0.34 
c) Peptide pool 3 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
 IFN 0.39 0,1.87 0 0,0.17 0 0,0.62  0.22 
 IL-17  0 0,0.6 0.04 0,0.73 0 0,0.16  0.60 
 TNF 0.09 0,2.72 0 0,1.25 0.04 0,0.67  0.98 
 IL-2 0.06 0,1.72 0 0,0.07 0.01 0,0.32 0.58  
Table 7 Dual expression in CD4+ cells against all peptides 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0.01 0,0.24 0 0,0.02 0 0,0.06  0.72 
IFN+ve TNF+ve   0.15 0.01,0.39 0 0,0.04 0 0,0  0.01* 
IFN+ve TNF-ve    0.5 0,1 0.01 0,0.14 0 0,0.02  0.03* 
IFN-ve  IL-17+ve   0 0,0 0 0,0.03 0 0,0  0.08 
IFN+ve IL-17+ve   0.01 0.01,0.03 0 0,0 0 0,0 0.006** 
IFN+ve IL-17-ve    0.7 0,1.48 0.01 0,0.16 0.01 0,0.04  0.09 
IFN-ve  IL-2+ve   0 0,0.05 0 0,0.01 0.02 0,0.03  0.40 
IFN+ve IL-2+ve   0 0,0.02 0 0,0 0 0,0  0.40 
IFN+ve IL-2-ve    0.14 0,0.36 0 0,0.01 0 0,0.01  0.02* 
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Table 8 Dual expression in CD4 positive cells by peptide pool: a) Peptide pool 1 b) Peptide pool 2 c) 
Peptide pool 3 
a) Peptide pool 1 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0.05 0,2.02 0 0,0.29 0.03 0,0.31  1.00 
IFN+ve TNF+ve   0.15 0,1.33 0 0,0.25 0.01 0,0.08  0.28 
IFN+ve TNF-ve    0.29 0,2.14 0.01 0,0.29 0.02 0,0.14  0.21 
IFN-ve  IL-17+ve   0 0,0.06 0 0,0.06 0 0,0.21  0.26 
IFN+ve IL-17+ve   0.01 0,0.06 0 0,0.01 0.02 0,0.04  0.69 
IFN+ve IL-17-ve    0.45 0,4.1 0.01 0,0.65 0.03 0,1.17  0.46 
IFN-ve  IL-2+ve   0 0,0.14 0 0,0 0 0,0.03  1.00 
IFN+ve IL-2+ve   0 0,0.02 0 0,0.01 0 0,0  0.46 
IFN+ve IL-2-ve    0.14 0,0.67 0 0,0.24 0 0,0.04  0.40 
 b) Peptide pool 2   
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0 0,0.51 0 0,0.02 0 0,0.15 0.87 
IFN+ve TNF+ve   0.01 0,0.55 0 0,0.14 0 0,0 0.38  
IFN+ve TNF-ve    0.31 0,4.61 0.01 0,0.68 0 0,0.03 0.63 
IFN-ve  IL-17+ve   0 0,0 0 0,0.06 0 0,0.02 0.05* 
IFN+ve IL-17+ve   0.01 0,0.03 0 0,0.01 0 0,0.01  0.29 
IFN+ve IL-17-ve    0.53 0,5.91 0.08 0,1.16 0 0,0.86  0.84 
IFN-ve  IL-2+ve   0 0,1.61 0.02 0,0.19 0.04 0,0.23  0.45 
IFN+ve IL-2+ve   0.01 0,0.62 0 0,0.02 0 0,0.03  0.69 
IFN+ve IL-2-ve    0.1 0,0.57 0 0,0.2 0 0,0.01  0.41 
c) Peptide pool 3 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0.01 0,2.29 0 0,0.19 0 0,0.06  0.62 
IFN+ve TNF+ve   0.37 0,2.67 0 0,0.04 0 0,0.03  0.03* 
IFN+ve TNF-ve    0.89 0,4.75 0.01 0,0.29 0 0,0.03  0.03* 
IFN-ve  IL-17+ve   0 0,0.55 0 0,0.09 0 0,0.05  1.00 
IFN+ve IL-17+ve   0.03 0,0.12 0 0,0 0 0,0  0.0007** 
IFN+ve IL-17-ve    1.53 0,9.34 0 0,0.08 0 0,0.16  0.05 
IFN-ve  IL-2+ve   0 0,0.12 0 0,0.01 0.02 0,0.09  0.50 
IFN+ve IL-2+ve   0 0,0.03 0 0,0.01 0 0,0.01  0.68 
IFN+ve IL-2-ve    0.37 0,0.88 0 0,0 0 0,0.01  0.03* 
Table 9 Dual expression in CD8+ cells against all peptides 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0 0,0.29 0 0,0.11 0.04 0,0.15 0.49 
IFN+ve TNF+ve   0.14 0.01,0.38 0 0,0.05 0 0,0.01 0.04* 
IFN+ve TNF-ve    0.31 0.03,0.83 0 0,0.16 0 0,0.01 0.01* 
IFN-ve  IL-17+ve   0 0,0.01 0.05 0,0.12 0 0,0.1 0.02* 
IFN+ve IL-17+ve   0 0,0.01 0 0,0.01 0.01 0,0.02 0.33 
IFN+ve IL-17-ve    0.67 0.06,1.34 0 0,0.26 0 0,0.11 0.02*  
IFN-ve  IL-2+ve   0 0,0.03 0 0,0.04 0 0,0.05 0.38 
IFN+ve IL-2+ve   0 0,0.02 0 0,0.01 0 0,0.01 0.50  
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IFN+ve IL-2-ve    0.05 0,0.2 0 0,0.01 0 0,0.01 0.24  
 
Table 10 Dual expression of by CD8 positive cells by peptide pool: a) Peptide pool, 1 b) Peptide 
pool 2, and c) Peptide pool 3 
a) Peptide pool 1 
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0 0,2.37 0.06 0,0.54 0.09 0,0.93 0.45 
IFN+ve TNF+ve   0.14 0.01,0.78 0.04 0,0.48 0.01 0,0.15 0.24 
IFN+ve TNF-ve    0.31 0.01,0.73 0.01 0,0.45 0 0,0.06 0.19  
IFN-ve  IL-17+ve   0 0,0.5 0 0,0.19 0.04 0,0.98 0.31 
IFN+ve IL-17+ve   0 0,0.02 0 0,0.01 0.01 0,0.12 0.25  
IFN+ve IL-17-ve    0.67 0.1,1.05 0 0,0.87 0.01 0,0.89 0.12  
IFN-ve  IL-2+ve   0 0,0.03 0 0,0.01 0 0,0.06 0.79  
IFN+ve IL-2+ve   0 0,0.05 0 0,0 0 0,0.01 0.43  
IFN+ve IL-2-ve    0.07 0,0.46 0 0,0.47 0 0,0.07 0.41  
b) Peptide pool 2  
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0 0,0.43 0 0,0.2 0.05 0,0.18 0.32 
IFN+ve TNF+ve   0.02 0,1.03 0 0,0.19 0 0,0.05 0.57 
IFN+ve TNF-ve    0.05 0,7.25 0.17 0,0.58 0 0,0.11 0.76  
IFN-ve  IL-17+ve   0 0,0 0.07 0,0.23 0 0,0.25 0.02* 
IFN+ve IL-17+ve   0 0,0.03 0.01 0,0.03 0.01 0,0.21 0.28 
IFN+ve IL-17-ve    0.04 0,9.09 0.12 0,0.88 0.02 0,0.23 0.80 
IFN-ve  IL-2+ve   0 0,4.34 0.12 0.02,0.34 0 0,0.67 0.34  
IFN+ve IL-2+ve   0.01 0,2.73 0.01 0,0.07 0.02 0,0.31 0.81 
IFN+ve IL-2-ve    0 0,2.62 0 0,0.01 0 0,0.01 0.56 
c) Peptide pool 3  
Cytokine Cleared 95% CI Fluctuating 95% CI Plateau 95% CI P value 
IFN-ve  TNF+ve   0.11 0,2.79 0 0,0.15 0 0,0.19 0.50 
IFN+ve TNF+ve   0.28 0,1.26 0 0,0.09 0 0,0.04 0.09 
IFN+ve TNF-ve    0.86 0.02,3.78 0 0,0.13 0 0,0.08 0.006**  
IFN-ve  IL-17+ve   0 0,0.54 0.06 0,0.23 0 0,0.4 0.47 
IFN+ve IL-17+ve   0.01 0,0.12 0 0,0.01 0 0,0.12  0.51 
IFN+ve IL-17-ve    1.54 0.06,6.96 0 0,0.69 0 0,0.62 0.02* 
IFN-ve  IL-2+ve   0 0,0.37 0 0,0.03 0 0,0.14 0.90 
IFN+ve IL-2+ve   0 0,0.09 0.01 0,0.02 0 0,0.02 0.75 
IFN+ve IL-2-ve    0.01 0,0.55 0 0,0.1 0 0,0.11 0.60  
Table 11: Total T cell responses; all peptides. 
Cytokine No IDU 95% CI  IDU 95% CI P value 
IFN 0.1 0.01,0.8 0.02 0,0.13  0.06 
IL-17  0.01 0,0.17 0.09 0,0.13 0.02* 
TNF 0.2 0.04,0.63 0.09 0,3.14 0.15 
IL-2 0.05 0.01,0.11 0 0,0 0.85 
Table 12: Total T cell responses by peptide: a) Peptide pool 1, b) Peptide pool 2, and c) Peptide 
pool 3. 
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a) Peptide pool 1 (HCV core, envelope E1 and E2, p7, NS2). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.09 0,1.23 0.05 0,0.5  0.25 
IL-17  0.15 0,0.59 0.09 0,0.33  0.35 
TNF 0.31 0,1.2 0.07 0,3.68  0.70 
IL-2 0 0,0.04 0 0,0.13  0.54 
b) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.14 0,1.57 0.04 0,0.48  0.16 
IL-17  0 0,0.15 0.11 0,0.19 0.84 
TNF 0.2 0.02,0.96 0.05 0,7.56 0.72 
IL-2 0.26 0.07,1.84 0 0,0.28  0.006** 
c) Peptide pool 3  (NS5A, NS5BI and II). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.11 0,1.43 0 0,0.62  0.22 
IL-17  0 0,0.31 0.09 0,0.18 0.90 
TNF 0.08 0,0.66 0.21 0,10.92 0.35 
IL-2 0.06 0.01,0.24 0 0,0.12  0.06 
 
Table 13: Total CD4+ cells: all pools. 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.01 0,0.1 0 0,0.04  0.26 
IL-17  0 0,0.02 0 0,0.04  0.90 
TNF 0.01 0,0.14 0 0,0.99  0.67 
IL-2 0.01 0,0.03 0 0,0 0.0004**  
 
Table 14: CD4 cell responses by peptide pool: a) Peptide pool 1, b) Peptide pool 2, and c) Peptide 
pool 3. 
a) Peptide pool 1  (HCV core, envelope E1 and E2, p7, NS2). 
Cytokine No IDU 95% CI  IDU 95% CI P value 
IFN 0.02 0,0.3 0 0,0.47  0.45 
IL-17  0.01 0,0.15 0 0,0.09 0.44  
TNF 0.02 0,0.39 0 0,1.43 0.37  
IL-2 0 0,0 0 0,0 0.96 
b) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.01 0,0.6 0 0.16,  0.37 
IL-17  0 0,0 0 0,0.07 0.49  
TNF 0 0,0.19 0 0,2.94 0.86  
IL-2 0.06 0.02,0.63 0 0,0.01  0.002** 
c) Peptide pool 3 (NS5A, NS5BI and II). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0 0,0.19 0 0,0.49 0.77  
IL-17  0 0,0.1 0.01 0,0.1 0.80 
TNF 0.01 0,0.32 0.1 0,4.38 0.38  
IL-2 0.01 0,0.03 0 0,0  0.05* 
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Table 15: Total CD8+ cells: all pools. 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.06 0,0.34 0 0,0.06  0.05* 
IL-17  0 0,0 0 0,0.06  0.65 
TNF 0.05 0,0.19 0 0,0.79  0.88 
IL-2 0.01 0,0.07 0 0,0  0.01* 
Table 16: CD8 cell responses by peptide pool: a) Peptide pool 1, b) Peptide pool 2, and c) Peptide 
pool 3. 
a) Peptide pool 1 (HCV core, envelope E1 and E2, p7, NS2). 
Cytokine No IDU 95% CI  IDU 95% CI P value 
IFN 0.05 0,0.6 0 0,0.1  0.32 
IL-17  0 0,0.27 0 0,0.11  0.45 
TNF 0.11 0,0.91 0 0,2.05 0.49  
IL-2 0 0,0 0 0,0.13 0.99  
b) Peptide pool 2 (NS3 protease and helicase, NS4A and NS4B). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.09 0,0.89 0.01 0,0.36  0.28 
IL-17  0 0,0.03 0.03 0,0.14 0.72  
TNF 0.11 0,0.68 0 0,4.6 0.88  
IL-2 0.12 0.04,1.25 0 0,0.25 0.01*  
c) Peptide pool 3 (NS5A, NS5BI and II). 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN 0.08 0,0.55 0 0,0.54  0.22 
IL-17  0 0,0.1 0 0,0.09 0.79  
TNF 0.01 0,0.21 0.15 0,6.18 0.31  
IL-2 0.01 0,0.11 0 0,0 0.08 
Table 17 Dual expression by CD4+ cells against all peptides 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.02 0 0,0.01  0.83 
IFN+ve TNF+ve   0.01 0,0.04 0 0,0.04 0.83 
IFN+ve TNF-ve    0.02 0,0.11 0.02 0,0.12 0.63 
IFN-ve  IL-17+ve   0 0,0.01 0 0,0.01 0.34  
IFN+ve IL-17+ve   0 0,0.01 0 0,0.01 0.71  
IFN+ve IL-17-ve    0.03 0,0.32 0.02 0,1.01 0.73  
IFN-ve  IL-2+ve   0.01 0,0.03 0 0,0 0.0001** 
IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.0003**  
IFN+ve IL-2-ve    0 0,0.01 0 0,0.03 0.77 
 
Table 18 Dual expression by CD4+ positive cells by peptide pool: a) Peptide pool 1, b) Peptide pool 
2, and c) Peptide pool 3. 
a) Peptide pool 1 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.01 0 0,1.29 0.69 
IFN+ve TNF+ve   0 0,0.04 0 0,0.28 0.59  
IFN+ve TNF-ve    0.02 0,0.12 0.03 0,1.31 0.86  
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IFN-ve  IL-17+ve   0 0,0.01 0 0,0.05 0.21  
IFN+ve IL-17+ve   0 0,0.01 0 0,0.03 0.32  
IFN+ve IL-17-ve    0.02 0,1.01 0.02 0,3.65 0.74  
IFN-ve  IL-2+ve   0 0,0 0 0,0 0.13  
IFN+ve IL-2+ve   0 0,0 0 0,0 0.09  
IFN+ve IL-2-ve    0 0,0.03 0 0,0.32 0.84  
b) Peptide pool 2  
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.11 0 0,0  0.29 
IFN+ve TNF+ve   0 0,0.14 0 0,0.38 0.86  
IFN+ve TNF-ve    0.01 0,0.73 0 0,0.36 0.21  
IFN-ve  IL-17+ve   0 0,0 0 0,0.11 0.83  
IFN+ve IL-17+ve   0 0,0.01 0 0,0.02 0.92  
IFN+ve IL-17-ve    0.03 0,1.26 0.04 0,1.17 0.59  
IFN-ve  IL-2+ve   0.06 0.02,0.28 0 0,0.02 0.003**  
IFN+ve IL-2+ve   0.01 0,0.02 0 0,0 0.01*  
IFN+ve IL-2-ve    0 0,0.13 0 0,0.27  
c) Peptide pool 3 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.03 0 0,2.81 0.40 
IFN+ve TNF+ve   0 0,0.05 0 0,0.42 1.00  
IFN+ve TNF-ve    0.01 0,0.35 0.04 0,1.1 0.61  
IFN-ve  IL-17+ve   0 0,0.11 0 0,0.03 0.50  
IFN+ve IL-17+ve   0 0,0 0 0,0.03 0.70  
IFN+ve IL-17-ve    0.01 0,0.44 0.01 0,3.78 0.77  
IFN-ve  IL-2+ve   0 0,0.02 0 0,0 0.03* 
IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.04*  
IFN+ve IL-2-ve    0 0,0.02 0 0,0.36 0.77  
 
Table 19 Dual expression by CD8+ positive cells by peptide pool:  a) Peptide pool 1, b) Peptide pool 
2, and c) Peptide pool 3 
Peptide pool 1 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.01 0 0,1.29  0.69 
IFN+ve TNF+ve   0 0,0.04 0 0,0.28 0.59  
IFN+ve TNF-ve    0.02 0,0.12 0.03 0,1.31 0.86  
IFN-ve  IL-17+ve   0 0,0.01 0 0,0.05 0.21  
IFN+ve IL-17+ve   0 0,0.01 0 0,0.03 0.32  
IFN+ve IL-17-ve    0.02 0,1.01 0.02 0,3.65 0.74  
IFN-ve  IL-2+ve   0 0,0 0 0,0 0.13  
IFN+ve IL-2+ve   0 0,0 0 0,0 0.09  
IFN+ve IL-2-ve    0 0,0.03 0 0,0.32 0.84  
Peptide pool 2 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.11 0 0,0  0.29 
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IFN+ve TNF+ve   0 0,0.14 0 0,0.38 0.86  
IFN+ve TNF-ve    0.01 0,0.73 0 0,0.36 0.21  
IFN-ve  IL-17+ve   0 0,0 0 0,0.11 0.83  
IFN+ve IL-17+ve   0 0,0.01 0 0,0.02 0.92  
IFN+ve IL-17-ve    0.03 0,1.26 0.04 0,1.17 0.59  
IFN-ve  IL-2+ve   0.06 0.02,0.28 0 0,0.02 0.003**  
IFN+ve IL-2+ve   0.01 0,0.02 0 0,0 0.01*  
IFN+ve IL-2-ve    0 0,0.13 0 0,0.27 0.95  
Peptide pool 3 
Cytokine No IDU 95% CI IDU 95% CI P value 
IFN-ve  TNF+ve   0 0,0.03 0 0,2.81 0.40 
IFN+ve TNF+ve   0 0,0.05 0 0,0.42 1.00  
IFN+ve TNF-ve    0.01 0,0.35 0.04 0,1.1 0.61  
IFN-ve  IL-17+ve   0 0,0.11 0 0,0.03 0.50  
IFN+ve IL-17+ve   0 0,0 0 0,0.03 0.70  
IFN+ve IL-17-ve    0.01 0,0.44 0.01 0,3.78 0.77  
IFN-ve  IL-2+ve   0 0,0.02 0 0,0 0.03* 
IFN+ve IL-2+ve   0 0,0.01 0 0,0 0.04*  
IFN+ve IL-2-ve    0 0,0.02 0 0,0.36 0.77 
 
 
